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Abstract 
 
Antibody-Directed Enzyme Prodrug Therapy (ADEPT) is an experimental cancer 
treatment. First, an antibody-enzyme is targeted to the tumour. After clearance from 
healthy tissue, a prodrug is administered and activated by the enzyme. MFE-CP, an 
anti-carcinoembryonic antibody fragment fused to the enzyme carboxypeptidase G2, 
has been used for ADEPT in combination with a nitrogen mustard prodrug.  Clinical 
trials are encouraging but highlight major challenges of sub-optimal MFE-CP 
pharmacokinetics and drug resistance. This thesis explores means to address these 
challenges. 
 
MFE-CP, manufactured in P. pastoris, clears rapidly from the circulation due to 
yeast mannosylation. This leads to excellent tumour:blood ratios but decreased 
opportunity for tumour uptake. MFE-CP was therefore mutated in an attempt to 
reduce glycosylation. Initially, N-linked glycosylated asparagine residues were 
mutated to glutamine. The enzyme remained active but cleared rapidly in vivo. O-
linked residue mutations were then explored. Changes that would least impede 
enzyme function were predicted using bioinformatics and a series of mutated 
constructs generated. The T55V mutation generated a functional enzyme that also 
cleared rapidly in vivo.   
 
The DNA damage response was investigated as a mechanism of drug resistance. 
Using the comet assay, DNA interstrand cross-links were shown to form rapidly in 
carcinoma cells and xenografts in response to ADEPT, but these were unhooked over 
48 hours. The γ-H2AX and RAD51 response indicated unhooking was due to DNA 
damage repair. Cell cycle studies showed that ADEPT treatment also led to G2/M 
arrest. G2/M arrest allowed DNA repair to occur and it was hypothesised that 
ADEPT could be made more effective by blocking arrest and driving entry into 
mitosis. To test this hypothesis, Chk1 inhibitors, UCN-01 and PF-477736, were 
investigated. Results demonstrated an enhanced anticancer effect with the ADEPT 
and PF-477736 combination, whereby increased cell death was observed at 48 hours 
post treatment. The approach has potential for clinical translation. 
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1 Introduction 
 
1.1 Cancer 
 
Cancer is a malignant disease characterised by the growth of tumours with a series 
of defined hallmarks (1) (2): uncontrolled cell growth, self-sufficiency in growth 
factors, insensitivity to anti-growth factors, evasion of apoptosis, limitless 
replicative potential, sustained angiogenesis, invasion and metastasis (spread to 
other organs), genome instability, chronic inflammation, evasion of immune 
destruction and reprogramming of energy metabolism. Cancer arises from the 
accumulation of genetic and epigenetic alterations within proto-oncogenes and 
tumour suppressor genes, which can lead to the disruption of various signalling 
pathways (3). De-regulation of a single pathway can provoke unscheduled 
proliferation leading to genomic and chromosomal instability – all of which 
contribute to the development of the primary tumour (4) (5).  
 
As the leading cause of mortality world-wide, cancer accounted for 13% of all 
deaths in 2008 (6). One in four of all deaths in UK are caused by cancer; in 
particular, cancer of the lung, bowel, breast and prostate (7). The latter being solid 
tumour carcinomas, highlights a great need for treatments in these areas.     
 
Traditional cancer treatments include surgery, radiotherapy, chemotherapy, or a 
combination of these for aggressive tumours. Chemotherapeutic agents tend to act 
systemically and exert their effects on proliferating cells, including healthy cells - 
hair follicles, blood cells and cells of the intestinal tract. This causes unwanted 
toxicity to healthy tissue. Targeted therapy aims to overcome these limitations by 
destroying the tumour while sparing healthy tissue. Monoclonal antibodies and 
small molecule drugs, developed for targeted therapy, have both demonstrated 
anti-tumour efficacy. Although antibodies dominate the sales market there is still 
a need for more effective targeted therapies, given the multiple types of cancer 
(8).  
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1.2 Antibodies for cancer therapy 
 
In the early twentieth century, Paul Ehrlich envisioned treating cancer with a 
“magic bullet” that would specifically target a therapeutic agent to cancer cells, 
whilst leaving healthy cells unharmed (9). Antibodies form an integral part of the 
immune defence system, in which they are designed to specifically bind to foreign 
proteins (or antigens). This specificity and exquisite selectivity means antibodies 
can be harnessed for therapeutic uses in the rationally targeted approach proposed 
by Ehrlich. 
 
Behring and Kitasoto were first to suggest that antibodies could be used for 
therapy using horse antisera. Initial attempts to treat cancer was with polyclonal 
antisera, that is, antibodies of differing specificity raised in animals against 
fragments of the patient’s own tumours (10) (11). Despite their potential efficacy, 
the use of polyclonal antibodies for cancer therapy was (and is) limited by safety 
concerns and short supply of antisera from immunized animals. The use of 
antibodies for targeting cancer was limited, until 1975, when the development of 
hybridoma technology enabled the production of mouse monoclonal antibodies 
(12) (13). These monoclonal antibodies (mAbs) could be generated in large 
quantities from the fusion of antigen-specific antibody-producing B cell clones 
isolated from spleens of immunised mice with immortalised myeloma cells. This 
revolutionary work paved the way for the generation of highly specific therapeutic 
antibodies. Antibodies derived from hybridoma technology that are currently used 
in the clinic for cancer therapy are listed in Table 1.1.  
 
1.2.1 Antibody structure  
 
Antibodies, also known as immunoglobulins (Ig), are a group of glycoproteins. 
They are produced by B-lymphocytes and act as soluble surface receptors for 
antigen recognition. Antibodies were first identified in 1939 by Kabat and Tiselius 
(14) and their structure was later elucidated by Porter (15) and Edelman (16) (17). 
Antibodies are bi-functional molecules composed of a highly specific antigen-
binding half and an immunological effector half.  In vertebrates, 5 classes of 
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antibodies exist based on the sequence of their heavy chain constant regions (IgG, 
IgM, IgA, IgE and IgD). IgG is the most frequently used for cancer therapy and its 
structure, as reviewed by Padlan (18), is shown in Figure 1.1. A full-size IgG 
antibody is a Y-shaped complex molecule composed of two identical light chains, 
each with a variable and constant domain; and two heavy chains, each with one 
variable and three constant domains. Each heavy chain is attached to a light chain 
by disulphide bonds, and the CH1 and CH2 heavy domains are also linked together 
by disulphide bonds. The antibody is subdivided into two distinct functional 
moieties: the antigen-binding region F(ab’)2 and the constant region (Fc). The Fab 
or F(ab’)2 region contains the variable fragments (Fv), VL and VH, each of which 
consists of three hypervariable complementarity-determining regions (CDRs) 
(19). These constitute the highly specific antigen binding site of the antibody (20). 
The IgG molecule has an exposed hinge region; a flexible proline-rich region 
between the CH1 and CH2 domains that is susceptible to proteases (Figure 1.1). 
Pepsin cleaves the Fc and releases the large F(ab’)2 moiety, which retains the 
bivalent antigen-binding properties of the parent IgG but without the effector 
capacity (Figure 1.2B). Alternatively, papain digestion releases the two identical 
Fab fragments containing the VH-CH1 and VL-CL segments linked together by 
disulphide bonds - each with monovalent antigen binding capacity, and the Fc 
region that has no antigen binding ability (21).  
 
The Fc portion of an antibody mediates both the biological half-life of the IgG and 
its ability to direct immunological effector functions for targeted cell-killing, 
including antibody-dependent cellular cytotoxicity (ADCC), complement-
dependent cytotoxicity (CDC) and immune complex clearance (22). IgG isotypes 
(e.g. IgG1, IgG2, IgG3 and IgG4) are defined by structural differences associated 
with the Fc region and these isotypes differ in their ability to elicit immune 
effector functions (23) (24)). The IgG serum half-life of antibodies is regulated by 
neonatal Fc receptors (FcRns) on various immune cells and is described in more 
detail in Section 1.7.  
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Figure 1.1 IgG antibody framework  
The antibody can be divided into fragment regions, which are each composed of variable and 
constant polypeptide chain domains, as described in the text. A flexible proline-rich hinge region 
separates the CH1 and CH2 domains of the heavy chain. The heavy and light chains are linked 
together through a disulphide bridge. Red spheres indicate glycosylation on the CH2 domain. 
Binding of the Fc region to various Fc receptors leads to the initiation of immune effector 
functions including, antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent 
cytotoxicity (CDC); or influences antibody retention. CDR, complementarity determining regions; 
CH, constant heavy; CL, constant light; Fc, constant fragment; Fab, variable fragment antigen 
binding region; Fv, variable fragment; VH, variable heavy; VL, variable light.  
  
1.2.2 Engineering antibodies for therapy 
 
During their initial use in the 1980s, clinical therapeutic success with murine 
monoclonal antibodies was limited by a number of factors, principally, their 
ability to invoke immune reactions in humans resulting in human anti-mouse 
antibodies (HAMA) after repeated treatments (25) (26) (27), and their poor ability 
to induce immune effector responses (23). This prompted the development of 
alternative strategies to improve the tumour targeting potential of antibodies.  
 
Approaches to overcome the immunogenicity presented by murine antibodies 
have involved incorporating the murine antigen-binding regions into the human 
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IgG framework. This has allowed the generation of chimeric and humanised 
antibodies, as illustrated in Figure 1.2A. A chimeric antibody consists of linking 
the variable domains of a murine antibody with the human constant regions (28) 
(29) (30). The first chimeric antibody to be approved by the US Food and Drugs 
Administration (FDA) was rituximab in 1997 for the treatment of B-cell non-
Hodgkin’s lymphoma (see Table 1.1). 
 
A humanised antibody contains only the murine CDRs grafted into the human IgG 
framework at the gene level (31) (32) (33). Multiple strategies have been 
developed to humanise antibodies as a result of intellectual property rights. 
However, they are all based on the CDR-grafting approach originally described by 
Winter and colleagues (33). The humanised antibodies clinically approved for the 
treatment of cancer are listed in Table 1.1.  
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Figure 1.2 Schematic diagram illustrating monoclonal antibody development  
A) murine IgG (green/blue shading) to humanised IgG (purple/pink shading); B) antibody 
fragments derived from an IgG antibody. Fabs and F(ab)2 can be derived directly from proteolytic 
digestion, and scFvs are engineered from the Fv fragment.  Murine, chimeric and humanised can 
also be engineered into antibody fragments (see Figure  
Figure 1.3). (scFv, single chain variable fragment). 
A 
B 
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Table 1.1 US Food and Drugs Administration (FDA)-approved anticancer monoclonal antibodies (mAb)  
ADCC: antibody-dependent cell-mediated cytotoxicity, ALCL: systemic anaplastic large cell lymphoma, BLyS: B-lymphocyte stimulator, CDC: complement-dependent 
cytotoxicity, CLL: chronic lymphoid leukaemia, CTLA-4: cytotoxic T-lymphocyte-associated antigen 4, EGFR: epidermal growth factor receptor, EpCAM: epithelial cell 
adhesion molecule NHL: non-Hodgkin’s lymphoma, NSCLC: non-small-cell lung cancer, RANKL: receptor activator of nuclear factor kappa-B ligand (belongs to the 
tumour necrosis family), VEGF: vascular endothelial growth factor. *Not approved in the European Union; **Approved in the European Union only. 
 
Drug name Antibody Antigen 
Type of 
mAb 
Indication Mechanism of action 
Year of 
approval 
Naked antibodies 
Rituxan Rituximab CD20 Chimeric NHL ADCC, CDC 1997 
Herceptin Trastuzumab HER2 Humanised HER2
+ 
breast cancer ADCC, receptor blockade 1998 
Campath Alemtuzumab CD52 Humanised B cell CLL ADCC, CDC 2001 
Avastin Bevacizumab VEGF Humanised 
Metastatic cancer of colon, breast; 
NSCLC 
Ligand blockade 2004 
Erbitux Cetuximab EGFR Chimeric 
Metastatic cancer of colon and head and 
neck 
Receptor blockade 2004 
Vectibix Panitumumab EGFR Human Metastatic colon cancer Receptor blockade 2006 
Arzerrza Ofatumumab CD20 Human CLL ADCC, CDC 2009 
** Removab Catumaxomab 
EpCAM and 
CD3 
Chimeric Malignant ascites Bispecific, tri-functional 2009 
Xgeva Denosumab RANKL Human Bone metastases from solid tumours Ligand blockade 2010 
Yervoy Ipilimumab CTLA-4 Human Unresectable or metastatic melanoma Receptor blockade 2011 
Perjeta Pertuzumab HER2 Humanised Late-stage breast cancer Receptor blockade 2012 
Gazyva Obinutuzumab CD20 Humanised CLL ADCC 2013 
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Drug name Antibody Antigen 
Type of 
mAb 
Indication Mechanism of action 
Year of 
approval 
Immunoconjugates 
Zevalin 
90
Y-Ibritumomab CD20 Murine Relapsed/refractory NHL Radiation (β-emission) 2002 
Bexxar 
131
I-Tositumomab CD20 Murine Relapsed/refractory NHL Radiation (β- and γ-emissions) 2003 
*Adcetris Brentuximab vedotin CD30 Chimeric Hodgkin’s lymphoma and ALCL 
Toxin blocks polymerisation of 
tubulin 
2011 
Kadcyla 
Ado-trastuzumab 
emtansine 
HER2 Humanised Late-stage breast cancer Toxin binds to tubulin 2013 
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Antibody therapy has had a profound impact on revolutionising cancer treatments, 
but its effectiveness has been limited due to poor tumour penetration because of 
the large IgG size (34), long in vivo half-life leading to increased toxicity, 
immunogenicity, and ability to initiate effector functions is often too toxic for 
repeat administrations (35). Other factors include mechanism-dependent toxicity, 
for example, in the binding of rituximab to normal B cells expressing CD20 
antigen (36), and cardiotoxicity induced by trastuzumab binding to receptors in 
the heart tissue (37) (38). The limiting factors are currently being addressed 
through advances in recombinant antibody engineering (39). 
 
 
1.3 Recombinant antibodies  
 
1.3.1 Recombinant technology 
 
Shortly after the introduction of antibody humanisation, technological advances 
facilitated the isolation of antibodies derived directly from human germ-line 
sequences and with enhanced features for tumour targeting, such as, defined 
affinity, avidity, specificity, and reduced immunogenicity. These technologies can 
be broadly classified into two distinct approaches: in vitro assembly of 
recombinant human antibody (fragment) libraries for use in phage display (40) 
(41) (42); and in vivo generation of human antibodies using transgenic mice 
engineered to encode human IgG heavy and light chains (43) (44) (45). At least 66 
different therapeutic drugs, derived from either phage display or transgenic mouse 
platforms, have entered human clinical trials (45).  
 
1.3.1.1 Phage display 
 
In vitro selection of antibodies was made possible by the introduction of phage 
display in the 1980s (46) (47) (20). Phage display involves the presentation of a 
library of antibody fragments on the surface of filamentous phage, by fusing the 
antibody fragment genes to the phage genome. For example, phage carrying 
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variable antibody fragment genes, express the antibody VH and VL domains on the 
surface of the phage as a single chain variable fragment (scFv) (see Section 
1.3.2.1). Affinity selection of antibody-phage by binding to an antigen (panning) 
(48) is followed by elution of bound antibody-phage, which can be used to infect 
E. coli, and generate a large amount of specific antibodies after several rounds of 
selections and re-amplification of the selected antibody-phage (49). In 2002, 
adalimumab became the first FDA-approved fully human antibody created by 
phage display technology (50) (51). Adalimumab is a monoclonal antibody for the 
treatment of rheumatoid arthritis, but has also been approved for other 
inflammatory diseases. 
 
Compared to hybridoma technology, antibodies selected from a phage display 
library are generally more stable, give high yields (> 10
10
 compared 10
2 
to 10
3
 
clones) and easier to genetically engineer to create higher affinity binding 
molecules (52). The antibody phage libraries are classified as naive (from non-
immunised donors) (40) (53) or immune (from immunised donors, but with biased 
antibody specificity) (54). The complexity of combinatorial libraries has been 
increased by creating semi-synthetic or synthetic libraries. For example, the fully 
synthetic Human Combinatorial Antibody Libraries (HuCAL) have been created 
to mimic the variable domains of antibodies seen in immune responses (55) (56). 
Other molecular selection strategies employed for engineering human antibodies 
include ribosome and mRNA display (57), yeast cell display (58) (59) (60), and 
lymphocyte display (61). The latter is a novel antibody selection platform based 
on T-cell activation.  
 
1.3.1.2 Transgenic mice 
 
Creating human antibodies from transgenic mice provides diverse, high affinity 
and high specificity monoclonal antibodies that aim to eliminate the production of 
HAMA reactions. Fully human monoclonal antibodies can be produced using this 
method which eliminates the need to “humanise” identified antibodies using 
earlier technologies. For example, the anti-EGFR monoclonal antibody, 
Panitunumab, was developed in this way (62) (63) (Table 1.1). In patients, the 
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antibody revealed decreased immunogenicity compared to an earlier chimeric 
antibody (cetuximab) for the same cancer (64) (65).  
 
1.3.2 Recombinant antibody fragments  
 
Intact IgGs are bivalent, that is, they have the ability to bind two antigens which 
greatly increases their functional affinity and avidity (retention). However, their 
large size means that they diffuse less efficiently through solid tumour mass (66) 
and are retained in the circulation for longer, which can lead to off-target toxic 
effects caused by Fc-mediated effector reactions. The advent of phage library 
technology has made it easier to generate a large variety of smaller, recombinant 
antibody fragments from the intact IgG with different binding kinetics, affinities 
and biophysical properties.  
 
The IgG molecule (150 kDa) can be dissected into smaller antigen-binding 
fragments by proteolytic digestion, as shown in Figure 1.2B. These include, 
F(ab’)2 (~100 kDa), (2x) Fabs (~ 55 kDa each), and the Fv (fragment variable), 
which is composed of the VL and VH regions only (67). These VL and VH domains 
can be expressed in recombinant form as a single polypeptide chain by joining the 
two regions using a flexible, neutral linker. The fragment is termed single chain 
variable fragment, scFv (~ 27 kDa) (68) (69), as shown in Figure 1.2B. The 
impact of molecular size on tumour penetration was revealed in early studies 
comparing the in vitro binding of IgG antibody fragments [scFv, Fab, F(ab)2] with 
the intact IgG, such that tumour penetration is inversely proportional to the size of 
the antibody molecules (70).  
 
1.3.2.1 ScFv 
 
ScFvs represent the smallest IgG fragment carrying the whole antigenic binding 
site and are sufficiently stable (35). Their small size means scFvs are an ideal 
platform for targeted-therapies because of their ease of use in display technologies 
and high production yields in non-mammalian expression systems for clinical use 
(71). In 2009, it was reported that scFvs accounted for 53% of recombinant 
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fragments in clinical development, although none of the FDA-approved fragments 
were anti-neoplastic antibodies (72).   
 
A scFv can have two possible orientations, VH-VL or VL-VH, which can affect the 
expression efficiency, stability and affinity of the resulting antibody. The most 
commonly used linker, (Gly4Ser)3, provides flexibility, hydrophilicity and 
resistance to proteases (68) (69). The small size of antibody fragments means they 
are capable of penetrating and distributing homogenously in tumours more 
efficiently which is advantageous in imaging and therapeutic applications (73) 
(74) (75). Antibodies < 50-65 kDa undergo rapid, first-pass renal clearance (76), 
and the monomeric nature of scFvs means these antibodies show fast dissociation 
rates and modest retention times on the antigen (35) (77). Although this can be 
advantageous for avoiding toxicity, it is a drawback for clinical therapy because of 
the low absolute concentrations of antibody in the tumour.  
 
One of the ways to improve retention of scFvs (and Fabs) is by increasing their 
valency, that is, the number of binding sites. ScFvs can be forced to form 
multivalent multimers by shortening the peptide linker (< 12 residues long), which 
encourages spontaneous multimerisation (78) (see Figure 1.3). Bivalent antibodies 
can be chemically or genetically engineered (79). Diabodies are scFv dimers (60 
kDa) consisting of two non-covalently associated scFvs, in which the variable 
domains of one scFv pair with complementary domains of another scFv (80). 
These bivalent diabodies can be further stabilised by a disulphide linkage (81) 
(82) (83). Bispecific diabodies are two scFvs of different antigen specificities 
linked together (~55-60 kDa). When the peptide linker is < 3 residues long, scFvs 
can be forced to associate into multimers of 3 or 4 scFvs together - known as 
triabodies (90 kDa) or tetrabodies (120 kDa), respectively. Larger fragments such 
as minibodies (~75 kDa) comprise of two scFv-hinge-CH3 chains covalently 
linked by disulfide bonds (81). ScFvs fused to intact Fc domains (scF-Fc; ~ 110 
kDa) have similar pharmacokinetic profiles as intact IgGs (84) because of the 
presence of the entire Fc region, including the FcRn binding site. However, it has 
been shown that inducing mutations in the FcRn binding site of the Fc region can 
alter the pharmacokinetic profile of these antibodies (85) (86). 
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Other strategies to address the poor retention times and rapid clearance of scFvs 
include: chemical coupling with polyethylene glycol (87) (88) (89); engineering 
fusions with albumin (90) (91); affinity maturation (92); and modification of size 
through conjugation/genetic fusions with radioisotopes, toxins, enzymes or drugs 
(93) (94) (95) (96) (Figure 1.3). In the latter strategy, antibodies are used to 
deliver a toxic payload to tumours, which greatly increases the efficacy of 
antibody-targeted anti-cancer therapy. This is discussed in more detail in Section 
1.4.  
 
                             
                             
 
Figure 1.3 Recombinant antibody fragments  
A) The single chain variable fragment (scFv) can be manipulated to create different antibody 
formats of different size and avidity. B) The scFv-fusion protein can be created with various 
effector proteins. Some of these are explained in more detail in Section 1.4. (RIT, 
radioimmunotherapy).  
A 
B 
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1.4 Modified antibodies for targeted therapy  
 
As single agents, monoclonal antibodies cause tumour cell-killing by altering the 
progression of signal transduction pathways (receptor blockade, agonist activity, 
induction of apoptosis); or by immune-mediated mechanisms (including CDC, 
ADCC and regulation of T-cell function). To increase the potency of tumour cell-
killing, whole antibodies and recombinant antibody fragments are being 
increasingly exploited as vehicles to deliver a toxic payload, such as 
radionuclides, toxins, drugs or enzymes (Figure 1.3).  
 
1.4.1 Radioimmunotherapy (RIT) 
 
Radio-labelled antibodies act by delivering lethal doses of radiation to 
disseminated tumour cells, primarily resulting in DNA damage, but do not always 
deliver enough radiation to completely eradicate solid tumours (97) (98). There 
are currently two approved therapeutic radio-immunoconjugates in the clinic (see 
Table 1.1). Pre-targeted RIT is a way of indirectly targeting radionuclides to the 
tumour using antibodies. A specific antibody localises to the tumour and is 
allowed to progress independently of the radiation-delivery phase. Once the target 
cell has achieved maximum antibody uptake, radioactivity can be delivered via a 
small ligand (e.g. biotin-labelled radionuclide) possessing high affinity for the 
pre-targeted antibody (e.g. fused with streptavidin) (99). The separation between 
the two phases of antibody distribution and radionuclide delivery results in more 
favourable tumour-to-normal tissue ratios compared to conventional RIT.  
 
1.4.2 Immunotoxins 
 
Immunotoxins are antibodies conjugated or fused to bacterial- or plant-derived 
toxins. These conjugate/fusion proteins are very potent and generally well-
tolerated by haematological cancers because the patients are immunosuppressed 
from their disease and previous drug treatment. However, these agents are 
immunogenic and cause toxicity in patients, such as vascular leak syndrome (94). 
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Antibodies conjugated or fused to ribonucleases (immunoRNases) offer the 
potential of a less immunogenic cancer therapeutic with similar potency to 
immunotoxins (100) (101) (102). A review of antibody-enzyme fusion proteins 
for cancer therapy can be found by Andrady et al., 2011 (96). 
 
1.4.3 Antibody-drug conjugates 
 
The first antibody-drug conjugate (ADC) to gain FDA approval for the treatment 
of cancer was gemtuzumab-ozogamicin (Mylotarg) (103) – a humanised anti-
CD33 IgG4 antibody conjugated to a DNA-binding cytotoxic antibiotic. 
Unfortunately, the drug was recently withdrawn from FDA-approval because it 
failed to show any clinical benefit compared to standard chemotherapy in a post-
approval study (104). In spite of this, antibody-drug conjugates are gaining 
renewed interest in the last couple of years as anticancer therapeutics. There are 
currently more than 20 ADCs in early phase cancer clinical trials (105) compared 
to 6 that entered the clinic between the years 2000-2005 (106). The FDA recently 
approved the ado-trastuzumab emtansine (T-DM1) antibody-drug conjugate for 
patients with HER2-positive, late-stage (metastatic) breast cancer (see Table 1.1). 
It comprises an anti-HER2 antibody conjugated to a microtubule-depolymerizing 
agent through a non-reducible thioether linkage that is cleaved upon 
internalisation into cancer cells (107) (108). The clinical efficacy of T-DM1 was 
evaluated in a recent clinical study of 991 patients randomly assigned to receive 
T-DM1 or HER2-specific tyrosine kinase inhibitor plus chemotherapy (109). 
Results showed that patients treated with T-DM1 had a median progression-free 
survival of 9.6 months compared to 6.4 months in patients treated with the 
alternative drug combination. One of the pitfalls of ADCs is combining highly 
potent drugs with safe, stable linkers.  
 
1.4.4 Antibody-directed enzyme prodrug therapy 
 
Another form of targeted therapy, involves pre-targeting of an antibody-enzyme 
followed by administration of an inactive prodrug that is converted by the targeted 
enzyme to an active drug. The targeting approach is known as antibody-directed 
enzyme prodrug therapy (ADEPT). ADEPT has a number of potential advantages 
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over standard chemotherapy and single antibody agents, by intending to eliminate 
the weaknesses of each individual approach. As opposed to ADCs, a high 
concentration of cytotoxic drug can be generated at the tumour site quickly and 
safely, all the while overcoming the non-specificity posed by chemotherapeutic 
compounds alone. ADEPT is the principal topic under investigation in this thesis 
and is discussed further in Section 1.5.  
 
 
1.5 ADEPT  
 
Chemotherapy kills cancer cells but also damages healthy cells, meaning less than 
optimal drug doses can be administered. If cytotoxic agents could be generated in 
vivo and restricted to cancer sites this would have the potential to deliver more 
drug to the tumours and avoid normal tissue toxicity. This is the principal concept 
behind antibody-directed enzyme prodrug therapy (ADEPT), which was first 
described in the late 1980s (110) (111) (112).    
 
ADEPT is a staged therapy (as shown in Figure 1.4), whereby an antibody-
enzyme is delivered systemically and allowed to localize to the target tumour 
antigen in vivo. After clearance of the antibody-enzyme from normal tissues, a 
low-toxicity prodrug is administered and activated by the enzyme to the toxic 
drug at the tumour site. The active drug can diffuse to nearby cells, creating a 
local bystander effect where antigen negative cells and tumour supportive stromal 
elements are destroyed.  
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Figure 1.4 Antibody-directed enzyme prodrug therapy (ADEPT)  
A staged system of cancer therapy. Stage 1: The antibody-enzyme fusion protein is allowed to 
localise in tumour tissue and is cleared or deactivated in healthy tissue. Stage 2: After 
administration, a non-toxic prodrug is converted by the targeted enzyme to the active drug. The 
active drug causes localised cytotoxicity to tumour cells bearing the antigen and mediates 
bystander effects to neighbouring tumour cells. (Adapted from Andrady et al., 2011 (96)) 
 
ADEPT allows the selective and specific generation of highly toxic 
chemotherapeutic drugs, which has many advantages over standard 
chemotherapy. By giving a relatively non-toxic prodrug, larger doses can be 
prescribed and result in less or ultimately no systemic side effects, thus toxicity is 
restricted to the tumour site. Furthermore, the efficacy of ADEPT is boosted by 
the fact that many prodrug molecules can be converted by one enzyme, so the 
tumour essentially becomes a factory for its own destruction.  
 
Most prodrugs for ADEPT are designed around the use of cytotoxic drugs 
currently licensed for chemotherapy (as noted in Table 1.2). This may be due to 
the fact that using a known drug for the therapy would reduce the clinical trial 
arms by one parameter. Since ADEPT provides the possibility of on-site 
generation of active drug, it is theoretically possible to use new and more potent 
drugs that would be too toxic to administer as standard chemotherapeutics. Whilst 
being a crucial part of ADEPT development, the field of prodrug/drug design is 
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beyond the scope of this Chapter. The reader is referred to further publications in 
this area (113) (114) (115). An ideal prodrug for ADEPT is one with a large 
differential in cytotoxicity between drug and prodrug, and is also a good substrate 
for the enzyme under physiologic conditions.  
 
A wide range of enzymes (human and non-human) have undergone pre-clinical 
investigation for ADEPT (see Table 1.2). The majority are of bacterial origin and 
do not have a human equivalent. Non-human enzymes are often highly 
immunogenic and ADEPT therapy can only be administered prior to the patient 
eliciting an immune response. The ideal enzyme would be human but inevitably 
these are not suitable for ADEPT systems as they would cause endogenous 
conversion of prodrugs at sites other than the tumour, leading to off-target 
toxicity. Human enzymes can, however, be mutated so that they no longer 
recognise their native substrates, and would therefore be useful in an ADEPT 
setting (116) (117). Carboxypeptidase G2 (CPG2) is the only enzyme to have 
been clinically investigated, and forms the basis of this PhD thesis.  
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Table 1.2 Summary of ADEPT systems – chemical conjugates and fusion proteins  
CEA, carcinoembryonic antigen; EpCAM, epithelial cell adhesion molecule; dsFv, disulfide-linked variable fragment; EDB, extra domain-B; TAG-72, tumour-
associated glycoprotein-72; TfR, transferrin receptor. (Taken and adapted from Helen et al., 2009 (118)). 
 
 
Enzyme Antibody Format Active Drug References 
Alkaline Phosphatase 
IgG2a antibody to carbohydrate antigen on 
carcinomas 
Chemical 
Conjugate 
Etoposide, Mitomycin C, 
Doxorubicin, Phenol mustard 
(112) (119) (120) 
(121) 
Carboxypeptidase A 
 
Monoclonal antibody to human lung 
adenocarcinoma 
Methotrexate 
 
(122) (123) 
Monoclonal antibody to glycosylated surface 
protein on human ovarian teratocarcinoma 
(124) 
Monoclonal antibody to Ep-CAM (125) 
Carboxypeptidase A1 Mutant 
(Human) 
Monoclonal antibody to EpCAM (126) 
scFv to seminoprotein 
Fusion 
Protein 
(127) 
Carboxypeptidase G2 
hCG antibody 
Chemical 
Conjugate 
 
 
 
Nitrogen mustard 
 
 
 
 
 
(111) (128) (129) 
CEA F(Ab’)2 
(130) (131) (132) 
(133) (134) (135) 
CEA scFv 
Fusion 
Protein 
(136) (137) (138) 
(139) 
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Cytosine Deaminase 
 
IgG2a to carcinoma 
Chemical 
Conjugate 
5-Fluorouracil 
 
(140) (141) (142) 
(143) 
scFv to gpA33 antigen in colon cancers 
Fusion 
Protein 
(144) (145) 
L19 scFv to extradomain B of fibronectin 
expressed in ovaries, uterus and during wound 
healing 
(146) 
β-Galactosidase 
Monoclonal anti-CEA antibody 
Chemical 
Conjugate 
(147) 
Humanised anti-TAG-72 (CH2 knocked-out) Geldanamycin (148) (149) 
β-Glucuronidase 
Monoclonal Antibody to carcinomas Daunorubicin and Doxorubicin (150) (151) (152) 
IgG2a antibody expressed on AS-30D cell line Phenol mustard (153) 
CEA 
Fusion 
Protein 
Doxorubicin 
 
(154) (155) 
β-Glucuronidase (Human) 
 
scFv to EpCAM (156) 
F(Ab’)2 to a tumour necrosis antigen (157) 
humanised scFV to TAG-72 
p-Hydroxyaniline mustard 
glucuronide 
(158) 
β-Lactamase 
IgG2a F(Ab’)2  to carbohydrate antigen on 
carcinomas 
Chemical 
Conjugate 
Nitrogen mustard (159) (160) 
dsFv to p185
HER2 
 
Fusion 
Protein 
 
 
Doxorubicin (161) 
scFv to melanotransferrin p97 Nitrogen mustard (162) (163) 
scFv to melanoma Paclitaxel (164) 
scFv to TAG72 carbohydrate epitope Melphalan (165) 
Nanobody to CEA Nitrogen mustard (166) 
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Penicillin-G-Amidase IgG2a Monoclonal antibody to carcinoma cells 
Chemical 
Conjugate 
 
N-(4-hydroxyphenylacetyl) palytoxin, 
Doxorubicin, Melphalan 
(167) (160) 
 
Penicillin V Amidase 
IgG2a antibody to carbohydrate antigen on 
carcinomas 
Doxorubicin and melphalan (168) 
Prolyl Endopeptidase (Human) 
Monoclonal antibody to EDB domain of 
fibronectin 
Methotrexate, Cephalosporin 
analogues and Melphalan 
(169) 
Purine Nucleoside 
Phosphorylase  (Mutant, 
Human) 
Anti-HER-/neu peptide mimetic (AHNP) (breast 
cancer) 
Fusion 
Protein 
2-Fluoroadenine (170) 
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1.5.1 Carboxypeptidase G2 ADEPT system 
 
Carboxypeptidase G2 (CPG2) (also known as glucarpidase), originally identified 
from Pseudomonas sp. (strain RS-16) (171), is a bacterial, zinc-dependent 
exopepetidase with a molecular weight of 41.8 kDa (per monomer). It forms a natural 
homodimer, comprised of two subunits, each of which contains two zinc ions 
necessary for catalysis (172). CPG2 has a natural affinity for mediating the 
hydrolysis of folates, which has made it ideal for controlling the side-effects of high-
dose chemotherapy with methotrexate (173) (174). In ADEPT, nitrogen mustard L-
glutamate prodrugs have been specifically designed for cleavage by CPG2 (175) 
(176).  
 
1.5.1.1 Chemical conjugate  
 
The first reported in vivo studies utilised CPG2 conjugated to anti-human chorionic 
gonadotrophin (hCG) murine monoclonal F(ab’)2 antibody (111). The antibody-
enzyme conjugate was used to target choriocarcinoma xenografts in nude mice, 
which were previously resistant to conventional chemotherapy. Due to the large 
concentration of hCG antigens in the blood, antibody-CPG2 bound to hCG to form 
immuno-complexes which accelerated clearance of the conjugate from the blood. 
This immune-complex formation had been demonstrated earlier by Begent et al. 
(177). The dichlorobenzoic acid mustard prodrug could then be safely administered 
between 56 and 72 hr after the conjugate. The ADEPT system proved to be 
successful, resulting in complete tumour growth regression of 9 out of 12 xenograft 
tumours (129).  
 
Following on from this initial success, a F(ab’)2 fragment derived from a murine 
monoclonal antibody was chemically conjugated to CPG2 to target carcinoembryonic 
antigen (CEA) (178). CEA (CEACAM5) is a tumour-associated glycoprotein that is 
highly expressed on epithelial cells of various adenocarcinomas, in particular 
colorectal carcinoma (179). CEA is an oncofoetal antigen. It is also present on 
normal adult colon tissue, but restricted to the luminal surface of the gut where it is 
virtually inaccessible by intravenously administered antibodies. CEA was the target 
of choice for the CPG2-ADEPT system, as there was a clinical need at the time. 
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The anti-CEA antibody-enzyme conjugate was tested for efficacy in mice bearing 
LS174T human colorectal carcinoma xenografts (180). However, clearance of the 
conjugate from the plasma was slow possibly due to low circulating levels of CEA 
(181). This meant that it was necessary to delay prodrug administration for several 
days to avoid toxicity (182).  As a result, no tumour response was observed. 
 
To increase the speed of conjugate clearance from the blood and healthy tissue, a  
hybridoma-derived anti-CPG2 (SB43) monoclonal antibody was generated to 
inactivate circulating antibody-enzyme conjugates (183). The enzyme-inactivating 
antibody was galactosylated (SB43gal) in order to accelerate the clearance of 
conjugate from the blood via carbohydrate-specific receptors in the liver (184) and 
without affecting enzyme levels in the tumour. It was found that the prodrug, 4-[2-
chloroethyl-(2-mesyloxyethyl) amino]benzoyl-L-glutamic acid (CMDA), (128) could 
be given within 24 hr after the conjugate without toxicity and this resulted in 
significant tumour growth delays of the human colon and ovarian carcinoma 
xenografts (180) (185) (186). Incorporating a glycosylated anti-enzyme antibody into 
the ADEPT system increased tumour-to-plasma ratios and meant that the prodrug 
could be administered safely. A pilot clinical trial of this ADEPT system was 
initiated following its in vivo success (130) (131).     
 
1.5.1.2 Chemical conjugate clinical trials 
 
The first ADEPT clinical trial used the system consisting of 3 components 
administered in the following order: 1) anti-CEA-CPG2 conjugate; 2) SB43gal and 
3) CMDA prodrug (130) (131) (187). The trial demonstrated that this ADEPT system 
could achieve high tumour levels of conjugate whilst levels remained low in healthy 
tissues and blood of patients with advanced metastatic colorectal cancer. Eight (out 
of 17) patients who received the highest prodrug doses showed a good response to 
therapy, 4 patients had partial responses and one had a mixed response (131) (187) 
(188).  Moreover, seven of the eight patients with a life expectancy of less than eight 
weeks, survived more than six months including three who survived 18, 25 and 36 
months (188). Most patients suffered myelosuppression and it was alleged that the 
active drug had leaked into the plasma from the tumour. 
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The same (3-phase) system was subsequently used in a smaller clinical trial (10 
patients) to investigate a lower dose of antibody-enzyme conjugate (134). One patient 
achieved a partial response and most of the other patients had stable disease for 
several months. The tumour-to-blood ratios of enzyme were in excess of 10,000:1 
and the myelosuppression seen in the patients was believed to result from the leak-
back of active drug from the tumours and not from prodrug conversion in the blood. 
It was, therefore, confirmed that the active drug as originally suggested (110) should 
have a very short half-life to avoid toxicity due to the leak-back effect. The active 
drug of CMDA has a half-life of approximately 20-30 minutes in humans (133). All 
patients developed anti-CPG2 antibodies and anti-mouse antibodies (HAMAs) which 
limited repeat therapy treatments.  
 
A new nitrogen mustard prodrug (ZD2767P) was synthesised to address this potential 
toxicity (176) (176) (189). ZD2767P had a shorter half-life than the CMDA drug and 
the active drug was found to be 300 times more potent than the prodrug (133). 
Together with the antibody-enzyme conjugate, the new prodrug generated impressive 
cell kill results in vivo (133). However, in a trial designed to simplify the 3-phase 
system, the use of the clearing antibody was omitted and there was no evidence of 
therapeutic efficacy (135). Without a clearing antibody the conjugate took too long to 
be eliminated from the blood and eventually insufficient conjugate remained in the 
tumour at the time of prodrug administration (135).     
 
1.5.1.3 Recombinant fusion protein  
 
Building on the early work with antibody-CPG2 chemical conjugates, CPG2 was 
tested for use as a fusion protein with an anti-CEA scFv antibody, MFE-23. MFE-23 
is a phage-derived, murine scFv (190). MFE-23 is specific for the N and A1 domains 
of CEA (191) (192) with an affinity of 2.4 nM (193). MFE-23 has been effective in 
radio-immunodetection (73), radio-immunoguided surgery (RIGS) (194) and as a 
fusion protein in ADEPT. It has been fully humanised with 29 mutations, affinity 
matured with 2 mutations and stabilised with 4 mutations. This new humanised 
MFE-23 was named SM3E (92). 
 
Chapter 1 
 
41 
 
The first antibody-enzyme fusion protein construct, MFE23-CPG2 (abbreviated to 
MFECP), was expressed in E.coli as a stable homodimer that exhibited high tumour 
specificity and functional affinity in vitro and in vivo (195). MFECP proved to 
effectively target LS174T CEA
+
 colon carcinoma xenografts in nude mice (136). 
However, the tumour-to-normal tissue ratios for MFECP were found to be 
considerably higher than the tumour-to-plasma ratios. Whilst the tumour-to-liver 
ratio was 371:1, tumour-to-lung 450:1, tumour-to-kidney 521:1 and tumour-to-colon 
1477:1, the tumour-to-plasma ratio was only 19:1 – it’s maximum within 48 hr (136). 
Thus, the study highlighted the need for greater tumour-to-plasma ratios to be 
established. Furthermore, antibody-enzyme production in E. coli was insufficient for 
clinical studies, at 0.7-1.4 mg/L (195).  
 
More favourable tumour-to-plasma ratios were subsequently obtained using the yeast 
(P. pastoris) expression system to generate glycosylated MFECP, that is, with the 
post-translational N-linked (Asn) addition of branched mannose (137). (Further 
explanation of glycosylation of proteins in P. pastoris can be found in Section 1.7). 
The rationale was to clear unbound MFECP from the circulation via mannose 
receptors in the liver, thus mediating rapid clearance and resulting in higher tumour-
to-normal tissue ratios. P. pastoris-expressed MFECP was tested in nude mice and 
shown to clear rapidly from the blood to less than 1/1000 of its original plasma value 
by 6 hr after administration (137) (138) and via the mannose receptors (196). Despite 
the rapid clearance, P. pastoris-expressed MFECP was able to penetrate xenograft 
tumours and co-localize with its cognate antigen (CEA) on the tumour cell surface 
leading to excellent tumour-to-normal tissue ratios within 6 hr after injection. 
Tumour-to-plasma ratios of 1400:1 in the LS174T colon carcinoma xenograft model 
and 339:1 in the SW1222 colon carcinoma xenograft model were obtained (138). A 
single therapy dose of MFECP followed by the bis-iodo-phenol mustard prodrug, 
given to mice with LS174T or SW1222 tumour xenografts, led to significant tumour 
regression; and repeat cycles of therapy led to sustained tumour regressions (138). 
 
1.5.1.4 Fusion protein clinical trial 
    
P. pastoris-expressed MFECP was manufactured to clinical grade and named 
MFECP1 - the first ADEPT antibody-enzyme fusion protein to enter clinical trials 
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(197) (198) (71). In its final genetic construct, a sequence encoding a hexa-histidine 
(His) tag was added to the C-terminal end of the CPG2 gene for column purification 
by Immobilized Metal Affinity Chromatography (IMAC) (197). MFECP1 was tested 
in a dose escalating Phase I/II clinical trial to test the safety and pharmacokinetics in 
patients with advanced metastatic colon cancer (139). Eleven out of 28 patients had 
disease stabilization and one patient had a 10% reduction in the tumour diameter 
(139). DNA interstrand cross-links were detected in the tumour, implying that 
prodrug activation had occurred and the active alkylating drug had been effective at 
the tumour site. However, after a single dose of MFECP1, 36% (11 out of 30) 
patients elicited an immune response to the CPG2 (139). 
 
More recently, a Phase I/II ADEPT study with the fusion protein and BIP prodrug 
was conducted to test the feasibility of repeat treatments in patients with colorectal 
adenocarcinoma (199). A therapeutic response was observed in only one of three 
patients treated successfully with 2 ADEPT cycles. Myelosuppression was the 
principal toxicity and repeat treatments significantly increased the incidence of anti-
CPG2 antibodies.   
 
1.5.2 Current challenges of ADEPT 
 
ADEPT has the potential to be a very potent anti-cancer therapy that combines the 
specificity and selectivity of drug delivery to tumour cells, but there are still major 
challenges to be addressed (200). ADEPT requires a balance of individual 
components (antibody, enzyme, antibody-enzyme, prodrug), each of which present 
their own challenges. Clinical trials with the CPG2 ADEPT systems highlighted 
immunogenicity of the fusion protein (or conjugate) as a limitation. However, before 
this issue can be addressed, the more immediate challenge is to overcome repeat 
treatment cycles for ADEPT to be more effective. This involves exploring the 
following two areas of ADEPT:  
 
1) ADEPT pharmacokinetics - the need to obtain high tumour-to-blood ratios 
prior to prodrug administration, whilst sustaining low or no circulating 
enzyme in the blood for reduced toxicity  
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2) ADEPT pharmacodynamics – the need to understand the DNA damage 
response after a single cycle of ADEPT, and be able to manipulate DNA 
damage repair to improve therapeutic efficacy.  
 
The ways these challenges can be met are discussed further in Sections 1.7 and 1.6.    
 
 
1.6 ADEPT Pharmacokinetics: Clearance mechanisms   
 
Pharmacokinetics is the study of how the body processes the drug after 
administration. Pharmacokinetics can be divided into the study of the following 
areas: absorption, distribution, metabolism and excretion. Within these areas, 
circulatory half-life, volumes of distribution, clearance rates and total bioavailability 
are of particular significance for protein drugs.    
 
Whole antibodies have their own built-in clearing/recycling system via the Fc region. 
IgGs are above the renal threshold and cleared through the cells of the reticulo-
endothelial system (RES), which is regulated through the interaction with various Fc 
receptors. The neonatal Fc receptors (FcRns), expressed on phagocytic cells of the 
RES, protect IgGs from rapid clearance, and thus are critical regulators of the half-
life of antibodies (201). Antibody fragments lack the Fc portion and therefore, 
depending on their size, are eliminated by renal filtration (<50kDa), proteolytic 
cleavage, hepatic uptake or immune complex formation (>50kDa). The same is true 
for most proteins. Antibody fragments lack the Fc domain and do not bind to FcRns, 
thus have substantially shorter half-lives (hrs) than the intact IgG (days). The Fc 
region can be manipulated to alter the clearance (and pharmacokinetic) profile of 
IgGs and antibody fragments for imaging or therapeutic applications. For example, it 
has been shown that introducing mutations into the Fc region at the FcRn binding site 
of anti-CEA scFv-Fc fragments results in variants exhibiting distinct clearance 
patterns in mice (85) (86). This demonstrated that serum half-life can be shortened by 
reducing the Fc-Rn interaction.  
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Cells of the RES also express various types of Fcγ receptors and interactions with 
these could potentially impact antibody clearance (202), such that polymorphism in 
the Fcγ receptors impacted the therapeutic response to rituximab (203) (204). In 
addition, the persistence of therapeutic antibodies in circulation depends, in part, on 
the structure and identity of N-linked oligosaccharides attached to Asn-297 within 
the Fc region. Human IgGs in serum consist of a number of glycoforms differing in 
number and heterogeneity of N-linked sugars on the Fc region. Glycosylation also 
plays a role in the plasma half-life of antibodies via binding to neonatal Fc gamma 
receptors (FcγRn) (205). Glycosylations can influence the half-life, clearance and 
effector function of antibodies, and can be manipulated to enhance efficacy and 
safety, as detailed in Section 1.6.2. 
 
For effective therapy with ADEPT, it is necessary that there is adequate antibody-
enzyme on the tumour and as little antibody-enzyme as possible in non-tumour tissue 
at the time of prodrug administration to minimise off-target toxicity. Without a 
clearing system, high concentrations of the antibody-enzyme can remain in the blood 
for extended periods of time (up to 72 hr (182) before the prodrug can be 
administered safely. This leads to low tumour-to-blood ratios. Strategies to increase 
the rate of clearance of the antibody-enzyme whilst attaining high tumour-to-blood 
ratios have been studied. Clearance strategies have included: the use of high-affinity 
complexing agents such as avidin/streptavidin (206) (207), EDTA (208), 
polyethylene glycol (PEG) (209) and sugars (210) (184); transfusion techniques such 
as plasmapheresis (211); and second antibody systems (212) (213). In the CPG2 
ADEPT system, strategies to accelerate the clearance of the antibody-enzyme 
conjugate or fusion protein have included second antibody systems and/or 
glycosylation. The significance of these two systems is explained in the following 
sections.   
 
1.6.1 Second antibody systems 
 
As mentioned in Section 1.5.1, a galactosylated anti-enzyme antibody was employed 
to inactivate and clear the antibody-enzyme conjugate in the 3-phase CPG2 ADEPT 
system, which greatly reduced residual enzyme in the blood and normal tissues 
without affecting enzyme in the tumour. The use of a second antibody to improve 
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tumour-to-blood ratios and therapeutic efficacy of ADEPT has also been 
demonstrated with the β-glucuronidase (214) (152) and cytosine deaminase (141) 
(142) enzyme systems.  
 
Initially, second antibody systems involved a liposome-entrapped antibody directed 
against anti-tumour antibodies (215). This was later followed by ‘free’ secondary 
antibodies (212), which have proven effective in radioimmunodetection studies (216) 
(217) (213) (218). The pioneering work with the anti-CPG2 enzyme inactivating 
antibody demonstrated effective clearance of the antibody-enzyme conjugate from 
blood, and addition of galactose sugars to the second antibody allowed rapid 
clearance of the conjugates via galactose receptors in the liver (183) (184) (186). 
Studies with the galactosylated anti-CPG2 antibody, SB43gal, showed a decrease in 
radiolabelled conjugate [percentage injected dose per gram (%ID/g)] in the blood, 
while %ID/g in the tumour remained unaltered (180). Rapid clearance of residual 
conjugates in the tumour improved tumour-to-blood ratios and minimised non-
specific uptake by healthy tissues, which would otherwise lead to toxicity (183) (180) 
(184). The mechanism of SB43 inactivation is thought to involve its binding at or 
near the active site or at a distant site of the CPG2 enzyme causing a conformational 
change in the enzyme and loss of its biological activity. SB43gal was also shown to 
inactivate and clear PEG-conjugated antibody-enzyme conjugates in the blood 
without affecting the tumour levels (219).  
 
In studies with the cytosine deaminase (CD) ADEPT system, a non-inactivating anti-
enzyme antibody was incorporated to clear the antibody-CD conjugates from the 
circulation in vivo (141). The anti-CD antibody bound to both free and conjugated 
enzyme, with a minimum loss of enzyme activity. Tumour-to-blood ratios increased 
from 1 to > 38. However, a 50% reduction in conjugate level in the tumour was also 
observed. The same group also reported the use of an anti-idiotype antibody to 
accelerate the clearance of the same conjugate from blood which led to a 30-fold 
reduction in enzyme activity in blood but also a 30% reduction in the tumour (142). 
Other studies have shown anti-idiotype antibodies to accelerate clearance from 
tumour cells (220) (221). 
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Haisma and colleagues (214) developed an antibody against the enzyme β-
glucuronidase. Antibody-enzyme conjugate levels were reduced in the blood of mice 
by 50% within 5 min after administration and it was believed that the antibody 
complexes formed were rapidly removed via the RES. No other pharmacokinetic data 
regarding the effect of the second antibody in other tissues was or has been reported. 
The same group also reported a 3-phase system to test a new glucuronide prodrug 
using the same anti-enzyme antibody (152). The in vivo studies revealed improved 
tumour growth inhibition by 3-fold compared to the prodrug alone; and tumour 
regression in 9 out of 11 compared to 0 out of 12 xenografts, respectively. 
 
1.6.2 Glycosylation 
 
Ong and colleagues (210) found that if antibodies were conjugated with galactose, 
their clearance could be modulated by the use of competitive inhibitors to galactose 
receptors in the liver. In this way, high concentrations of antibody can be maintained 
in the circulation for longer periods of time to obtain high tumour-to-blood ratios 
prior to rapid clearance. The group also mention the liver-receptor inhibition method 
to be advantageous over the second antibody method. For example, clearance of 
circulating antibody is more orderly involving the uptake and degradation at only one 
site, whereas the second antibody would form immune complexes in the circulation 
and interstitial fluid. Immune complexes in the interstitial fluid may persist in the 
tissues for longer and be degraded much less efficiently.   
 
The initial understanding of the role of the in vivo circulatory behaviour of 
glycoproteins can be attributed in part to the discovery of the hepatic 
asialoglycoprotein receptor in the 1970s (222) (223). Galactose-terminating proteins 
are eliminated by specific endocytosis, which is mediated by these asialoglycoprotein 
receptors expressed by the hepatocytes. It is also known that glycoproteins with 
terminating mannose, N-acetylglucosamine (GlcNAc) or fucose residues can also be 
removed from the circulation via the liver by specific mammalian lectin-like 
receptors. For example, the uptake of mannosylated albumins by mannose receptors 
was shown in isolated perfused rat livers (224), hepatic sinusoidal cells (225) and in 
vivo in mice (226). 
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Glycosylation by attachment of galactose to the antibody-CPG2 conjugate was 
studied as another approach to accelerate clearance in ADEPT without the need for a 
secondary antibody (184). However, radiolabelled galactosylated conjugates cleared 
from the blood too rapidly and no localisation in the tumour occurred. Galactose 
receptors in the liver were blocked with various competitive protein binders, e.g. 
asialo-fetuin (AF) or asialo-bovine sub-maxillary gland mucin (a-BSM) (210), to 
inhibit rapid clearance. Studies in mice using the a-BSM receptor blocking protein 
prior to the administration of the radiolabelled galactosylated conjugate was shown to 
inhibit conjugate clearance for up to 10 hrs. As the inhibitor degraded, the conjugate 
was cleared rapidly from the blood and tissues except the tumour. This led to higher 
tumour-to-blood ratios of 45:1 at 24hrs increasing to 100:1 at 72 hr after injection 
(186). This allowed prodrug to be given 24 hr after conjugate injection without 
toxicity. The likelihood of this going to clinical trials was small because of the 
possible immunogenicity of a-BSM and its associated toxicity was unknown. 
 
The development of the genetic fusion protein, MFECP, and its expression in yeast 
allowed for its self-clearance via mannose receptors in the liver (138), which created 
a 2-phase ADEPT system. However, the high tumour-to-blood ratios obtained with 
the secondary antibody system were never achieved with MFECP, because it cleared 
from the circulation too quickly as a result of the glycosylation. One of the objectives 
in this thesis is to remove these glycosylations and generate a non-glycosylated 
fusion protein. Glycosylation by yeast P. pastoris is explained in more detail below.  
 
1.6.2.1 Protein glycosylation by yeast P. pastoris 
 
Protein glycosylation is an essential post-translational modification in eukaryotic 
cells. Glycosylation can play an important role in determining the function, 
pharmacokinetics, pharmacodynamics, stability and immunogenicity of antibodies 
and protein drugs (205) (227) (228). Protein glycosylation can be manipulated to 
modify various properties of a protein including: physical properties (stability, 
increased solubility, resistance to proteolysis or denaturation); folding (prevents 
aggregation); activity (altered protein recognition, increased/decreased 
multimerisation); and targeting (intracellular/extracellular, altered clearance) (229).  
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In yeast, secretory proteins are commonly mannosylated by protein 
mannosyltransferases (pmts) in the endoplasmic reticulum (ER), and subsequently 
glycosylated by several glycosyltransferases in the Golgi apparatus to form 
glycoproteins with diverse N and O-glycan structures (230). The type of 
glycosylation (N- or O-linked), site occupancy, and the site of glycosylation can vary 
from glycoprotein to glycoprotein, in addition, the actual oligosaccharide structures 
(branching or linkages) can differ, even on the same site. The structural variation 
arises because glycosylation is a process that is not driven by a template, thus making 
full characterisation of protein glycosylations a challenge. The glycosylation pattern 
at a given site depends on many factors, including cell-specific and growth-
dependent availability of glycosyltransferases and exo-glycosidases found in the 
Golgi bodies and ER. In yeast, the enzymatic N- and O-linked glycosylations are the 
two most studied glycosylations that affect the bioactivity of a protein.  
 
1.6.2.1.1 N-linked glycosylation 
 
The role of N-glycosylation is usually protein trafficking and secretion of the protein. 
N-glycosylation occurs via the amide nitrogen of asparagine residues in the 
consensus sequence Asn-Xaa-Ser/Thr (where X is any amino acid except proline) 
(231) (232) (233). N-glycans are categorised as high mannose, hybrid, or complex, 
depending on the extent of processing. High-mannose N-glycans contain two core 
GlcNAc residues and 5 to 9 mannose residues, and lack galactose or GlcNAc at the 
distal ends on the branched chains. Such chains are typically found in yeast-
expressed proteins (232). N-glycosylation on MFECP was found to comprise 5 to 13 
sugar units per site (196). In the yeast Saccharomyces cerevisiae, however, the Asn 
residues are hypermannosylated with 50-150 mannose residues making them very 
long chains. In hybrid mannose structures, both substituted GlcNAc residues and 
terminal mannose residues are present in the antennae, whereas complex mannose 
structures have both 1,6- and 1,3-mannose residues substituted with GlcNAc 
moieties.  
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1.6.2.1.2 O-linked glycosylation 
 
The O-glycosylation pathway and glycan structures differ between species/host and 
the type of protein expressed. O-linked glycosylation occurs via the hydroxyl groups 
on serine or threonine residues (predominantly), but no consensus primary amino 
acid sequence exists for O-glycosylation (234) (235). Various types or structural 
motifs of O-glycosylation exist (236). Examples include: addition of N-
acetylgalactosamine (GalNAc) to Ser/Thr of animal proteins especially mucins; 
addition of mannose to Ser/Thr residues of yeast proteins; addition of arabinose to 
hydroxyproline residues and galactose to Ser of plant proteins; addition of galactose 
to hydroxylysine residues of collagen and addition of N-acetylglucosamine (GlcNAc) 
to Ser/Thr residues of cytoplasmic and nuclear proteins. In P. pastoris, the most 
common O-mannosyl glycan structures are α1-2-mannose polymers of 2 or 3, or 
rarely, 4 mannose residues long and arranged in linear chains (237). A common 
feature of O-glycosylated proteins is that the side-chains are often clustered together 
in distinct Ser/Thr-rich regions (238). Such areas are thought to adopt rod-like 
structures important for protein function. In yeast, O-glycosylation is usually 
favoured by the presence of proline, one residue before or 3 residues after the 
glycosylation site and the absence of charged amino acids proximal to Ser/Thr (239). 
The sequence and isomeric linkage of monosaccharides in O-glycans show greater 
variety than in N-glycans. It has been suggested that O-mannosylation precedes and 
potentially controls N-glycosylation of glycoproteins (240).  
 
 
1.7 ADEPT Pharmacodynamics: DNA damage response 
 
Pharmacodynamics is the study of the biochemical and physiological effects of a 
drug on an organism; the mechanisms of drug action and the relationship between 
drug concentration and effect. Knowledge of the mechanisms of therapeutic response 
to ADEPT at the DNA level could help to improve the efficacy of treatment.  
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1.7.1 ADEPT-induced DNA damage 
 
The prodrug used in the CPG2 ADEPT system, ZD2767P (chemically known as 4-
[bis(2-iodoethyl)amino]phenoxycarbonyl-L-glutamic acid or bis-iodophenol-L-
glutamate), is the inactive form of a toxic nitrogen mustard chemotherapeutic drug. 
The chemical structures of the two drug forms are illustrated in Figure 1.5.  
 
 
 
Figure 1.5 Chemical structure of the ZD2767P prodrug and its conversion to the active drug, 
ZD2767D, in the presence of CPG2 enzyme  
(Taken with permission from a presentation by Prof. Kerry Chester). 
 
The ZD2767D active drug is a bifunctional alkylating agent. Alkylating agents have 
the ability to bind covalently to electron-rich bases in DNA, especially the guanine-
rich sequences (241). Nitrogen-7 of guanine is strongly nucleophilic, and is the main 
target for alkylating agents. Most chemotherapeutic agents have two alkylating 
groups, that is, they are bifunctional and capable of producing various DNA strand 
cross-links. These include cross-links formed within the same DNA strand 
(intrastrand), between the two complementary strands of DNA (interstrand) or with a 
reactive group on a protein (DNA-protein). DNA interstrand cross-links (ICLs) are 
generally considered to be cytotoxic lesions (242) and difficult to repair because they 
greatly distort the DNA structure, and thus inhibit DNA replication (243) and 
transcription (244). However, ICLs only constitute a small proportion (5-10% 
induced by alkylating agents) of the total adducts formed (245); the majority being 
monoadducts. ZD2767P/ZD2767D has previously been shown to induce DNA ICLs 
in tumour cells, xenograft tumour tissue and patient tumour biopsies upon treatment 
with ADEPT (242) (246) (139). The mechanism of repair of these ADEPT-induced 
ICLs has not been investigated in detail, but is thought to be similar to other classical 
nitrogen mustard drugs, such as melphalan and chorambucil (242) (247). The 
mechanisms determining the cellular pharmacology of these nitrogen mustards, such 
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as membrane transport, intracellular detoxification (both chemical and enzymatic) 
and DNA damage repair, (248) (249) may be equally the same for ZD2767D.  
 
1.7.2 The DNA damage response (DDR) 
 
The DNA damage response (DDR) constitutes a network of evolutionary conserved 
signalling cascades, which involves sensing DNA damage, followed by amplification 
and transmission of the damage signal to evoke a multitude of effector responses 
(250) (251). These effector responses either promote the survival or death of a cell, 
either by stalling the cell cycle to provide time for repair, or activating cell death 
pathways, respectively (252) (253) (254). 
 
Cell cycle arrest is mediated by specific checkpoints in response to DNA damage. 
The main checkpoints include the G1/S checkpoint (preparation for DNA synthesis), 
intra-S or S checkpoint (DNA replication) and the G2/M checkpoint (preparation for 
cell division). These checkpoints are activated by the DDR transducers: ataxia 
telangiectasia mutated (ATM), which triggers the G1 checkpoint; and ataxia 
telangiectasia and Rad3-related protein (ATR), which triggers the S and G2/M 
checkpoints. ATM and ATR are both members of the phosphatidyl-inositol-3 (PI-3) 
kinase family and their association with checkpoint kinases, Chk1 and Chk2 
(respectively), further amplifies the cell cycle signalling and arrest depending on the 
nature of the DNA damage (255). To some extent there is cross-talk between 
ATM/Chk2 and ATR/Chk1 pathways (256). Cyclins and cyclin-dependent kinases 
(CDKs) are also key regulatory molecules that determine a cell's progress through the 
cell cycle checkpoints (257).  
 
DNA repair is arguably the most important component of the DDR. However, repair 
of DNA damage in cancer cells can reduce the highly potent activity of DNA 
damaging agents by removing lesions before they become toxic - a common 
mechanism for cancer-therapy resistance. Current research investigates and develops 
approaches to overcome therapy resistance, whilst limiting toxicity to healthy cells, 
by exploiting defective or lost signalling genes or controls, such as BRCA1/2 or p53 
deficiency, in cancer cells (258) (259).  
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Repair of genetic lesions is mediated by different pathways and even a combination 
of pathways. These are summarized in Figure 1.6. The choice of repair mechanism is 
largely defined by the type of lesion, but other factors including p53 status and cell 
cycle phase also play a role. Detailed explanations of each of the different repair 
pathways are beyond the scope of this thesis, thus the reader is referred to the 
following reviews: (260) (261) (262) (258). The principal DNA damage repair 
pathways believed to be associated with the response to the CPG2 ADEPT system 
are explained in context in the following sections.  
 
 
Figure 1.6 The principal DNA repair pathways in mammalian cells  
Only key repair proteins are noted. Full term and genes expressing these proteins are listed in the 
Appendix. (Adapted from Lord and Ashworth (250)).   
 
1.7.3 Repair of DNA ICLs 
 
Drug resistance to nitrogen mustards has been associated with increased repair of 
DNA ICLs (263) (264). ICL repair is a well-established pathway in E. coli (265) and 
is thought to be different to that in yeast (266) (267), which is different to that in 
mammalian cells. ICL repair in mammalian cells is complex and is thought to require 
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the co-ordinated activities of different repair pathways, most notably nucleotide 
excision repair (NER), homologous recombination (HR) and translesion bypass 
synthesis (TLS) (268) (269) (270) (271) (272). Other repair pathways have also been 
reported to be involved in ICL repair, including base excision repair (BER) (273) and 
mismatch repair (274). A considerable amount of the knowledge of ICL repair 
mechanisms in mammalian cells has come from studies conducted in cells from 
patients with Fanconi anaemia (FA) - a human cancer-prone disorder that is 
particularly sensitive to ICL-inducing agents (275) (276) (277) (278) (279) (280).  
 
It is believed that ICLs alone do not activate the G1 or G2 cell cycle checkpoint, but 
are tolerated by the cell until a DNA replication fork is encountered (281). ICLs 
cause the replication fork to stall during S phase of the cell cycle, thus allowing 
repair of the damage. However, if the checkpoint proteins for stabilising the fork are 
not activated in time, the replication fork will collapse because of the strong covalent 
bond linking the DNA strands together. If the ICL lesion is recognised as too 
cytotoxic and cannot be repaired, the cell will ultimately undergo apoptosis. The 
proposed model for ICL repair in mammalian cells is illustrated in Figure 1.7. The 
stalled replication fork is recognised and cleaved by a specific NER-related 
endonuclease in the leading-strand template, which makes an initial 3’ incision. The 
incision is thought to be made by an enzyme called XPG, but there have also been 
reports that another enzyme, MUS81-EME1, may be responsible (282) (283) (284) 
(285). This event creates a one-sided double-strand break (DSB) (as shown in Figure 
1.7). A second structure-specific heterodimeric NER-related endonuclease, XPF-
ERCC1, creates a 5’ incision on the other side of the ICL, thus releasing the covalent 
linkage between the DNA strands (286) (287). The importance of XPF-ERCC1 in 
mammalian cells was recognised when mutant cells deficient in this and other NER-
related proteins were sensitive to nitrogen mustard (288) (289) (290). This initial ICL 
repair process is known as the “unhooking” step. The “unhooking” step creates a gap 
in the gene sequence which requires resection by proteins involved in HR repair 
(288) (269) and post-replication TLS (291) (292) (293). The classic model of DSB 
repair by HR (as shown in Figure 1.7) is based on experimental data from 
Saccharomyces cerevisiae (266) (294) and involves exchange of genetic information 
between the undamaged intact duplex and the break-containing duplex in order to 
Chapter 1 
 
54 
 
restart the replication fork (295). DSB repair in the context of ICL repair is described 
in more detail below.   
 
 
 
Figure 1.7 Schematic of ICL repair during S phase in mammalian cells  
(A) When a replication fork approaches an ICL, the replication fork stalls. (B) An initial 3’ incision is 
made in the leading-strand template adjacent to the lesion by a NER-related endonuclease (MUS81-
EME1). This creates a one-sided double-strand break (DSB) (C). (D) A second incision is made by 
XPF-ERCC1 which unhooks the ICL. (E) Translesion synthesis (TLS) provides the missing sequence 
across from the unhooked ICL. (F and G) Removal of the unhooked cross-link and a second excision-
resynthesis event occurs to fill in the single-strand gap. End resection of the DSB generates a 3’-OH-
ending single-stranded tail. (H) This tail invades the template DNA to generate a D-loop. Homologous 
recombination takes place. (I) The replication fork is restored as the 3’ end of the DSB is integrated 
into the homologous duplex. Taken and adapted from Hinz (296) and Niedernhofer et al., (284), 
(HRR: homologous recombination repair). 
 
1.7.4 Repair of ICL-associated DSBs  
  
DSBs are extremely cytotoxic lesions and difficult to repair (297) (298). If mis-
repaired or left unrepaired, this can lead to translocations and other potentially 
carcinogenic abnormalities. DSBs are well-characterised lesions formed upon 
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exposure to ionising radiation, but they are less well-known as an intermediate lesion 
formed during ICL repair (as shown in Figure 1.7). The endogenous formation of 
DSBs is also not unusual. For example, DSBs may form during rearrangement of 
gene segments (VDJ recombination) in meiosis and antibody and T-cell receptor 
development (299); and they may also form as a result of normal metabolic processes 
which generate reactive oxygen species that attack DNA (300).  
 
There are two pathways for DSB repair: the homology-driven HR pathway or the 
non-homology-driven non-homologous end joining (NHEJ) pathway. HR allows for 
replication-dependent error-free repair of ICL-associated DSBs during S or G2 phase 
of the cell cycle (301) (285). HR is not favoured during G0/G1 phase and ICL lesions 
may be by-passed altogether by TLS although this mechanism is less well-known and 
prone to errors (302) (303). In NHEJ the two ends of the DSB are directly joined 
together, requiring little or no sequence homology, and thus prone to error. DSB 
repair by NHEJ is particularly favoured in the G1 phase. NHEJ is thought to not be 
important for mediating ICL repair (304) (305), but recent evidence suggests that 
some proteins from the NHEJ pathway may be involved in repair of DSBs formed 
during ICL repair (306).  
 
1.7.4.1 Gamma-H2AX 
 
In response to ionising radiation, DSBs have been shown to rapidly induce the 
phosphorylation of the histone variant, H2AX (on Ser139 in mammalian cells) (307) 
(308). H2AX is a member of the histone H2A family, which constitutes one of the 5 
types of histones that package and organise eukaryotic DNA into chromatin. It has 
been reported that phosphorylated H2AX, γ-H2AX (309), accumulates at sites of 
DSBs to form discrete nuclear foci (310) (or ionising radiation induced foci (308)). 
These foci are thought to contain a collection of DNA damage signalling and repair 
proteins required for DSB repair (307) (311) (312) (313).  
 
γ-H2AX is a key component of the DDR network and is widely used as a highly 
sensitive, prognostic marker of DNA damage, namely DSBs formed in response to 
ionising radiation (314) (315) (316) (317) (318). H2AX phosphorylation in response 
to ICL agents is considered to reflect the presence of ICL-associated DSBs. 
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However, it has been suggested that this may not be true for all ICL-inducing agents, 
as some γH2AX foci may form independently of readily detectable ICL-associated 
DSBs (319) (284) (320) (321). Nitrogen mustard has been shown to rapidly induce 
ICL-associated DNA DSBs in dividing human and Chinese hamster ovary (CHO) 
cells, but the same was not true after treatment with cisplatin (288) (322) (320) (323). 
Thus, suggesting that γH2AX may represent a DNA damage response to ICL-
inducing agents rather than a prognostic biomarker. 
 
1.7.4.2 RAD51 
 
One the repair proteins recruited by γ-H2AX is RAD51. RAD51 is a key protein 
involved in HR-mediated repair of DSBs. DSBs are first processed by exonucleases 
to generate protruding ssDNA tails in a process called resection (324). A single-
stranded DNA-binding heterotrimeric complex, known as replication protein A 
(RPA), then binds to the exposed ssDNA. The bound RPA serves to protect the DNA 
from degradation by nucleases and formation of secondary structures. RPA is then 
removed from DNA to allow binding of RAD51, forming a helical nucleoprotein 
filament (325) (326). The RAD51 filament carries out the search for homologous 
dsDNA in a process known as strand invasion and this promotes the exchange of 
genetic information (327) - the fundamental step of HR. Following strand invasion 
by RAD51, DSBs may be resolved via a number of HR sub-pathways, including 
break-induced repair, double Holliday Junction, synthesis-dependent strand 
annealing. These models of HR repair are beyond the scope of this Chapter and are 
described in detail in the following reviews by Li et al. (302) and Hinz et al. (296).    
 
The presence of RAD51 in S-phase has been linked to repair of stalled or arrested 
replication forks (328). Indeed, the role of RAD51 has previously been observed in 
experiments investigating ICL repair in cross-linked plasmids (329) (330). Single-
stranded DNA bound by RPA at stalled replication forks recruits ATR and other 
ATR signalling components to the sites of replication stress (331). Other factors 
recruited that are critical for RAD51 activity and DSB repair include BRCA1 and 
BRCA2 (307) (332). This accumulation of factors centred on RAD51 forms discrete 
nuclear foci (333) (334) and this formation is thought to be controlled by cyclin-
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dependent kinases and checkpoint kinases (335) (332). RAD51 foci formation has 
been used as a functional assay to indicate HR repair or even it’s deficiency (336) 
(337) (338). 
 
 
1.8 Thesis Aims 
 
The aim of this thesis was to explore a means to address the sub-optimal 
pharmacokinetics and pharmacodynamics of ADEPT.  
 
For pharmacokinetics, it was hypothesised that mutation of P pastoris-produced 
MFECP could lead to non-mannosylated protein with potential for longer circulatory 
times. The aim was to test this hypothesis by systematic informatics-based mutation 
of potential glycosylation sites and testing of the newly generated MFECP variants in 
vitro and in vivo.   
 
For pharmacodynamics, it was hypothesised that interfering with the DNA damage 
response would lead to impairment of drug resistance. The aim was to discover 
potential targets for intervention by study of the DNA repair response to ADEPT.  
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2 Materials and Methods 
 
2.1 Materials 
 
All chemicals were purchased from Sigma (Poole, UK) unless otherwise stated. 
 
2.1.1 Molecular Biology Reagents 
 
2.1.1.1 Primers and enzymes 
  
Rationally designed oligonucleotide primers were ordered from Integrated DNA 
Technologies (Glasgow, Scotland). Each vial was reconstituted to a working dilution 
of 100 µM in double distilled water. The restriction enzymes, EcoRI, NotI, PmeI, 
PstI, XbaI and XhoI were obtained from New England Biolabs (Hitchin, 
Hertfordshire, UK) with their respective buffers for optimal use (see Table 2.4). T4 
DNA Ligase was also purchased from New England Biolabs (Hitchin, Hertfordshire, 
UK). 
  
Table 2.1 Primers  
Primer Sequence 
AOX1 5’ 5’ GACTGGTTCCAATTGACAAGC 3’ 
AOX1 3’ 5’ GCAAATGGCATTCTGACATCC 3’ 
Rev_MFE_NOT 5’ AATATTTATAGCGGCCGCTTTCAGCTCCAGCTTGGTGC 3’ 
MFE_FW_seq1 5' GTACTACTTTGACTACTGG 3' 
MFE_FW_seq2 5' GAATGGAGGCTGAAGATGCTGC 3' 
MFE_FW_seq3 5' TCGCGGTCACGCGAAGCAAG 3' 
CP_Rev_seq1 5' GTGTCCATGTGCGACATCAGC 3' 
CPMOL_Rev1 5’ TAATTATCTAGATTATTAGTGGTGGTGATGATGGTGCTTACCAGC 3’ 
CPMOL_FW1 
5’ ATTAATCTCGAGAAAAGAATGGCGGCCGCTGACAACGTTTTGTTCCA 
GGCTGC 3’ 
GAPDH 5’ 5’ ACCACAGTCCATGCCATCAC 3’ 
GAPDH 3’ 5’ TCCACCCTGTTGCTGTA 3’ 
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2.1.1.2 Plasmids 
  
All CPG2 and MFECP constructs generated in this thesis were cloned into the yeast 
expression vector, pPICZαB (Invitrogen, Paisley, UK) unless otherwise stated. 
Mutated CPG2 constructs were based on the CPG2-3Q or mCPG2_3Q sequences, as 
described in Table 2.2 CPG2 template sequencesThe P. pastoris CPG2_3Q sequence is 
shown in Figure 2.1. Bacterial CPG2, kindly provided by Mologic Ltd (Bedford, 
UK), was used as a non-glycosylated comparison for the mutated CPG2 constructs.  
 
Table 2.2 CPG2 template sequences  
Construct 
name 
Mutations in the CPG2 
gene sequence 
Cloning 
CPG2_3Q 3x Asn mutated to Gln 
3_Q mutations were previously constructed by 
site-directed mutagenesis by Dr Berend Tolner 
mCPG2_3Q 3x Asn mutated to Gln 
codon-optimised CPG2 sequence ordered from 
GenScript with permission from Mologic Ltd 
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                                        ATGagattt...... 
                                        M  R  F...... 
.........agagaggctgaagctgccgctcagaagcgcgacaacgtgctgttccag 
.........R  E  A  E  A  A  A  Q  K  R  D  N  V  L  F  Q 
gcagctaccgacgagcagccggccgtgatcaagacgctggagaagctggtcaacatcgag 
A  A  T  D  E  Q  P  A  V  I  K  T  L  E  K  L  V  N  I  E 
accggcaccggtgacgccgagggcatcgccgctgcgggcaacttcctcgaggccgagctc 
T  G  T  G  D  A  E  G  I  A  A  A  G  N  F  L  E  A  E  L 
aagaacctcggcttcacggtcacgcgaagcaagtcggccggcctggtggtgggcgacaac 
K  N  L  G  F  T  V  T  R  S  K  S  A  G  L  V  V  G  D  N 
atcgtgggcaagatcaagggccgcggcggcaagaacctgctgctgatgtcgcacatggac 
I  V  G  K  I  K  G  R  G  G  K  N  L  L  L  M  S  H  M  D 
accgtctacctcaagggcattctcgcgaaggccccgttccgcgtcgaaggcgacaaggcc 
T  V  Y  L  K  G  I  L  A  K  A  P  F  R  V  E  G  D  K  A 
tacggcccgggcatcgccgacgacaagggcggcaacgcggtcatcctgcacacgctcaag 
Y  G  P  G  I  A  D  D  K  G  G  N  A  V  I  L  H  T  L  K 
ctgctgaaggaatacggcgtgcgcgactacggcaccatcaccgtgctgttcaacaccgac 
L  L  K  E  Y  G  V  R  D  Y  G  T  I  T  V  L  F  N  T  D 
gaggaaaagggttccttcggctcgcgcgacctgatccaggaagaagccaagctggccgac 
E  E  K  G  S  F  G  S  R  D  L  I  Q  E  E  A  K  L  A  D 
tacgtgctctccttcgagcccaccagcgcaggcgacgaaaaactctcgctgggcacctcg 
Y  V  L  S  F  E  P  T  S  A  G  D  E  K  L  S  L  G  T  S 
ggcatcgcctacgtgcaggtccaaatcaccggcaaggcctcgcatgccggcgccgcgccc 
G  I  A  Y  V  Q  V  Q  I  T  G  K  A  S  H  A  G  A  A  P 
gagctgggcgtgaacgcgctggtcgaggcttccgacctcgtgctgcgcacgatgaacatc 
E  L  G  V  N  A  L  V  E  A  S  D  L  V  L  R  T  M  N  I 
gacgacaaggcgaagaacctgcgcttccaatggaccatcgccaaggccggccaagtctcc 
D  D  K  A  K  N  L  R  F  Q  W  T  I  A  K  A  G  Q  V  S 
aacatcatccccgccagcgccacgctgaacgccgacgtgcgctacgcgcgcaacgaggac 
N  I  I  P  A  S  A  T  L  N  A  D  V  R  Y  A  R  N  E  D 
ttcgacgccgccatgaagacgctggaagagcgcgcgcagcagaagaagctgcccgaggcc 
F  D  A  A  M  K  T  L  E  E  R  A  Q  Q  K  K  L  P  E  A 
gacgtgaaggtgatcgtcacgcgcggtcgcccggccttcaatgccggcgaaggcggcaag 
D  V  K  V  I  V  T  R  G  R  P  A  F  N  A  G  E  G  G  K 
aagctggtcgacaaggcggtggcctactacaaggaagccggcggcacgctgggcgtggaa 
K  L  V  D  K  A  V  A  Y  Y  K  E  A  G  G  T  L  G  V  E 
gagcgcaccggcggcggcaccgacgcggcctacgccgcgctctcaggcaagccagtgatc 
E  R  T  G  G  G  T  D  A  A  Y  A  A  L  S  G  K  P  V  I 
gagagcctgggcctgccgggcttcggctaccacagcgacaaggccgagtacgtggacatc 
E  S  L  G  L  P  G  F  G  Y  H  S  D  K  A  E  Y  V  D  I 
agcgcgattccgcgccgcctgtacatggctgcgcgcctgatcatggatctgggcgccggc 
S  A  I  P  R  R  L  Y  M  A  A  R  L  I  M  D  L  G  A  G 
             aagcatcaccatcatcaccattaataa 
              K  H  H  H  H  H  H  -  -   
 
 
Figure 2.1 CPG2_3Q DNA and protein sequence  
The pPICzαB plasmid α-factor signal sequence is shown in part in bold, and is 225bp long. The 
mature CPG2 protein is represented after the dashed vertical line. The black arrow represents the 
Kex2 signal cleavage site; the blue arrows represent the Ste 13 signal cleavage sites. The internal 
Kex2 cleavage site is highlighted in green. Asn-to-Gln (x3) mutations are highlighted in blue. (The 
sequence originates from the CPG2 wild-type Genbank entry: AAA62842.1 - bacterial CPG2 
Variovorax paradoxus).  
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Commercial kits were used to clean-up and purify genomic DNA. These are stated in 
Table 2.3. 
 
Table 2.3 Commercial kits for purifying genomic DNA 
Name of Kit Company  
Wizard
®
 Minipreps DNA purification system Promega, Madison, WI, USA 
Plasmid Midi Kit Qiagen, Crawley, UK 
Wizard
®
 SV Gel and PCR Clean-Up system Promega, Madison, WI, USA 
 
2.1.1.3 Electrophoresis consumables 
 
For agarose gel electrophoresis, DNA Molecular Weight Markers II (Hind III-
digested λ DNA) and IX (Hae III-digested φx174 DNA) were obtained from Roche 
Diagnostics Ltd (Burgess Hill, East Sussex, UK). A 1 kbp DNA from Promega 
(Madison, WI, USA) was also used in this thesis. The sizes of the standards for each 
ladder are shown in Figure 2.2. 
 
 
       
 
Figure 2.2 DNA ladders used in agarose gel electrophoresis  
The separation and sizes of the DNA standards for Hind III and Hae III are shown on a 1% agarose 
gel (A); and the Promega ladder is shown on a 0.7 % gel (B). (Images take from catalogues Roche 
Diagnostics and Promega, respectively).  
 
 
 λ Hind III
23,130
9,416
567
2,027
2,322
6,557
4,361
 φ 174 Hae III
72
1,353
1,078
872
603
310
281/271
234
194
118
Promega 1 kbp 
DNA ladder 
A B 
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Pre-cast Tris-Glycine SDS-PAGE gels (10 or 17 well, 4-20% polyacrylamide, 1 mm 
thick) and protein molecular weight marker (See Blue Plus2) were obtained from 
Invitrogen Ltd (Paisley, UK). The Pro™Sieve™ QuadColor™ protein molecular 
weight marker from Lonza (Basel, Switzerland) is also mentioned in this thesis. 
Figure 2.3 shows the molecular weight markers. Polyvinylidene difluoride (PVDF) 
membrane and chromatography Whatman filter paper was purchased from BioRad 
(Herts., UK).  
 
                                            
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3 Pre-stained protein molecular weight markers used with precast Tris-Gly gels for 
SDS-PAGE  
(A) SeeBlue Plus2 and (B) Pro™Sieve™ QuadColor™. (Taken from the Invitrogen and Lonza 
catalogues, respectively). 
 
For determining the molecular weights of proteins run on the FPLC, molecular 
weight markers were run routinely on the Superdex 75 and 200 columns using the 
Gel Filtration Standard kit (Bio-Rad, UK). Figure 2.4 shows the molecular weight 
markers run on both columns.   
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Figure 2.4 Gel filtration molecular weight markers  
A) Superdex 75, 500 ml column.  Flow rate 4 ml/min. B) Superdex 200, 125 ml column. Flow rate 1.5 
ml/min. 
 
A 
B 
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Table 2.4 Buffers for DNA manipulation 
 
 
Table 2.5 Buffers for protein manipulation 
Buffer Formula 
2 x Reducing SDS-PAGE 
loading buffer 
4% SDS, 10% β-mercaptoethanol, 20% glycerol, 0.02% 
bromophenol blue, 100mM Tris 
1 x SDS-PAGE running 
buffer 
25mM Tris base; 192mM glycine; 0.1%( w/v) SDS 
1 x Transfer buffer 25mM Tris base; 192mM glycine; 20% (v/v) methanol 
Coomassie gel stain 
 
0.1% (w/v) Coomassie Blue R-250; 45% (v/v) methanol; 10% 
(v/v) glacial acetic acid 
Coomassie gel destain 30% (v/v) methanol; 10% (v/v) glacial acetic acid 
 
 
 
 
Buffer Formula 
Tris-borate (TBE) buffer stock 
(10X) 
100mM Tris, 10mM Boric acid, 1.25mM EDTA 
Tris-acetate (TAE) buffer 
stock (50X) 
40mM Tris, 1mM EDTA, 20mM glacial acetic acid, pH 8.0 
Loading Dye blue/orange 6x 
(Promega, Madison, WI, USA) 
0.03% Bromophenol Blue, 0.03% Xylene Cyanol FF, 0.4% 
orange G, 15% Ficoll® 400, 10mM Tris-HCl (pH 7.5), 50mM 
EDTA (pH 8.00) 
PCR ‘master’ mix 
(GeneAmp® PCR reagent kit, 
Applied Biosystems) 
1000µl 10 x PCR buffer, 250µl each 2.5mM dATP, dCTP, 
dGTP, dTTP, 6.5ml sterile dH20 
1 x NEBuffer 1 (NEBiolabs 
Ltd, UK) 
10mM Bis Tris Propane-HCl, 10mM MgCl2, 1mM 
dithiothreitol (pH 7.0 @ 25ºC) 
1 x NEBuffer 2(NEBiolabs Ltd, 
UK) 
10mM Tris-HCl, 10mM MgCl2, 50mM NaCl, 1mM 
dithiothreitol (pH 7.9 @ 25ºC) 
1 x NEBuffer 3 (NEBiolabs 
Ltd, UK) 
50mM Tris-HCl, 10mM MgCl2, 100mM NaCl, 1mM 
dithiothreitol (pH 7.9 @ 25ºC) 
1 x NEBuffer 4 (NEBiolabs 
Ltd, UK) 
20mM Tris-acetate, 10mM magnesium acetate, 50mM 
potassium acetate, 1mM dithiothreitol (pH 7.9 @ 25ºC) 
1 x T4 DNA Ligase buffer 
(NEBiolabs Ltd, UK) 
50mM Tris-HCl (pH 7.5), 10mM MgCl2, 10mM dithiothreitol, 
1mM ATP 
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2.1.1.4 Microbial strains 
 
Bacterial (E.coli) TOP10 and the wild-type yeast (P. pastoris) X-33 cells were 
obtained from Invitrogen (Paisley, UK). Genotypes are given in Table 2.6. 
 
Table 2.6 Microbial genotypes 
Strain Genotype 
Transformation vector 
and use 
TOP10F’ 
F’ {proAB, lacI
q
, lacZM15, Tn10, (Tet
R
)} mcrA, 
(mrr-hsdRMS-mcrBC), Φ80lacZM15, lacX74, 
deoR, recA1, λ
- 
araD139, (ara-leu)7697, galU, 
galK, rpsL(Str
R
), endA1, nupG 
pPICZαB-based vectors 
used for DNA propagation 
X-33 
Wild-type 
Mut
+
 (phenotype) 
pPICZαB-based vectors 
used for protein expression 
in Pichia pastoris 
 
 
 
Table 2.7 Culture media for bacterial expression 
Media Formula 
2TY broth 
16g tryptone, 10g yeast extract, 5g NaCl. Complete to 1L with dH20. 
Autoclave. 
For 2 X TY Agar, add 15g/L agar prior to autoclaving. 
Luria Bertani Broth 
(LB ) 
 
10g tryptone, 5g yeast extract, 10g NaCl. Complete to 1L with dH20. 
Autoclave. 
For LB Agar, add 15g/L agar prior to autoclaving. 
Low salt LB 
 
10g tryptone, 5g yeast extract, 5g NaCl. Complete to 1L with dH20. 
Autoclave. 
For Low salt LB Agar, add 15g/L agar prior to autoclaving. 
 
 
 
 
 
 
 
 
Chapter 2 
67 
 
Table 2.8 Culture media and solutions for yeast expression 
Media Formula 
Yeast Extract Peptone Dextrose 
Medium (YPD) 
(2% peptone; 1% yeast extract; 2% 
dextrose) 
Dissolve 10g yeast extract and 20g peptone in 
900ml dH20. Autoclave. When cool add 100ml 
20% glucose solution. Store at 4°C. 
For YPD agar add 20g/L agar prior to autoclaving. 
YPD with sorbitol (YPDS) 
(2 % peptone; 1% yeast extract; 2% 
dextrose; 1M sorbitol) 
Dissolve 10g yeast extract, 20g peptone and 
182.2g sorbitol in 900ml dH20. Autoclave. When 
cool add 100ml 20% glucose solution. Store at 
4°C. 
For YPDS agar add 20g/L agar prior to 
autoclaving. 
Buffered Glycerol-complex Medium 
(BMGY) (1% yeast extract; 2% 
peptone; 100mM potassium phosphate 
pH 6.0; 1.34% YNB; 4 x 10
-5
% biotin; 
2% caseamino acids; 1% glycerol) 
Dissolve 10g yeast extract and 20g peptone in 
600ml dH20. Autoclave. When cool add 100ml 1M 
potassium phosphate buffer, pH 6.0, 100ml 13.4% 
YNB, 600μl 0.02% biotin, 100ml 20% caseamino 
acids, 100ml 10% glycerol. Store at 4°C. 
Buffered Methanol-complex Medium 
(BMMY) (1% yeast extract; 2% 
peptone; 100mM potassium phosphate, 
pH 6.0; 1.34% YNB; 4 x 10
-5
% biotin; 
2% caseamino acids;  0.5% methanol) 
Dissolve 10g yeast extract and 20g peptone in 
600ml dH20. Autoclave. When cool add 100ml 1M 
potassium phosphate buffer, pH 6.0, 100ml 13.4% 
YNB, 600μl 0.02% biotin, 100ml 20% caseamino 
acids, 100ml 5% methanol. Store at 4°C. 
 
Colonies containing gene of interest were selected against ampicillin (Roche 
Diagnostics, Burgess Hill, UK) or Zeocin™, both of which were purchased from 
Invitrogen (Paisley, UK).  
 
2.1.1.5 RT-PCR  
 
The following kits were employed for determining gene expression levels by RT-
PCR using the RT
2
 Profiler™ PCR array system (SABiosciences, West Sussex, UK), 
Table 2.9. The DNA Damage Signalling Pathway PCR array plate was also 
purchased from SABiosciences (PAHS-029A, human-specific). The 96-well plate 
contained primers for 84 pre-selected DNA damage signalling genes and the 
remainder were for regulatory control genes. A list of the genes can be found in the 
Appendix 1.  
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Table 2.9 Commercial kits used for RT-PCR prep  
Name of Kit Use  
RNeasy mini kit (Qiagen, Crawley, UK) 
Purification of total RNA from mammalian 
cells 
First strand cDNA synthesis kit 
(SABiosciences, West Sussex, UK) 
Synthesis of cDNA using reverse 
transcriptase 
RT
2
 qPCR master mix (SABiosciences, 
West Sussex, UK) 
Initiating PCR reaction 
 
 
2.1.2 Detection of proteins 
 
The following details a list of antibodies and various buffers for detecting proteins 
using various methods. 
 
2.1.2.1 Antibodies 
 
Antibodies used for Western blotting and immunofluorescence, are provided in Table 
2.10. 
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Table 2.10  Antibodies for protein detection  
(HRP, Hydrogen peroxidase) 
Antibody Manufacturer Clone 
Working 
dilution 
Mouse anti-tetra His Qiagen, Crawley, UK Monoclonal 1:1000 
Rabbit anti-MFE-23 (serum) In-house Polyclonal 1:1000 
Rabbit anti-CPG2 (serum) In-house (183) 
SB43gal, 
monoclonal 
1:1000 
Mouse anti-CPG2 (serum) 
Mologic Ltd, 
Bedfordshire, UK 
Polyclonal 1:1000 
Biotinylated mouse anti-γ-H2AX (Ser 
139) 
Millipore, Watford, UK 
JBW301, 
Monoclonal 
1:1000 
Mouse anti-γ-H2AX (Ser 139) Millipore, Watford, UK 
JBW301, 
Monoclonal 
1:1000 
Rabbit anti-RAD51 
Santa Cruz Biotech, 
Texas, USA 
H-92, 
Polyclonal 
1:100 
Mouse anti-PCNA 
Dako, Glostrup, 
Denmark 
PC10, 
Monoclonal 
1:1500 
Mouse anti-NBS1 BD, NJ, USA 
34/NBS1, 
Monoclonal 
1:1000 
Rabbit anti-phospho-CHK1 (Ser296) 
Cell Signalling Tech, 
Danvers, MA, USA 
Polyclonal 1:1000 
Rabbit anti-phospho-CHK2 (Thr68) 
Cell Signalling Tech, 
Danvers, MA, USA 
Polyclonal 1:1000 
Mouse anti-α-tubulin Sigma Monoclonal 1:5000 
Goat anti-actin 
Santa Cruz Biotech, 
Texas, USA 
I-19, 
Polyclonal 
1:1000 
Sheep anti-mouse-HRP 
GE Healthcare, 
Buckinghamshire, UK 
 1:1000 
Goat anti-rabbit-Alexa Fluor® 488 Invitrogen, Paisley, UK  1:1000 
Rabbit anti-goat-HRP Sigma  1:6000 
Goat anti-mouse- Alexa Fluor® 488 Invitrogen, Paisley, UK  1:2000 
Goat anti-rabbit-HRP Sigma  1:3000 
 
Non-antibody detecting agents included: biotinylated Con A (1mg/ml), streptavidin-
HRP (Invitrogen) (1/1000 dilution) and streptavidin-Alexa Fluor® 488 (Invitrogen) 
(1 in 1000 dilution). 
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2.1.2.2 Buffers 
 
Table 2.11 details a list of the buffers used with antibodies for protein detection. 
 
Table 2.11 Buffers for protein detection using antibodies  
(Marvel skimmed milk powder; 10x TBS: 0.15 M Tris-HCl, 1.37 M NaCl, pH 7.6). 
Buffer Formula 
Western blot 
Wash PBS 
Blocking  5% Marvel/PBS 
Western blot, detection of phosphorylated proteins 
Wash 1x TBS/0.1% Tween-20 (TBST)  
Blocking  5% BSA/TBST 
Immunofluorescence 
Permeabilisation  0.5% Triton-X-100/PBS 
Blocking  0.2% Marvel/0.1% Triton-X-100/PBS 
Wash buffer 0.1% Triton-X-100/PBS 
 
For reblotting PVDF membranes, primary and secondary antibodies were removed 
using a stripping buffer containing the following: 10% SDS, 0.5M Tris HCl pH 6.8 
and 0.8% β-mercaptoethanol. 
 
2.1.3 Protein deglycosylation  
 
2.1.3.1 Deglycosylating enzymes 
 
The enzymes used for removing the N-glycosylations on proteins included: 
endoglycosidase Hf (EndoH, EC 3.2.1.96) (100 U/ml or 1 x10
6
 NEB U/ml) or 
peptide-N-glycosidase F (PNGase F, EC 3.5.1.52) (7.7 U/ml or 5 x10
5
 NEB U/ml). 
Enzymes purchased from New England Biolabs Ltd (Hitchin, Hertfordshire, UK) 
were each stored in enzyme buffer (20 mM Tris/HCl, 50 mM NaCl, 5 mM EDTA, 
pH 7.5).  
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2.1.3.2 Chromatography buffers 
 
The glycosylation status of proteins were analysed by affinity chromatography using 
the HiTrap Con A 4B 1 ml column (GE Healthcare, Amersham, UK) and the buffers 
were made up accordingly, as listed in Table 2.12. 
 
Table 2.12 HiTrap Con A 4B column buffers 
Buffer Formula  
Binding Buffer 20mM Tris-HCl, 0.5M NaCl, 1mM MnCl2, 
1mM CaCl2, pH7.4 
Elution Buffer 0.25M methyl-α-D-mannopyranoside, 20mM 
Tris-HCl, 0.5M NaCl, pH7.4 
Equilibration Buffer 20mM Tris-HCl, 0.5M NaCl, pH 8.5 
 
 
2.1.4 Modified single-cell gel electrophoresis (comet) assay 
   
The comet assay buffers are listed in Table 2.13. All buffers were kept at 4ºC prior to 
usage.   
 
Table 2.13 Comet assay buffers 
Buffer Formula  
Lysis buffer 
100mM disodium EDTA , 2.5M NaCl, 10mM, 
Tris-HCl, 1% Triton-X-100, pH 10.5 
Alkali buffer  
50mM NaOH, 1mM Disodium EDTA, pH 
12.5 
Neutralisation buffer  0.5M Tris-HCl, pH 7.5 
 
 
2.1.5 Cell culture 
 
The human colorectal carcinoma SW1222 CEA
+ve
 cell line was obtained from within 
the Department and A375M CEA
-ve
 amelanotic human melanoma cell line was 
obtained from ATCC. Both cell types are adherent. Cell lines were passaged under 
sterile conditions in microbiological Class II safety cabinets and cultured into vented 
flasks in medium containing the necessary nutrients for optimal growth (see Table 
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2.14). Cells were incubated at 37ºC humidified with 5% CO2. Cells were grown in 
the exponential phase prior to conducting in vitro assays. All cells were tested for 
mycoplasma on a regular basis. For long term storage, aliquots of cells (1 
x10
6
cells/ml) were stored in freezing medium (see Table 2.14) in liquid nitrogen.  
 
Table 2.14  Tissue culture and freezing media  
Cell culture media was purchased from PAA (PAA, Pasching, Austria), unless otherwise stated.    
Media Formula 
Dulbecco’S Modified Eagle Medium (DMEM) 
culture medium for SW1222 and A375M cell 
lines 
DMEM containing  10% foetal calf serum 
(Bio Sera Ltd, East Sussex, UK), 2mM L-
glutamine, 1% Non-essential amino acids, 
100U/ml penicillin and 100μg/ml 
streptomycin 
Freezing medium 
90% foetal calf serum, 10% dimethyl  
sulphoxide (DMSO) 
 
 
2.1.5.1 ADEPT reagents   
 
MFECP was supplied as a clinical grade sample (MFECP1, Batch B0131, 0.63 
mg/ml in PBS, 78.1 U/ml) previously produced and purified for the Phase I clinical 
trial (139) (198) (197). This particular batch was used consistently for all in vitro and 
in vivo experiments, unless otherwise stated.  
 
The bis-iodophenol prodrug (ZD27267P) was generously supplied by AstraZeneca 
(UK), supplied as a salt to be dissolved in DMSO. Stock concentration was 100 mM. 
A detailed account of its synthesis was published by Springer et al. (176).  
 
2.1.5.2 Cell cycle inhibitors 
 
Checkpoint kinase 1 (Chk1) inhibitors were purchased from Sigma: UCN-01 (2 mM 
stock) and PF477736 (2.38 mM stock) were stored as aliquots at -80°C.  
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2.1.6 In vivo studies  
 
Therapy studies were conducted in nude mice bearing SW1222 human colorectal 
carcinoma xenografts. SW1222 cells were cultured in vitro and implanted (5 x10
6
 
cells per 100 µl serum-free media) subcutaneously into the flanks of 2-3 month old 
female nude mice, each weighing 20-25 g. Treatment occurred when the tumours had 
grown to ~ 2.5-3.5 mm in diameter. Clearance studies were conducted in 2-3 month 
old female, balb/c hairy mice, each weighing 20-25 g.   
 
All animal handling was undertaken by Mr Matthew Robson (Dept. of Oncology, 
UCL Cancer Institute, London) under the project licence held by Professor Barbara 
Pedley (Dept. of Oncology, UCL Cancer Institute, London). All animal experiments 
complied with the UK Coordinating Committee on Cancer Research Guidelines for 
the Welfare of Animals in Experimental Neoplasia, UK Home Office and UCL 
regulations. 
 
 
2.2 Methods 
 
2.2.1 Cloning and propagation of DNA    
 
2.2.1.1 Plasmids 
 
The DNA sequences for the CPG2 mutated constructs, CPG2_3Q_12A (1236bp) and 
mCPG2_3Q (1224bp), were ordered from GenScript Corporation (New Jersey, USA) 
in a bacterial pUC57 plasmid. These sequences were modelled on the CPG2_3Q 
sequence previously mutated within the Department. The CPG2_3Q_12A sequence 
was flanked by the restriction enzyme sites EcoRI and Xba I for genetic 
manipulation into the yeast pPICzαB plasmid (Invitrogen, Paisley, UK). The 
mCPG2-3Q sequence was flanked by XhoI and XbaI for cloning and genetic 
insertion into pPICzαB. Oligonucleotides (145bp each) for cloning into mCPG2_3Q 
were also ordered from GenScript Corporation cloned into a pUC57 plasmid, and 
each gene sequence was flanked by restriction sites XhoI and PstI.  
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Bacterial puc57 plasmid DNA was propagated into bacterial TOP10 cells (see 
Sections 2.2.1.4-2.2.1.6 for more details) prior to being cloned into the pPICZαB 
vector for further genetic manipulation and protein expression.   
 
2.2.1.2 Plasmid digestion 
 
Vector (pPICZαB) and inserts were cut with respective restriction enzymes (as 
mentioned above) using the correct buffers specific for the enzymes for 2hrs at 37°C 
followed by heat inactivation at 65ºC for 10 minutes. Restriction digest mix included 
approximately (vector:insert) 10:5 μg, 5 µl each of restriction enzymes (New 
England Biolabs), 10 µl 10X NEBuffer (New England Biolabs), 10 µl BSA (10X 
BSA; final concentration 100 µg/ml), and made up to a final volume of 100 µl with 
sterile dH2O. 
 
To check the vectors and inserts were cut and digested and to the correct size, the 
samples were run on an agarose gel. 2% (inserts) and 0.8-1% (vectors) agarose gels 
containing 5 µl (10 mg/ml) ethidium bromide were made in TBE buffer and run in a 
Hi-Set mini horizontal electrophoresis unit (Anachem, UK) at 50-60V for 30 
minutes. Samples were mixed with 20% loading dye and molecular weight markers 
(Figure 2.2) were used to determine size. Gels were visualised using a G:BOX Gel 
Doc transilluminator (Syngene, Cambridge, UK). A sample of the uncut vector or 
insert was run alongside the cut samples to distinguish differences in size, confirming 
that the restriction enzymes had cut.  
 
Provided the digested DNA was the correct size, the bands were cut from the gel 
under UV light and put into an Eppendorf tube. The isolated fragments of DNA were 
cleaned using the Wizard® Gel and PCR Clean-Up System (Promega, Madison, WI, 
USA) kit according to manufacturer’s instructions. DNA fragments were purified to 
a final volume of 50 µl in nuclease-free dH2O. DNA was measured in ng/μl at 
260nm on the Nanodrop® ND-1000 UV-VIS spectrophotometer. 
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2.2.1.3 Ligation and clean-up 
 
Ligation reactions were carried out using different molar ratios of vector: insert (1:1, 
3:1 or 1:3). Reactions were carried out at 16ºC overnight using 2 µl T4 DNA Ligase 
(NEBiolabs), 5 µl T4 Ligase buffer (NEBiolabs) and proportionally enough vector 
and insert. A reaction without the insert was also prepared as a control. Distilled 
water was added to give a final volume of 50 µl.  
 
Ligated DNA was extracted from the mix using phenol/chloroform extraction and the 
DNA precipitated. Samples were made up to 100 μl with dH2O and an equal amount 
of phenol was added, samples shaken vigorously and centrifuged for 10 min (14, 000 
x g) at room temperature. The aqueous phase was then carefully transferred to a 
clean tube and an equal volume of phenol:chloroform:isoamyl alcohol (25:24:1 
v/v/v) (saturated with 10 mM Tris, pH 8.0, 1mM EDTA) was added, shaken 
vigorously and centrifuged for 10 min (14, 000 x g) at room temperature. The 
aqueous phase was then carefully transferred to a clean tube and to this 1/10 volume 
of 3 M sodium acetate (pH 6.0), 2.5x volumes of 100% ethanol and 1 μl glycogen 
were added. The reaction mixture was incubated at -80°C for 1hr or -20°C overnight. 
Precipitated DNA was recovered by centrifugation (14, 000 x g) for 10 min at room 
temperature. The pellet was then washed with 70% (v/v) ethanol by centrifugation 
(14, 000 x g) for 10 min and resuspended in 10 μl of dH20. 
 
2.2.1.4 Transformation into competent bacterial cells 
 
Electro-competent TOP10 E.coli cells were thawed on ice. To a 50 μl aliquot of 
cells, 2 μl of the pPICZαB ligation or puc57 plasmid was added and mixed by gentle 
pipetting. (Control samples included vector DNA/cells mixture and cells only). The 
mixture of cells and DNA was transferred to an ice-cold, sterile 0.2 cm disposable 
cuvette (BioRad Laboratories, Hertfordshire, UK) and pulsed once for 4-5 ms in the 
electroporator (BioRad MicroPulser™, Bio-Rad Laboratories Ltd., Hemel 
Hampstead, U.K.). The apparatus was set to 2.5kV, 25μFD, and 200Ω (Ec2 
programme). One millilitre of LB (puc57) or low salt LB (pPICZαB) (see Table 2.7) 
was immediately added to the pulsed cells and the culture was incubated for 1hr at 
37°C. 50, 100 and 200 μl of culture was spread onto LB agar plates containing 100 
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µg/ml ampicillin or low-salt LB agar plates containing 100 μg/ml Zeocin™ and 
incubated at 37°C overnight. 
 
2.2.1.5 Checking for positive clones 
 
The polymerase chain reaction (PCR) was performed to determine whether the 
correct size insert was expressed in bacterial cells. Single colonies were picked with 
an inoculating loop and mixed into 20 μl sterile H2O and labelled for reference. All 
reagents were mixed on ice in the following PCR reaction mixture: 104 μl PCR 
‘mix’ (Applied Biosystems, Life technologies, UK), 16 μl forward primer (AOX1 5’ 
for pPICZαB) and 16 μl reverse primer (AOX1 3’ for pPICZαB), 3.2μl Taq 
polymerase (Applied Biosystems, Life technologies, UK) and 12.8 μl dH2O. 20 μl 
aliquots were added to 0.5 ml Eppendorf tubes and 1 μl of single colonies from the 
reference tubes were mixed well to each of the tubes. PCR was carried out using a 
Biometra Personal Cycler programmed as follows (1 kb per 90 sec): one cycle of 
95°C for 3 min to detach the DNA from the template; 30 cycles of 95ºC for 60 sec, 
60ºC for 60 sec (annealing), 72ºC for 90 sec (elongation); one cycle of 72ºC for 600 
sec and cooled at 4ºC until the samples were required. PCR products were run on 
agarose gel electrophoresis, as described above. 
 
2.2.1.6 Isolation of plasmid DNA  
 
Plasmids were isolated using two systems depending on the amount of DNA 
required. For small-scale DNA purification (10-20 µg) the Wizard Plus SV DNA 
Miniprep Kit (Promega, Southampton, UK) was used, and for larger-scale 
purification the Qiagen Midi Kit (up to 100 μg) was used. For mini-prep cultures, a 
single bacterial colony transformed with plasmid DNA (plate or reference tubes, as 
described above) was used to inoculate 5 ml of the appropriate medium (LB with 100 
μg/ml ampicillin for bacterial vectors, low salt LB with 25 μg/ml Zeocin™ for yeast 
vectors) in a sterile, 20 ml polypropylene tube. The culture was grown overnight at 
37°C in an orbital shaker (Innova 4000 incubator shaker, New Brunswick Scientific) 
at 250 rpm. For midi-prep cultures, 25 ml of fresh medium plus antibiotic was 
inoculated in a sterile, 250 ml conical flask and grown overnight shaking at 37°C.  
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100 ng/μl of purified plasmid was sent for sequencing (UCL Cancer Institute Support 
Services, London, UK) together with 2-5 pmoles/µl of suitable primers, listed in 
Table 2.1. 
 
2.2.2 Expression and purification of proteins from P. pastoris 
 
2.2.2.1 Linearisation of plasmid DNA 
 
pPICZαB plasmids containing DNA insert were linearised for transformation into the 
X-33 yeast genome. 10 µg of plasmid DNA was digested with 2.5 µl Pme I (New 
England Biolabs) for 2 hr at 37°C in the presence of 5 µl 10X NEB buffer 4 (New 
England Biolabs), 5 µl BSA (10X BSA; final concentration 100 µg/ml), and made up 
to 50 µl with sterile dH2O. Reactions were stopped by heat inactivation at 65°C for 
20 min. Digested DNA was purified by phenol:chloroform extraction and 
precipitated, as described in Section 2.2.1.3.    
 
2.2.2.2 Preparation of electro-competent X-33 cells 
 
Yeast wild-type X-33 cells were prepared for electroporation following protocols by 
Invitrogen. Five millilitres of YPD media (see Table 2.8) was inoculated with X-33 
cells. The inoculated culture was grown overnight at 30°C, 250 rpm in an orbital 
shaker. The next day, 500 ml YPD media was inoculated with 0.5 ml of the 
overnight culture and grown at 30°C, 250 rpm until an OD600 of 1.3 was reached.  
 
Cultures were centrifuged at 1,500 x g for 5 min at 4°C and pellets resuspended in 
500 ml ice cold sterile dH2O. Cells were centrifuged as before, and pellets 
resuspended in 250 ml ice cold sterile dH2O. Cells were again centrifuged and the 
pellet resuspended in 20 ml ice cold sterile 1 M sorbitol. The process was repeated 
once more and the cells were resuspended in 1 ml ice cold sterile 1 M sorbitol. Cell 
were stored on ice and used the same day. 
 
 
 
Chapter 2 
78 
 
2.2.2.3 Electroporation of electro-competent yeast cells 
 
80μl of freshly prepared X33 electro-competent cells were added to 10 µl of 
linearised plasmid DNA and incubated on ice for 1 min. Cells were transferred to a 
pre-chilled 0.2 µm cuvette (Biorad) and pulsed once using a BioRad MicroPulser™ 
set at 2.0kV, 5ms (Pic programme). One millilitre of ice-cold, sterile 1 M sorbitol 
was added to the cuvette immediately after pulsing and cells were incubated at 30°C 
for 2 hr with no shaking. 10, 50, 100 and 200 µl of transformed cells were spread 
onto YPDS/Zeocin™ (100 µg/ml) plates and incubated at 30°C for 3-5 days until 
colonies formed. 
 
2.2.2.4 Protein expression in yeast 
 
With an inoculating loop, individual colonies (4 colonies per construct) were picked 
and dabbed on to separate YPDS plates for glycerol stocks and the same loop was 
used to inoculate 5 ml BMGY medium (containing 100 µg/ml Zeocin™) (see Table 
2.8) and grown (overnight) at 30°C, 250 rpm until an OD600 of 2-5 was reached. 
Cultures were centrifuged at 3,000 x g for 5 min and pellets were resuspended in 50 
ml BMMY (containing 100 µg/ml Zeocin™) (see Table 2.8) to a final OD600 = 1. 
The cultures were transferred to sterile 250 ml conical flasks and protein of interest 
was expressed at 30°C, 250 rpm with the addition of 100% methanol for a final 
concentration of 0.5% (v/v) every 24 hr for 72 hrs. Supernatant was extracted every 
24 hr and visualised by Western blot. At the final time point cultures were 
centrifuged for 30 min at 3,000 x g and supernatants were filtered through 0.2 um 
Nalgene filters and stored at 4°C for enzyme activity testing and at -80°C for long-
term storage.  
 
2.2.2.5 Preparation of glycerol stocks 
 
Seed lots of the clones that expressed protein were prepared and taken forward for 
scaled-up fermentation and purification. Preparations took place in a sterile 
microbiological Class II safety cabinets with UV lamp turned on. Using a sterile 
inoculating loop, a single yeast colony was transferred into 50ml YPD (containing 
100 μg/ml Zeocin™) in a 250 ml conical flask and grown overnight at 30ºC, 250 rpm 
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until an OD600nm of 15-20 was reached (doubling time ~ 2-3 hr). Cultures were 
transferred to 50 ml falcon tube and centrifuged at 3000 rpm for 5 min, 4ºC. 
Supernatant was discarded and pellet resuspended in YPD and 15% (final 
concentration) glycerol. For example, if OD600nm is 15, then 10 ml YPD was added 
with 5 ml 60% glycerol. 1 ml aliquots were dispensed into cryovials (Nunc 
International, Hereford, UK) and stored at -80°C. 
  
2.2.2.6 Fermentation and purification of proteins 
 
Large-scale protein production was carried out in a 10 litre Bioflo 3000 
Batch/Continuous Bioreactor (New Brunswick Scientific, Edison, NJ, USA) by Dr 
Berend Tolner and Mr Gaurav Bhavsar, according to Good Manufacturing Practice 
(GMP) guidelines (198) (197). The protein was purified by radial bed IMAC and 
concentrated on a lab-scale Tangential Flow Filtration (TFF) system (Millipore, UK). 
Final purification was performed by gel filtration chromatography using an ÄKTA 
FPLC™ system (GE Healthcare, Little Chalfont, UK). A HiLoad™ Superdex 200 
column (16/60, 150 ml or 200 ml; GE Healthcare, UK) was used to separate proteins 
larger than 100 kDa and a HiLoad™ Superdex 75 column (16/60, 120 ml or 200 ml; 
GE Healthcare, UK) was used for proteins less than 75 kDa. Proteins were filter 
sterilised (0.2 μm; Acrodisc, UK) and injected onto the column at a constant flow 
rate of 1.5 ml/min PBS. Fractions (1.5 ml) were collected immediately after the void 
volume (40 ml for S200 and 34 ml for S75 column) for a total of 120 ml. Peak 
fractions were pooled and stored at -80°C. 
 
2.2.2.7 Determination of protein concentration 
 
Protein samples were measured at 280nm using a spectrophotometer (Cecil, CE2041, 
Cecil Instruments Ltd, Cambridge, UK). The protein concentration was determined 
using the Beer-Lambert’s law: 
   OD280=ε280 x c x l      
OD280 is the absorbance of the protein sample at 280 nm, ε280 is the extinction 
coefficient of the protein at 280nm (0.1%, 280 nm, 1 cm path length) (mg/ml
-1
 cm
-1
), 
c is the concentration of protein (mg/ml), l is the path length of the cuvette (cm). 
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ε280 was calculated from the primary amino acid sequence of each protein using the 
EXPASY Protparam web tool (http://www.expasy.ch/tools/protparam.html).  
 
For protein from cell lysates, protein concentration was determined using the 
Bradford Assay (Bio-Rad Protein Assay kit, California, USA).   
 
2.2.3 Characterisation of proteins 
 
2.2.3.1 Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis (SDS-
PAGE)  
 
Proteins were characterised by SDS-PAGE and Coomassie staining. The samples 
were diluted in 2x reducing buffer loading and boiled for 5 minutes prior to loading 
on a pre-cast 4-20% Tris-glycine gel (Novex, San Diego, CA). A protein ladder of 
known molecular weights was also loaded in order to determine size and presence of 
the protein of interest (Figure 2.3). Proteins were subject to electrophoresis at 125V 
35mA for 90 min. Once the gel had run it was removed from its casing and incubated 
overnight in Coomassie dye. Destaining eliminated the dye from the gel leaving only 
the protein bands stained. This is carried out with several washes of destain buffer 
over a period of 3-4 hours. The gel was dried using the DryEase kit (Invitrogen, 
Paisley, UK).  
 
2.2.3.2 Western Blotting 
 
Western blotting was performed following SDS-PAGE to determine the true 
presence of a protein of interest. After electrophoresis the gel was removed from the 
casing and proteins transferred onto polyvinyl difluoride (PVDF) membrane 
(BioRad) by electro-blotting at 25V 125mA for 90 mins. The membrane was then 
blocked with 5% Marvel/PBS overnight to remove any non-specific binding. The 
membrane was then washed three times with PBS and the primary antibody (diluted 
in 1% blocking buffer) was added for 1 hr with gentle agitation. The membrane was 
washed five times with PBS. The secondary antibody conjugated to horse radish 
peroxidase (HRP) (diluted in 1% blocking buffer) was added for 1 hr and then 
washed as before. The antibodies were stained using 10 mg 3,3’-diamino-benzidine 
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(DAB) in 40 ml water in the presence of 20 μl hydrogen peroxide.  The reaction was 
stopped with tap water and the membrane was left to air dry. The Amersham ECL™ 
Western Blotting System (GE Healthcare, Buckinghamshire, UK) was also used in 
some cases for a more sensitive mode of detection. The chemiluminescent signal was 
captured on photographic film.  
 
2.2.3.3 Glycosylation analysis of proteins 
 
Proteins were checked for glycosylation by affinity chromatography using the 
HiTrap™ Con A 4B 1 ml column (GE Healthcare, Amersham, UK). The column is 
pre-packed with concanavalin A Sepharose™, a medium used for the separation and 
purification of glycoproteins, polysaccharides and glycolipids. Con A is a tetrameric 
metalloprotein (lectin) that binds molecules containing α-mannopyranosyl, α-D-
glucopyranosyl and sterically related residues (339). 
 
The protocol provided by GE Healthcare was followed using a peristaltic pump 
(Pharmacia LKB-Pump P-1) or the chromatographic ÄKTA FPLC™ system. The 
column was primed with 10 ml of Con A binding buffer (Table 2.12 HiTrap Con A 4B 
column buffers). Up to 500 µg protein was diluted in binding buffer and applied to the 
column. The column was washed with binding buffer and unbound material (flow 
through) fractions were collected in 500 µl aliquots. Bound protein was recovered 
with 5 ml of Con A elution buffer (Table 2.12 HiTrap Con A 4B column buffers). 
Fractions were analysed by SDS-PAGE and Western blotting.  
 
Protein samples were also sent to Dr. Daniel Spencer (Ludger, Oxford) for expert 
analysis of the glycosylation patterns by mass spectrometry.  
 
2.2.3.4 Enzymatic deglycosylation 
 
MFECP was incubated with deglycosylating enzymes, EndoHf or PNGaseF, for 24 
hr at 37°C under non-denaturing conditions. Deglycosylation was assessed by Con A 
column chromatography, followed by SDS-PAGE and Western blotting. 
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2.2.3.5 Enzyme kinetics 
 
The enzyme activity (U/ml) of MFECP and CPG2 protein variants was measured 
using a dual beam spectrophotometer fitted with a cell temperature controller (U-
2001, Hitachi Instruments Inc., Japan). As described previously (137), protein was 
diluted 100x and added to 1 ml assay buffer (5x PBS tablets and 0.2 mM ZnCl2) 
containing methotrexate (MTX) (60 mM) at 37°C and the rate of change of 
absorbance at 320nm was measured. Activity was calculated from standard 
regression analysis using the UV solutions software, version 1.2 (where 1 U/ml of 
enzyme activity is defined as the amount of enzyme catalysing the hydrolysis of 1 
µM of MTX per min per ml at 37°C).  
 
2.2.4 In vitro assays 
 
2.2.4.1 Drug treatment 
 
Cells were incubated with 0.1 U/ml MFECP for 1 hr at 37°C and this was followed 
by incubation with the 0.25 µM or 50 nM prodrug (unless stated otherwise) for 1 hr. 
For tumour response measured over time, cells were incubated in drug-free medium 
before harvesting at different time points. For Chk1 inhibitor combination 
experiments, cells were exposed to 25 nM UCN-01 or 0.1 µM PF-477736 during and 
after ADEPT treatment.    
 
2.2.4.2 Growth inhibition assay 
 
Sulphorhodamine B (SRB) assay was used to determine the cellular growth 
inhibition of ADEPT-treated cells, which was conducted in accordance with the first 
published protocol (340). Preliminary experiments using different cell-seeding 
densities (non-drug-treated) were conducted in order to determine the optimal cell 
seeding densities per well for each cell line. 
 
Cells were seeded in a 96-well plate and left to adhere overnight prior to drug 
exposure. SW1222 cells were seeded at a density of 5 x10
4 
cells/well and A375M 
cells were seeded at 2.5 x10
4 
cells/well. Cells were treated with ADEPT (as 
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described in Section 2.2.4.1) using various concentrations of prodrug. Alternatively, 
cells were treated with the fusion protein and washed with PBS prior to addition of 
the prodrug; or treated with the fusion protein or prodrug, alone. Supernatant was 
aspirated, cells washed with PBS and drug-free medium replaced. Cells were 
incubated at 37°C for 96 hr or 120 hr for SW1222 cells or A375M cells, respectively. 
 
 
Cells were fixed with 100 μl 10% trichloroacetic acid (TCA) for 20 min at 4°C. 
Wells were washed four times with water and tapped on paper towels to remove 
excess water. 100 μl of 0.4% SRB (in 1% acetic acid) was next added to stain the 
cells for 20 min at room temperature. Wells were washed with 1% acetic acid and 
tapped to remove excess. The SRB-stained cells were left to air-dry overnight before 
solubilising in 100 μl of 10 mM Tris base. OD540nm was measured using the plate 
reader (Varioskan Flash Multimode Reader, Thermoscientific, Philadelphia, US).  
 
2.2.4.3 Modified single-cell gel electrophoresis (comet) assay 
 
For drug treatment, 10 x10
4 
cells/well SW1222 cells were seeded in a 6-well plate 
and allowed to adhere overnight. Next day, cells were treated with ADEPT, as 
described in Section 2.2.4.1 - using various concentrations of prodrug for 
determining ICL damage, and 0.25 μM prodrug for ICL repair. Drug-containing 
medium was then removed and cells incubated at 37°C in drug-free medium for up to 
48 hr. Control experiments included cells incubated with fusion protein only, prodrug 
only, and no treatment.  
 
Following drug-treatment, media was aspirated and the cells were washed with PBS 
followed by Trypsin/EDTA 1x (PAA, Pasching, Austria) to detach the cells. The 
trypsin was neutralised with fresh medium and the suspension of cells were 
centrifuged at 1200 rpm for 4 min. The cell pellet resuspended in freezing mix (Table 
2.14) and stored in cryovials at -80°C until required for the comet assay.  
 
All procedures were carried out on ice and in subdued lighting. Cells were thawed 
and diluted to give a final concentration of 2.5 x10
4 
cells/ml and irradiated with 17.5 
Gy in a X-ray irradiator to deliver a fixed number of random DNA strand breaks. 
After embedding cells in 1% low gelling temperature agarose on pre-coated 
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microscope slides, the cells were lysed in lysis buffer (Table 2.13) for 1 hr, and then 
washed every 15 min with distilled water for 1 hr. Slides were then incubated in 
alkali buffer (Table 2.13) for 45 min followed by electrophoresis in the same buffer 
for 25 min at 18 V (0.6 V/cm), 250 mA. The slides were finally rinsed in neutralising 
buffer (Table 2.13) followed by PBS.  
 
After drying, the slides were stained with propidium iodide (2.5 µg/ml) for 20 min 
and then rinsed in distilled water for 30 min. Comet images were visualised using an 
inverted fluorescent microscope (Nikon, UK) with a high-pressure mercury lamp 
(Nikon, UK) at 20x magnification. Images were captured using a digital camera and 
analysed using the Komet Analysis software Version 6 (Andor Technology, Kinetic 
Imaging, UK) (Figure 2.5). For each duplicate slide, 25 cells were analysed. The tail 
moment (Tm) was calculated as the product of the percentage DNA in the comet tail 
and the distance between the means of the head and tail distributions, based on the 
definition by Olive et al. (341). DNA interstrand cross-linking was expressed as the 
percentage decrease in tail moment compared to the irradiated non-treated samples, 
as calculated in Equation 2.1. Percentage repair was calculated at 48 hr following the 
peak of DNA interstrand cross-linking.  
 
% decrease in tail moment 
 
Equation 2.1: Calculation for calculating the % decrease in tail moment in in vitro assays.  
TMdi = tail moment of drug-treated, irradiated sample  
TMci = tail moment of irradiated non-treated sample 
TMcu = tail moment of unirradiated non-treated sample 
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Figure 2.5 Screen-shot of the Komet Analysis software used to calculate the tail moment of the 
captured comet images  
 
2.2.4.4 Measurement of γ-H2AX and RAD51 foci by immunofluorescence 
 
SW1222 cells were seeded in 6-well plates and treated with ADEPT, as described in 
Section 2.2.4.1, using 50 nM prodrug and cells were then incubated in drug-free 
medium. At different time points cells were trypsinised, centrifuged, resuspended in 
freezing mix and stored in cryovials at -80°C, as previously described.  
 
Frozen vials of cells were defrosted on ice, centrifuged at 430 x g for 5 min and re-
suspended in 1 ml PBS. 16% paraformaldehyde (Alfa Aesar, MA, USA) was added 
to give a final concentration of 2% and cells were incubated for 20 min. Cells were 
washed with PBS, centrifuged again at the same speed, pellet resuspended in 1 ml 
70% ice-cold ethanol and incubated for 10 min on ice. The cells were centrifuged 
and resuspended in 200 μl ice-cold 70% ethanol. The final cell resuspension was 
applied to a Shandon EZ single cytofunnel (Thermofisher Scientific, Loughborough, 
UK) and spun at 650 rpm for 5 min at room temperature onto Superfrost® Plus slides 
(25 x 75 x 0.1 mm, VWR International, Leicestershire, UK). 
 
Fixed cells were permeabilised with 0.5 % Triton-X-100/PBS for 5min at room 
temperature. Cells were placed in a humidified chamber and blocked overnight at 
4ºC in blocking buffer (Table 2.11). Blocked cells were washed three times with cold 
PBS and then  incubated overnight at 4ºC with either anti-γ-H2AX (Millipore, UK) 
at a 1:1000 dilution in blocking buffer or anti-RAD51 (Santa Cruz Biotech) at a 
1:100 dilution in blocking buffer. After washing three times with cold wash buffer 
(Table 2.11), cells were then incubated for 4 hr at 4ºC in the dark with either Alex 
Fluor® 488 goat anti-mouse secondary antibody (Invitrogen, Paisley, UK) at a 
dilution of 1:2000 in blocking buffer or Alex Fluor® 488 goat anti-rabbit secondary 
antibody (Invitrogen, Paisley, UK) at a dilution of 1:2000 in blocking buffer. Cells 
were then washed three times in cold wash buffer. Slides were mounted with Pro-
Long® gold anti-fade reagent with DAPI (Invitrogen, Paisley, UK), a coverslip 
applied (24 x 50 mm thickness, VWR International VWR International, 
Leicestershire, UK) and the edges sealed with clear nail polish. Images were 
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visualised with a Perkin Elmer Ultraview Spinning Disk Confocal, driven by 
Volocity Acquisition (63x oil immersion objective) equipped with a cooled ECCD 
camera and laser lines at 405nm, 440nm, 488nm, 514nm, 568nm and 614nm 
wavelengths. Foci were counted in 100 cells per dose or time point and results 
expressed as average number of foci per cell (mean ±standard error).     
 
2.2.4.5 Cell cycle analysis 
 
SW1222 cells were seeded at a density of 1 x10
6
 cells in 6-well plates and left to 
adhere overnight at 37°C. The next day, cells were treated with ADEPT using 0.25 
μM prodrug (as described in Section 2.2.4.1), and cells were incubated in drug-free 
media and harvested at different time points. Supernatant containing detached cells 
was removed and centrifuged at 1200 rpm for 4 min. Adherent cells were trypsinised 
and also centrifuged. Cell pellets from both supernatant and trypsinised mix (as per 
time point) were pooled together and fixed in 1 ml ice-cold 70% ethanol – drop-wise 
while vortexing before storing at 4°C, until required.  
 
In preparation for cell cycle analysis, cells were centrifuged at high-speed > 3000 
rpm for 6 min. The pellet was washed with PBS and centrifuged again at high speed. 
This process was repeated. The cell pellet was treated with 50 μl of 50 μg/ml 
Ribonuclease A (Invitrogen) to remove RNA and this was followed by the addition 
of 500 μl of 0.1 mg/ml propidium iodide (PI) per million cells and mixed well. The 
PI/RNase cell suspension was then incubated for 10 min at room temperature or 
overnight at 4 ºC. Samples were passed through a 40 μm cell strainer (BD, JY, USA) 
to remove cell clumps prior to analysis by flow cytometry using the CyAn ADP 
High-Performance Flow Cytometer and Summit analysis software (Dako, 
Cambridge, UK). A blue 488 nm laser line was employed for propidium excitation 
and red fluorescence was measured using 670 LP filter. Samples were analysed at a 
low flow rate, that is, fewer than 800 events/second. Ten thousand events were 
collected per sample. PI fluorescence data was collected in a linear scale and a dot 
plot (PI area versus pulse width) was used to gate out cell doublets and higher 
aggregates.  
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2.2.4.6 Real-time PCR array  
 
Exponentially growing cells seeded at a density of 3 x10
6
 cells per T25 flask 
(Corning® Tewksbury, MA, USA) were treated with ADEPT, as described in 
Section 2.2.4.1, and replaced with drug-free medium following prodrug incubation. 
Cells were harvested at 1, 3 and 24 hrs-post-ADEPT and total RNA was extracted 
from adherent cells using the RNeasy Mini kit (Qiagen) according to the 
manufacturer’s instructions. (The on-column DNase treatment step was performed 
for each sample). Concentration (ng/μl) of RNA was measured at 260nm on the 
Nanodrop® ND-1000 UV-VIS spectrophotometer. RNA purity and integrity was 
verified on the Agilent 2100 Bioanalyser and associated RNA 6000 Nano LabChip 
kit (25-500 ng/µl) (Agilent Technologies UK, Cheshire), and using the Eukaryote 
Total RNA assay. RNA samples were stored at -80°C until required. 
 
Template cDNA was generated from 1 μg of RNA using the RT2 First Strand 
(SABiosciences). cDNA was checked with PCR (as described in Section 2.2.1.5) 
using GAPDH forward and reverse primers and the PCR reaction per sample was run 
on a 1.5% agarose gel. The cDNA template was then amplified in 24 μl volumes 
using the DNA Damage Signalling Pathway PCR array plate and RT
2
 qPCR 
Mastermix (SABiosciences) which contained Hot-Start Taq DNA polymerase, 
dNTPs, SYBR green and ROX. Amplification was carried out in an Applied 
Biosystems ABI7500 RT-PCR machine. The cycling conditions were as follows: 1 
cycle of 95ºC for 10 min followed by 45 cycles of 95ºC for 15 sec and 60ºC for 60 
sec. Cycle Threshold (CT) values were automatically calculated using the Applied 
Biosystems SDS software version 1.3.1 and changes in gene expression were 
analysed using the online RT
2
 Profiler™ PCR array data analysis application at 
http://www.sabiosciences.com/pcrarraydataanalysis.php. 
 
2.2.4.7 Detection of intracellular proteins by Western blotting 
 
Equal numbers of cells were seeded in a 25 cm
2
 tissue culture flask (1 x10
6
 cells/25 
cm
2
) and allowed to adhere overnight. The next day cells were treated with ADEPT, 
as described in Section 2.2.4.1, and replaced with drug-free medium following 
prodrug incubation. Cells were harvested at 1, 3 and 24 hrs-post-ADEPT. Cells were 
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lysed in lysis buffer [150 mM sodium chloride, 1 % Triton-X-100, 1 % sodium 
deoxycholate, 0.1 % SDS, 50 mM Tris, pH 7.2 and  1x protease inhibitor cocktail 
(Roche Diagnostics Ltd, West Sussex)] on ice (1 ml per 10
7
 cells per 150 cm
2
 flask). 
A cell scraper was used to lift the cells and then left on ice for 30 min. Insoluble 
debris was pelleted (12, 000 rpm, 10 min, 4 °C) and the protein concentration of the 
resulting supernatant was determined using the Bio-Rad DC Protein Assay kit 
(California, USA), according to the manufacturer’s protocol. Total cell lysates (15-20 
μg of protein) were mixed with loading buffer (Table 2.5) and boiled for 5 min 
before loading onto a 4-20% pre-cast SDS-gradient gel (Novex, San Diego, CA). 
SDS-PAGE and protein transfer onto PVDF membrane was carried out as previously 
described in Sections 2.2.3.1 and 2.2.3.2 
 
Membranes were blocked overnight in blocking buffer: 5% Marvel/PBS or 5% 
BSA/TBST (for phoshorylated proteins). The membrane was then washed briefly 
with PBS or TBST and the primary antibody (diluted in 1% blocking buffer) was 
applied and incubated overnight at 4°C with gentle agitation. The membrane was 
then washed in PBS or TBST 3x 10 min. The secondary antibody conjugated to 
horseradish peroxidase (HRP) (diluted in 1% blocking buffer) was added and 
incubated with the membrane for 1 hr at room temperature, followed by washing 3x 
10 min. Bands were visualised using Amersham ECL™ Western Blotting System 
(GE Healthcare, Buckinghamshire, UK) or the Luminata™ Classico ECL reagent 
and autoradiographic film. For re-blotting: membranes were stripped by incubating 
in stripping buffer (Section 2.1.2.1) at 50°C for 30 min, washed with distilled water 
for 1-2 hs with a final 5 min extensive wash with TBST, and then blocked with 5% 
BSA/TBST.  
 
Specific bands were quantified by densiometry using Image J software (v.1.44, 
National Institutes of Health, USA). The relative density value of protein in the 
ADEPT-treated samples was calculated against non-treated samples, and these 
values were normalised against the relative densities of the loading control protein.   
 
2.2.5 In vivo studies 
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2.2.5.1 Clearance study 
 
Balb/c hairy mice were injected with 1000 U/kg (i.v.) bacterial or yeast CPG2 and 
blood was taken at 1, 3 and 5 hrs. The blood was diluted 10x in PBS and the amount 
of enzyme present in the blood was measured by determining the enzyme activity 
using the UV-spectrophotometer (as described in Section 2.2.3.5) or high 
performance liquid chromatography (HPLC). HPLC analysis was performed 
according to the protocol described by Bhatia et al. (136) with the help of Dr. 
Surinder Sharma (Dept. of Oncology, UCL Cancer Institute, London).    
 
2.2.5.2 Analysis of therapeutic response 
 
The therapeutic response to ADEPT was conducted in nude mice bearing SW1222 
human colorectal carcinoma xenografts. ADEPT-treated mice were injected with 
1000 U/kg (i.v.) of MFECP fusion protein followed by 70 mg/kg (i.p.) of ZD2767P 
prodrug (x3) at 6, 7 and 8 hr later. Tumours were excised at 1, 3 and 24 hr after the 
last prodrug dose. Each tumour tissue was cut into 3 equal pieces and processed 
accordingly: snap-frozen, snap-frozen in iso-pentane and fresh tissue. Fresh tumour 
tissue was cut into tiny fragments with a sterile scalpel to create a single-cell 
suspension and stored in freezing medium at -80°C until required for analysis. Blood, 
also withdrawn at these time points, were collected into 4 ml EDTA Vacutainer® 
tubes (Becton Dickinson, Oxford, UK) and processed into a single-cell suspension of 
peripheral blood lymphocytes. To do this, blood was gently added to 2 ml Ficoll-
Paque™ PLUS (GE Healthcare) and centrifuged at 450xg for 20 min at  room 
temperature with slow deceleration. PBLs were obtained by removing the fluffy 
white mononuclear layer at the interface of the two layers with a pipette and 
transferring to 15 ml Falcon tube (VWR International Limited, Leicestershire, UK). 
Cells were washed with PBS, centrifuged at 450xg for 5 min and resuspended in 
freezing medium for -80°C storage until required for analysis. 
 
Analysis using the comet assay was carried out in the same way as described in 
Section 2.2.4.3. The percentage decrease in tail moment was calculated using 
Equation 2.2 which takes into consideration the unirradiated drug-treated tail 
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moment and is used to compensate for additional single strand breaks that may have 
been induced by drug treatment.  
 
 
% decrease in tail moment 
 
Equation 2.2: Calculation for calculating the % decrease in tail moment in in vivo assays.  
TMdi = tail moment of drug-treated, irradiated sample  
TMci = tail moment of irradiated non-treated sample 
TMcu = tail moment of unirradiated non-treated sample 
TMdu = tail moment of the drug-treated, unirradiated sample  
 
2.2.6 Statistical analysis 
 
Statistical analysis was performed using Prism 6 (GraphPad Software Inc.). For 
ADEPT experiments conducted in vivo all post-treatment samples were compared 
with pre-treatment samples by using ordinary one-way ANOVA analysis. For cell 
cycle analyses, the two-way ANOVA (repeated-measures) was used with the 
Bonferroni post-test for determining the p value. The significance level was 
expressed as ns = non-significant, * p < 0.05, ** p < 0.005, *** p < 0.001 and **** p 
< 0.0001. 
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3 Modifying Antibody-Enzyme Pharmacokinetics 
 
3.1 Introduction 
 
Early ADEPT clinical trials with the antibody-enzyme conjugate incorporated an 
additional component, that is, a glycosylated anti-enzyme antibody to inactivate and 
clear circulating antibody-enzyme conjugates (183) (184). The system increased 
tumour-to-blood ratios in excess of 10, 000:1 (134), the highest recorded with CPG2. 
The 2-phase ADEPT system, which incorporates the glycosylation on the antibody-
enzyme fusion protein, showed promise in Phase I/II clinical trials (139), but its 
efficacy was limited by rapid clearance and myelosuppression caused by activated 
drug in the bone marrow (199).  
 
Obtaining maximal antibody-enzyme in the tumour, whilst maintaining low enzyme 
activity in the blood is crucial to the efficacy of ADEPT. Using a bacterially-
generated non-glycosylated form of MFECP (137) allows the antibody-enzyme to 
remain in circulation longer than the P. pastoris-generated glycosylated form (139); 
with consequent improvement in tumour loading. Theoretically, non-glycosylated 
MFECP could be followed by a CPG2-inactivating/clearance step prior to the 
administration of the prodrug: mimicking the early clinical trials (135). This would 
create a 3-phase ADEPT, as outlined diagrammatically in Figure 3.1. Unfortunately, 
it has proved to be too difficult to generate sufficient quantities of MFECP in 
bacteria, although P. pastoris manufacture was readily achievable to clinical grade 
(140). It was therefore hypothesised that P. pastoris-generated MFECP could be 
modified to remove glycosylations in order to prolong its circulation time and 
maximise tumour loading.    
 
Chapter 3 
93 
 
 
 
Figure 3.1 Proposed 3-Phase ADEPT 
1. An antibody-enzyme localises in vivo to the target tumour antigen 
2. An enzyme-inactivating antibody/agent binds to non-bound fusion protein 
3. After circulatory clearance, an un-harmful prodrug is administered. The prodrug is converted 
to a potent DNA-damaging toxic drug by the pre-targeted enzyme in the tumour.   
 
3.1.1 Aims and Objectives 
 
The aim: to remove glycosylations from MFECP in order to prolong its circulation 
time in blood prior to addition of a clearing agent. The objectives:   
1. To remove N-linked glycosylations.  
2. To determine the presence and sites of O-linked glycosylations. 
3. To remove O-linked glycosylations. 
 
 
3.2 Results 
  
3.2.1 MFECP stability  
 
Several batches of clinical grade MFECP were checked for degradation, purity and 
activity by SDS-PAGE and size-exclusion chromatography (Figure 3.2A and B). 2 
ml of a 1 in 10 dilution of each batch of MFECP was run (separately) onto a 
Superdex 200 column and the FPLC profile of each batch is shown in Figure 3.2B. 
The proteins each produced a single peak, all eluting at approximately 78 ml. 
Coomassie staining (Figure 3.2A) revealed several bands: one at ~ 72 kDa, which 
represents MFECP; and two thinner bands close together at ~ 45 kDa, which 
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represents the CPG2 moiety of MFECP. This was an indication that the protein had 
degraded over time during storage at -80ºC, and/or the expressed protein was 
susceptible to protease cleavage. The smear of Coomassie stain above the MFECP 
band indicated the presence of glycosylation. MFECP, batch B0131, was chosen for 
use throughout this thesis. Functional activity of MFECP was also checked by 
measuring the absorbance of enzyme-catalysed reduction of methotrexate in the dual 
beam spectrophotometer (as described in Section 2.2.3.5) and found to be 120 U/mg 
(where 1 U is the amount of enzyme required to hydrolyse 1 mmol of methotrexate 
per min at 37ºC). The fusion protein was checked for thermo-stability by incubating 
at 37ºC over several hours and then loading the protein onto a 12% Tris-Gly gel, as 
shown in Figure 3.3. The Western blot showed no change in the protein between 6 
and 96 hr at 37ºC. 
 
     
 
Figure 3.2 MFECP clinical batches  
A) Coomassie gel of different MFECP1 clinical batches. Lane 1: marker, lane 2: positive control, lane 
3: B0120 (0.5 mg/ml), lane 4: B0121 (0.71 mg/ml), lane 5: B0131 (0.63 mg/ml), B0133 (0.4mg/ml). 
B) FPLC profile of the MFECP batches B0121, B0131 and B0133. Superdex 200 separation column 
was used. (MW markers in kDa). 
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Figure 3.3 Western Blot of MFECP (0.63 mg/ml) after incubation at 37ºC over several hours  
Lane 1: marker, lane 2: MFECP pre-incubation, and in subsequent lanes 3, 4, 5 and 6: MFECP 
incubated for 6, 24, 72 and 96 hr. Protein was detected with anti-MFE antibody/goat anti-rabbit-HRP. 
(MW markers in kDa). 
 
3.2.2 Removal of N-linked glycosylation from MFECP or CPG2 
 
3.2.2.1 Using enzymes 
 
In the first instance, MFECP was deglycosylated with enzymes specific for N-linked 
glycans on MFECP using peptide-N-glyco-hydrolase F (PNGase F) and endo-β-N-
acetylglucosaminidase (EndoH). PNGase F is not specific for the conserved N-
glycan core structure and catalyses the hydrolysis of the GlcNAcβ-Asn linkage. 
EndoHf catalyses the hydrolysis of the glycosidic bond between two N-
acetylglucosamine residues (GlcNAcβ-1,4GlcNAc) in the conserved N-glycan core 
structure resulting in the release of the GlcNAc residues. The effect of incubating 
MFECP with PNGase F at 37ºC was demonstrated, as shown in Figure 3.4. MFECP 
was identified without the smear above the protein band when treated with PNGase F 
(Figure 3.4A, lane 2), compared to non-treated MFECP (lane 1). The bands were 
detected with the mannose-binding lectin concanavalin A (Con A), which implied 
that the N-linked glycosylations had been cleaved. However, the smear above the 
PNGase-treated MFECP band (lane 2) remained in those blots detected with anti-His 
and anti-CPG2 antibody, suggesting that glycosylations other than N-glycosylation 
were present on the enzyme molecule (Figure 3.4 B and C). PNGase-treated MFECP 
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was detected with anti-His and anti-CPG2 antibodies also showed that the enzyme 
had no affect on the overall protein structure of MFECP.  
 
 
 
Figure 3.4 X-ray film of MFECP digested with PNGase F and detected with biotinylated Con A 
(A), anti-His antibody (B) and anti-CPG2 antibody (C) 
Lane 1: 0.126 mg/ml MFECP, lane 2: MFECP (6 µg) treated with PNGase F. Enzymatic reaction was 
left for 24 hr at 37°C. Con A detects N-glycosylation which is absent in (A), whilst (B) and (C) 
suggest the presence of other glycosylations. Protein was detected with anti-mouse-HRP, anti-rabbit-
HRP or streptavidin-HRP and the Amersham ECL™ Western Blotting System used. 
 
Upon treatment of MFECP with EndoHf, the incubation mixture was loaded onto a 
Con A HiTrap affinity chromatography column to separate glycosylated proteins 
from non-glycosylated proteins. The purified fractions were run on a Tris-Gly gel, 
and Western blots of the column fractions of PNGase F- and EndoHf-treated MFECP 
are shown in Figure 3.5A and B (respectively). Both reactions revealed the presence 
of MFECP in the flow-through (binding buffer) as shown in lane 7. This revealed 
that sugars, notably the N-linked mannose sugars, had been removed from the fusion 
protein by the enzyme. MFECP, in the absence of deglycosylating enzymes, was also 
run through the Con A column for comparison and the fractions were analysed by 
Western blotting (Figure 3.6). Fractions that contained protein in the elution buffer 
confirmed N-glycosylation on MFECP.  
 
 
A B C 
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Figure 3.5 Con A column fractions of MFECP digested with PNGase F (A) and EndoHf (B)  
Lane 1: marker, lane 2: MFECP (0.144 mg) treated with PNGase F (A) or EndoHf (B) after 24 hr 
incubation, lane 3: MFECP (35 µg) and enzymes – column load, lane 4-9: binding buffer fractions, 
lane 10: MFECP (0.63 mg/ml). The boxes mark the presence of MFECP band. Protein was detected 
with anti-MFE/goat anti-rabbit-HRP. (MW markers in kDa). 
 
 
   
 
Figure 3.6 Con A column fractions of MFECP only 
Lane 1: marker, lane 2: MFECP (0.315 mg/ml) column load, lanes 3-6: binding buffer fractions 1-4, 
lanes 7-10: elution buffer fractions 1-4. MFECP is present in lanes 9 and 10. Protein was detected 
with anti-CPG2/goat anti-rabbit-HRP. (MW markers in kDa). 
  
3.2.2.2 Genetic manipulation of CPG2   
 
From previous studies, we know that there are 3 potential N-glycosylated asparagine 
(Asn) residues of CPG2 when it is expressed in yeast (137) and in mammalian cells 
(342). In addition, the CPG2 moiety of MFECP is most vulnerable since its structure 
dictates the enzyme’s activity, affinity and specificity for its substrate - the prodrug. 
Thus, in order to properly address the issue of deglycosylation, it was decided to 
focus on CPG2. A mutated CPG2 variant was previously generated by mutating the 3 
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N-glycosylated Asn residues (Asn-222, Asn-272, Asn-264) to glutamine (Gln) and 
was found to be functionally  active when expressed in mammalian cells (342). A 
similar CPG2 variant was also generated within the Department using site-directed 
mutagenesis and expressed in yeast when genetically fused to an antibody. For this 
work, the non-N-linked glycosylated CPG2, CPG2_3Q, was cloned into pPICzαB 
vector plasmid via NotI and XbaI restriction sites and the ligated plasmid sequence 
was transformed into X33 cells. Protein expressed in yeast P. pastoris supernatant at 
48 and 72 hr after methanol induction in shake-flask cultures, as shown in Figure 3.7. 
Protein production from one of the yeast clones was scaled-up to 10 L batch 
fermentation. The protein was harvested after 72 hrs and purified. Twenty-five 
millilitre pooled fractions of purified protein was loaded and run through a 120 ml 
Superdex 75 size-exclusion column. The FPLC profile of the purified protein is 
shown in Figure 3.8A. The Gaussian shape of peak appears to be skewed, probably 
an indication of partial dimerisation of the enzyme. 0.4 ml fractions were collected 
and run on SDS-PAGE and from the Coomassie stain (Figure 3.8B) fractions 12 to 
21 were pooled. Final protein concentration was 2.8 mg/ml and total protein yield 
was 20 mg. Enzyme activity of the purified protein was measured by methotrexate 
reduction on the UV-spectrophotometer and found to be 202 U/ml (specific activity 
72 U/mg).  
 
 
    
 
Figure 3.7 Protein expression of CPG2_3Q at 48 hrs (A) and 72 hrs (B) from shake flask 
cultures  
A) Lane 1: marker, lane 2-5: expression of CPG2_3Q from 4 yeast cell clones at 24 hrs post-methanol 
induction; lane 6-9: expression of CPG2_3Q from the same yeast cell clones at 48 hrs post-methanol 
induction; lane 10: positive control. B) Lane 1: marker, lane 2-5: blank; lane 6-10: expression of 
CPG2_3Q from the same yeast cell clones at 72 hr post-methanol induction; lane 10: positive control. 
Protein was detected with anti-His/anti-mouse-HRP. (MW markers in kDa). 
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Figure 3.8 Purified CPG2_3Q  
A) Size exclusion chromatography. 25 ml of purified protein from the fermentor was applied to a 
Superdex 75 column. 0.4 ml fractions were collected at a flow rate of 0.5 ml/min. B) SDS-
PAGE/Coomassie stain of the collected fractions. Lane 1: MW marker, Lane 2-10: FPLC fractions 11, 
13, 15, 19, 21, 23, 25, 27. 
 
A codon-optimised sequence of CPG2 obtained with permission from Mologic Ltd 
(Bedford, UK) [used in later cloning experiments (Section 3.2.3.2)], was also cloned 
into pPICzαB with the N-linked glycosylations knocked-out (mCPG2_3Q), as 
before. The CPG2 DNA sequence is very GC-rich, and codon-optimisation reduces 
the GC content without affecting the overall protein structure and enzyme activity to 
facilitate genetic manipulation. In the fermentor, this protein was produced at a final 
concentration of 2.5 mg/ml (total protein yield 38 mg) and enzyme activity was 
found to be 578 U/ml (specific activity 231 U/mg). FPLC of the purified mCPG2_3Q 
protein is shown in Figure 3.9 and the pooled fractions indicated. The peak, also 
skewed here by the protein shoulder (200-220 mls), may indicate partial 
dimerization. 
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Figure 3.9 FPLC profile of purified mCPG2_3Q (Mologic Ltd)  
25 ml of purified protein from the fermentor was applied to a Superdex 75 column. 0.4 ml fractions 
were collected at a flow rate of 0.5 ml/min. 
 
3.2.2.2.1 Verifying glycosylation status of CPG2_3Q 
 
Glycosylation status of the purified CPG2_3Q protein was checked using Con A 
affinity chromatography. Protein was diluted in Con A column binding buffer (see 
Section 2.1) and applied to a 1 ml Con A HiTrap affinity column. Fractions (0.5 ml) 
were collected in the binding and elution phases at a flow rate of 1 ml/min (Figure 
3.10 A and B). An early peak in the binding phase indicated the presence of protein 
and protein was not detected in the elution buffer. There was, however, a very large 
peak upon exchange of buffers, as shown in Figure 3.10 A. This was the result of the 
methyl-α-D-glucopyranoside in the elution buffer which caused a change in the 
absorbance (and conductivity). Fractions were analysed for the presence and activity 
of CPG2_3Q, as presented in Figure 3.11 and Table 3.1, (respectively). The Western 
blot in Figure 3.11 verified the presence of CPG2_3Q in the binding phase, 
indicating that it hadn’t bound to the Con A lectin in the column and was, therefore, 
not glycosylated. The findings demonstrated an in vitro method of detection for the 
glycosylation status of CPG2_3Q, and subsequent testing in vivo would clarify the 
results. 
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Figure 3.10 Con A column FPLC elution profile of purified CPG2_3Q  
A) 0.56 mg of CPG2_3Q protein was loaded to a 1 ml Con A HiTrap affinity column and 0.5 ml 
fractions collected in the binding buffer and elution phases. The blue profile is the change in 
absorbance over time and the red profile is the change in conductivity over time. The small peak at 7-
10 min is the column purified CPG2_3Q, also shown in B) in absorbance vs volume. The large peak 
at 65 min coincides with the absorbance detection of methyl-α-D-glucopyranoside in the elution 
phase.   
 
 
Absorbance 280nm (mAu)  
Conductivity (S/m)  
 
Conductivity 
Elution phase Binding phase 
Time (min) 
A 
B 
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Figure 3.11 Western blot of the CPG2_3Q Con A column fractions  
Lane 1: marker, lane 2: CPG2_3Q (0.56 mg) column load, lane 3-9: column flow-through fractions 1-
7, lane 10: MFECP (0.63 mg/ml; positive control). Protein was detected with antibodies anti-
CPG2/anti-rabbit-HRP. (MW markers in kDa). 
 
 
Table 3.1 Enzyme activity of the Con A column flow-through fractions of CPG2_3Q  
Enzyme activity was determined by measuring the absorbance of enzyme-catalysed reduction of 
methotrexate, as described in Section 2.2.3.5. Each measurement is a mean of triplicate readings.   
 
Flow-through fractions (500 µl) Activity U/ml 
1 0 
2 0 
3 5.61 
4 8.50 
5 8.41 
6 5.78 
7 3.21 
8 1.17 
 
A small clearance study was undertaken in hairy balb/c mice, whereby the blood 
clearance of the yeast-expressed CPG2_3Q was compared against the bacterial (non-
glycosylated) CPG2 (produced within the Department) over 5 hr. Enzyme activity 
was measured using HPLC (136). The HPLC assay was based on the enzyme-
catalysed reduction of methotrexate and the peaks formed by the metabolite of 
methotrexate was measured against a standard curve. This assay was more sensitive 
than the spectrophotometric assay with a limit of detection of 0.002 U/ml. As shown 
in Figure 3.12, CPG2_3Q (1.12% injected enzyme activity/g at 5 hr) cleared faster 
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than the bacterial CPG2 (38.6% injected enzyme activity/g at 5 hrs), although there 
appeared to be a discrepancy in the injected enzyme units of bacterial CPG2 because 
of the >100% injected activity/g observed at 1 hr (see Table 3.2). The study revealed 
the following: 1) CPG2_3Q remained gycosylated; 2) the Con A column was not a 
reliable measure of the ability of CPG2_3Q to bind mannose receptors in vivo; and 3) 
the limited sensitivity of the Con A column to detect additional glycosylations, other 
than N-linked glycosylations. The results suggested that other glycosylations were 
present on CPG2_3Q, which were likely to be O-linked. Further manipulation of 
CPG2 would be necessary to remove additional glycosylations in order to evade the 
mannose receptor.  
 
 
 
Figure 3.12 Plasma clearance of CPG2_3Q and bacterial non-glycosylated CPG2 in mice  
Hairy balb/c mice were given yeast-expressed CPG2_3Q (blue) or bacterial CPG2WT (red) (25 U per 
mouse, i.v.). CPG2 activity was measured in the blood at 1, 3, and 5 hr after injection. Enzyme 
activity was measured indirectly by HPLC. (Mean of 2 mice per group ± stdev).  
 
 
Table 3.2 Plasma biodistribution of CPG2_3Q in mice over time  
Balb/c mice were given yeast-expressed CPG2_3Q or bacterial CPG2WT (25 U per mouse, i.v.) and 
enzyme activity measure in the plasma at 1, 3, and 5 hr after injection. Results expressed as the mean 
enzyme activity of 2 mice per group. 
 
Time (hr) CPG2_3Q (% injected activity/g) Bacterial CPG2WT (% injected activity/g) 
1 28.7 101.6 
3 1.64 50.4 
5 1.12 38.6 
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3.2.3 Removal of O-linked glycosylation from CPG2 
 
Little is known about the pattern and specificity of O-linked glycosylation in P. 
pastoris. In an attempt to knock-out the O-linked residues on CPG2, strategies to 
mutate CPG2 were undertaken, as explained in the following sections. All O-linked 
residue mutations were constructed into the CPG2_3Q or mCPG2_3Q gene 
sequence. 
 
3.2.3.1 Rationally predicted mutations: CPG2_3Q_12A 
 
O-linked glycosylation occurs via serine (Ser) and threonine (Thr) residues. There 
are 17 Ser and 22 Thr residues per CPG2 monomer. The first attempt to rationally 
mutate CPG2 focused on surface-located O-glycosylations based on in silico 
predictions. To achieve this, the CPG2 protein sequence was analysed for potential 
O-glycosylation sites using the program NetOGlyc, which is designed to predict all 
potential O-glycosylation sites (343). No residues were marked by the program with 
a high prevalence for O-glycosylation but the highest-rated of the 12 potential 
surface-located O-glycosylated residues were selected. Surface location was 
predicted by visual examination of the position of the NetOGlyc predicted residues 
on a rotating model of the crystal structure. The 12 ‘surface residues’ are shown in 
the computer-assisted protein model (Molecular Operating Environment) of the 
crystal structure of CPG2 (PDB 1cg2) (344), Figure 3.13. These residues were 
substituted to alanine (Ala) to form the protein CPG2_3Q_12A. Figure 3.14 shows 
the protein sequence CPG2_3Q DNA highlighting the Ser/Thr residues mutated to 
Ala. Alanine is a neutral amino acid that is also hydrophobic and small, thus 
preventing any kind of molecular steric hindrance or shifts in protein folding.  
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Figure 3.13 Computer-assisted protein model of (bacterial) CPG2 dimer representing surface 
modifications for CPG2_3Q_12A  
Location of potential surface located residues involved in O-glycosylation by P. pastoris of CPG2 
predicted with the program NetOGlyc. The residues are depicted only on the left monomer unit. All 
12 residues were mutated to alanine to generate CPG2_3Q_12A (grey/red/blue). The 3 light cyan 
(aqua blue/red/blue) residues indicate the potential N-glycosylation sites. (The blue and red spheres on 
each amino acid represent nitrogen and oxygen atoms, respectively). Zinc ions (2x black spheres on 
both chains) represent the active site. The image was produced using the bacterial CPG2 crystal 
structure (PDB: 1cg2) with the kind assistance of Dr Paul Gane (Department of Medicinal Chemistry, 
UCL).  
 
 
 
                             
Figure 3.14 Primary protein sequence of CPG2_3Q highlighting the rationally predicted 
Ser/Thr residues  
12 Ser/Thr residues substituted to Ala are highlighted in pink and 3 mutated N-glycosylated residues 
(Asn→Gln) are highlighted in blue. Full DNA and protein sequence can be found in Section 2.1.1.2. 
(The sequence originates from the Genbank entry: AAA62842.1 - bacterial CPG2 Variovorax 
paradoxus).  
 
      A  Q  K  R  D  N  V  L  F  Q  A  A  T  D  E  Q  P  A  V  I  K  
      T  L  E  K  L  V  N  I  E  T  G  T  G  D  A  E  G  I  A  A  A   
      G  N  F  L  E  A  E  L  K  N  L  G  F  T  V  T  R  S  K  S  A  
               G  L  V  V  G  D  N  I  V  G  K  I  K  G  R  G  G  K  N  L  L  
               L  M  S  H  M  D  T  V  Y  L  K  G  I  L  A  K  A  P  F  R  V  
               E  G  D  K  A  Y  G  P  G  I  A  D  D  K  G  G  N  A  V  I  L  
               H  T  L  K  L  L  K  E  Y  G  V  R  D  Y  G  T  I  T  V  L  F  
               N  T  D  E  E  K  G  S  F  G  S  R  D  L  I  Q  E  E  A  K  L  
               A  D  Y  V  L  S  F  E  P  T  S  A  G  D  E  K  L  S  L  G  T  
      S  G  I  A  Y  V  Q  V  Q  I  T  G  K  A  S  H  A  G  A  A  P 
      E  L  G  V  N  A  L  V  E  A  S  D  L  V  L  R  T  M  N  I  D  
      D  K  A  K  N  L  R  F  Q  W  T  I  A  K  A  G  Q  V  S  N  I  
      I  P  A  S  A  T  L  N  A  D  V  R  Y  A  R  N  E  D  F  D  A  
               A  M  K  T  L  E  E  R  A  Q  Q  K  K  L  P  E  A  D  V  K  V  
               I  V  T  R  G  R  P  A  F  N  A  G  E  G  G  K  K  L  V  D  K  
      A  V  A  Y  Y  K  E  A  G  G  T  L  G  V  E  E  R  T  G  G  G  
               T  D  A  A  Y  A  A  L  S  G  K  P  V  I  E  S  L  G  L  P  G   
      F  G  Y  H  S  D  K  A  E  Y  V  D  I  S  A  I  P  R  R  L  Y  
       M  A  A  R  L  I  M  D  L  G  A  G  K  H  H  H  H  H  H  -  -   
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CPG2_3Q_12A gene was generated by GenScript Inc. and cloned into the bacterial 
pUC57 vector. The CPG2_3Q_12A gene was digested with EcoRI and XbaI and 
cloned into an empty pPICzαB vector and the protein was expressed in methanol-
induced yeast culture supernatant at 48 and 72 hr (see Figure 3.15). Two out of the 4 
yeast clones expressed protein at these time points, and one of them was taken 
forward for scaled-up 10 L batch fermentation. The protein was harvested after 72 hr 
and purified. However, during the final concentration step, after radial bed 
chromatography, the concentration of CPG2_3Q_12A did not sufficiently increase 
from start to end. Starting OD at 280nm was 0.084 in 500 ml increased only to 0.118. 
Insufficient protein was produced during the fermentation to run through a gel-
filtration column. Furthermore, the resultant CPG2_3Q_12A had very low activity 
(<10 U/mg).  
 
 
 
 
Figure 3.15 Protein expression of CPG2_3Q_12A at 48 and 72 hr in shake flask cultures  
Lane 1: marker, lane 2-5: expression of CPG2_3Q_12A from 4 yeast cell clones at 48 hr post-
methanol induction; lane 6-9: expression of CPG2_3Q_12A from the same yeast cell clones at 72 hr 
post-methanol induction; lane 10: positive control. Protein was detected with anti-His/anti-mouse-
HRP. 2 out of 4 yeast clones expressed the protein. (MW markers in kDa).  
 
3.2.3.2 Mass spectrometry-predicted mutations 
 
In the second approach to address the O-glycosylation status of P. pastoris-generated 
CPG2-3Q, mass spectrometry (MS) was used to identify and define the Ser/Thr 
residues that were occupied. MS is a separation technique that generates charged 
molecules or molecule fragments within a heterogeneous sample that can be 
identified by differences in their mass-to-charge ratio. MS was performed in 
collaboration with Dr Daniel Spencer at Ludger Ltd (Culham Science Centre, 
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Oxfordshire). MS confirmed the presence of O-glycosylated glycopeptides, and a 
total of 10 residues were identified as depicted in the computer-assisted model of the 
CPG2 crystal structure (Figure 3.16), and in the CPG2_3Q protein sequence (Figure 
3.16). The glycans on the first two threonine residues (T55 and T57) were 
definitively ascribed as intact glycopeptides and the remainder glycans were 
identified in glycopeptides that had been liberated from the denatured protein. The 
predicted amino acid substitutions of the potentially O-glycosylated Ser/Thr residues 
are listed in Table 3.3. 
 
 
Figure 3.16 Computer-assisted protein model of (bacterial) CPG2 monomer illustrating the MS-
predicted O-glycosylated Ser/Thr residues  
10 Ser/Thr residues (grey/red/blue) and 3 Asn residues (aqua blue/red/blue) are illustrated on a single 
CPG2 monomer chain. (The blue and red spheres on each amino acid  represent nitrogen and oxygen 
atoms, respectively). Zinc ions (2x black spheres) represent the active site. The image was produced 
using the bacterial CPG2 crystal structure (PDB 1cg2) with the kind assistance of Dr Paul Gane 
(Department of Medicinal Chemistry, UCL). 
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Figure 3.17 Primary protein sequence of CPG2_3Q highlighting the MS-predicted O-
glycosylated Ser/Thr residues  
The 10 Ser/Thr residues selected for mutation are highlighted in yellow and 3 mutated N-glycosylated 
residues (Asn→Gln) are highlighted in blue. Full DNA and protein sequence can be found in Section 
2.1.1.2. (The sequence originates from the Genbank entry: AAA62842.1 - bacterial CPG2 Variovorax 
paradoxus).  
 
Table 3.3 Summary of the MS-predicted O-glycosylated Ser/Thr residues, their location within 
CPG2 and suggested amino acid substitutions for cloning 
T57N denotes T57 to N57 substitution.   
 
Residue 
position 
Location of amino 
acid 
Note Suggested substitution 
T55 Buried 
potentially near active 
site 
Gln (Q), Val (V) or Ala (A)  
OR Asn (N) + T57N 
T57 
Near surface, frame 
work 
 oxygen on surface 
potentially near active 
site 
Asn (N) 
S198 Buried 
 
Asn (N) or Ala (A) 
T202 Semi surface 
 
Gln (Q) 
S203 Semi surface 
 
Gln (Q) 
S228 Surface 
at dimerisation 
interface 
Gln (Q) or Ala (A) or Asn (N) 
S245 Buried 
at dimerisation 
interface 
Asn (N) or Ala (A) 
S274 Surface 
at dimerisation 
interface 
Gln (Q) or Ala (A) 
S280 Surface 
at dimerisation 
interface 
Gln (Q) or Ala (A) 
T282 Surface 
at dimerisation 
interface 
Gln (Q) or Ala (A) 
      A  Q  K  R  D  N  V  L  F  Q  A  A  T  D  E  Q  P  A  V  I  K  
      T  L  E  K  L  V  N  I  E  T  G  T  G  D  A  E  G  I  A  A  A   
      G  N  F  L  E  A  E  L  K  N  L  G  F  T  V  T  R  S  K  S  A  
               G  L  V  V  G  D  N  I  V  G  K  I  K  G  R  G  G  K  N  L  L  
               L  M  S  H  M  D  T  V  Y  L  K  G  I  L  A  K  A  P  F  R  V  
               E  G  D  K  A  Y  G  P  G  I  A  D  D  K  G  G  N  A  V  I  L  
               H  T  L  K  L  L  K  E  Y  G  V  R  D  Y  G  T  I  T  V  L  F  
               N  T  D  E  E  K  G  S  F  G  S  R  D  L  I  Q  E  E  A  K  L  
               A  D  Y  V  L  S  F  E  P  T  S  A  G  D  E  K  L  S  L  G  T  
      S  G  I  A  Y  V  Q  V  Q  I  T  G  K  A  S  H  A  G  A  A  P 
      E  L  G  V  N  A  L  V  E  A  S  D  L  V  L  R  T  M  N  I  D  
      D  K  A  K  N  L  R  F  Q  W  T  I  A  K  A  G  Q  V  S  N  I  
      I  P  A  S  A  T  L  N  A  D  V  R  Y  A  R  N  E  D  F  D  A  
               A  M  K  T  L  E  E  R  A  Q  Q  K  K  L  P  E  A  D  V  K  V  
               I  V  T  R  G  R  P  A  F  N  A  G  E  G  G  K  K  L  V  D  K  
      A  V  A  Y  Y  K  E  A  G  G  T  L  G  V  E  E  R  T  G  G  G  
               T  D  A  A  Y  A  A  L  S  G  K  P  V  I  E  S  L  G  L  P  G   
      F  G  Y  H  S  D  K  A  E  Y  V  D  I  S  A  I  P  R  R  L  Y  
       M  A  A  R  L  I  M  D  L  G  A  G  K  H  H  H  H  H  H  -  -   
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The position of T55 and T57 molecules within CPG2 were both located very close to 
the active site (the zinc ions depicted as black spheres), as illustrated in Figure 3.18A 
and B (respectively). Interestingly, T55 was buried within the molecule and not 
exposed on the surface (Figure 3.18A). T55 was shown to be linked to lysine 143 by 
hydrogen (H) bonds, which was also very near the active site. As a result, mutating 
T55 could potentially quench enzyme activity. However, the H bond with K143 may 
have already broken if residues have had to fold and orientate differently to 
accommodate for the glycan chains in P. pastoris-expressed protein. T57 is a surface 
residue in contact with a water molecule (see Figure 3.18B), which helps to make it 
available for glycosylation. By mutating T57 to N57, the bond with water is not lost, 
although it is a more bulky amino acid.  
 
 
 
 
 
 
 
 
 
 
 
A 
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Figure 3.18 Computer-assisted representation of the location of residues T55 and T57 within 
CPG2  
A) T55 (grey/red/blue) shown here as buried and in close proximity to the active site (Zinc ions, black 
spheres). B) T57 (grey/red/blue) close to the surface and hydrogen bonded to a water molecule 
(red/light blue). Red sphere, oxygen atom; blue sphere, nitrogen atom; light blue sphere, hydrogen 
atom. The image was produced using the bacterial CPG2 crystal structure (PDB: 1cg2) with the kind 
assistance of Dr Paul Gane (Department of Medicinal Chemistry, UCL). 
 
Five mutated constructs of CPG2_3Q containing T55 and/or T57 substitutions were 
proposed for cloning, as shown in Table 3.3. T55 was substituted with glutamine 
(T55Q; charge is similar), valine (T55V; hydrophobic but isosterically similar), 
alanine (T55A; small and hydrophobic), asparagine (T55N), or asparagine in the 
presence of a T57 substitution to asparagine (T55N_T57N). Gene sequences of 145 
base pairs (…NIETGT…), each containing the amino acid change, were ordered 
from GenScript Inc. The 5 genes were substituted individually with PstI and XhoI 
restriction enzymes into the pPICZαB_mCPG2_3Q vector (as mentioned in Section 
3.2.2.2). Protein was expressed in methanol-induced yeast culture supernatant at 24, 
48 and 72 hr and enzyme activity of the mutated mCPG2_3Q constructs was tested 
on the UV-spectrophotometer and/or by HPLC. The results are summarised in Table 
3.4. Protein expression, as determined by Western blot using anti-His and anti-CPG2 
antibodies, was very weak (almost visible with naked eye) for all 5 mutants. Enzyme 
activity was not detected on the spectrophotometer but activity down to 0.002 U/ml 
could be detected with HPLC. The T55V mutant was found to exhibit the most 
activity at 72 hr expression in shake flasks, which was almost half of that detected 
for mCPG2_3Q. Nevertheless, a yeast clone was chosen to be taken forward for 
B 
T57 
Water 
molecule 
Chapter 3 
111 
 
scaled-up batch fermentation. The purified protein was loaded and run through a 
Superdex 75 column. The FPLC profile is shown in Figure 3.19. The T55V purified 
protein was found to exhibit activity of 274 U/ml (see Table 3.4).  
 
Due to the high enzyme activity obtained with T55V, two additional mutated 
mCPG2_3Q constructs were generated: T55V_T57N and T55V_T57V. These were 
cloned and expressed in yeast in the same way as described above. The mutations 
were successful and adequate concentrations of protein were produced by 
fermentations. FPLC profile of the purified protein is shown in Figure 3.19. 
However, these constructs showed decreased enzyme activity compared to the parent 
T55V construct - 181 and 122 U/ml for T55V_T57N and T55V_T57V, respectively 
(see Table 3.4).  
 
Table 3.4 T55 and/or T57 mutated constructs of CPG2 and their corresponding enzyme 
activities  
The constructs that were taken forward for fermentation are shown in bold. *Enzyme activity was 
measured using HPLC, except for T55V_T57N and T55V_T57V, which were measured on the UV-
spectrophotometer.  
 
 
Clone 
Sequence 
Change 
Enzyme activity 
(U/ml) 72hrs 
shake flasks* 
Specific activity 
(U/mg) of purified 
protein 
Total yield (mg) 
purified protein from 
9 L feedstock 
mCPG2_3Q actggtact 1.06 231 166.3 
T55Q cagggtact 0.01   
T55V gttggtact 0.47 152.4 44.5 
T55A gctggtact 0.32   
T55N_T57N aacggtaac 0.06   
T57N actggtaac 0.13   
T55V_T57N gttggtaac <1 50 75 
T55V_T57V gttggtgtt <1 29 84 
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Figure 3.19 FPLC profile of purified mCPG2_3Q mutated constructs: A) T55V, B) T55V_T57N 
and C) T55V_T57V  
25 ml of purified protein from the fermentor was applied to a Superdex 75 column. 0.5 ml fractions 
were collected. B) 8-12 fractions, inclusive, were pooled, C) 9-12 fractions, inclusive, were pooled. 
 
The loss of enzyme activity was probably the direct result of the mutated T55 and 
T57 residues, which may have caused a disruption in proper folding of the protein 
leading to a distorted binding/catalytic site. The FPLC profiles appeared to convey 
this as shown by the broad shape of the peaks for the doubly-mutated constructs 
(Figure 3.19 B and C), in contrast to the peak for singly-mutated T55V construct 
(Figure 3.19A). Consistent with this explanation, conservation analysis revealed that 
the T55 and T57 residues are highly conserved within CPG2 (Figure 3.20) with an 
amino acid conservation score of 9; the highest conservation score that can be 
obtained between sequences (345).  
 
A 
B 
A 
C 
Absorbance 
280nm mAu 
ml 
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Figure 3.20 Structural computation of bacterial CPG2 highlighting the conserved (pink), 
medium conserved (white) and non-conserved (blue) residues  
T55 is shown here in a green outline indicating that it is a highly conserved residue (dark pink). 
Conservation analysis of CPG2 scores were calculated against homologous sequences using the 
Consurf server programme http://consurftest.tau.ac.il/  (Image and computational analyses are 
courtesy of Harpal Sahota, Institute of Structural and Molecular Biology, Birkbeck College, London). 
 
To determine whether the mutations had an effect on the clearance of yeast CPG2 in 
vivo, an experiment was conducted in mice, as previously described in Section 
3.2.2.2.1. Twenty-five units of purified protein was injected i.v. into balb/c hairy 
mice and enzyme activity measured in blood at 1, 3 and 5 hr. The constructs to be 
measured included bacterial CPG2 (provided by Mologic Ltd), yeast-expressed 
mCPG2_3Q, yeast-expressed CPG2 (provided by Mologic Ltd), T55V and 
T55V_T57N mutated constructs. Unfortunately, the mutated constructs, T55V and 
T55V_T57N, cleared too rapidly to be detected. Bacterial CPG2 and mCPG2_3Q 
were detected and % injected activity/g noted in Table 3.5.  
 
 
 
 
 
 
 
 
T55 
Chapter 3 
114 
 
 
Table 3.5 Plasma biodistribution of mCPG2_3Q and bacterial CPGWT in mice  
Balb/c mice were given yeast-expressed mCPG2_3Q or bacterial CPG2 (25 U per mouse, i.v.) and 
enzyme activity measure in the plasma at 1, 3, and 5 hr after injection. Enzyme activity was measured 
by methotrexate catalysed-reduction on UV-spectrophotometer. Results expressed as the mean 
enzyme activity of 2 mice per group. N/D: not detected 
 
Time 
(hrs) 
mCPG2_3Q (% injected 
activity/g) 
Bacterial CPG2WT (% injected 
activity/g) 
1 17.2 61.2 
3 N/D 31.2 
5 N/D N/D 
 
 
3.3 Discussion 
 
The work detailed in this Chapter described strategies to create non-glycosylated 
MFECP for the proposed 3-phase ADEPT system. The strategies to deglycosylate 
MFECP have focused on the CPG2 component of the fusion protein, mainly because 
it is most susceptible to glycosylation by P. pastoris, but also most vulnerable to 
modifications that could affect its functional activity. The strategies investigated 
included using deglycosylating enzymes and genetically mutating the glycan-linked 
residues, both of which failed to generate a non-glycosylated yeast-expressed 
protein.  
  
Stability tests showed that the clinical grade batches of fusion protein appeared to be 
degraded after long-term storage at -80°C, but had not lost activity. This degradation 
may have occurred as a result of protease cleavage during the fermentation process, 
since MFECP contained a Kex2 protease cleavage site (Lys-Arg) located at the point 
of fusion between the antibody and enzyme. Removal of this site could potentially 
prevent partial degradation of the protein. The enzyme activity, 120 U/mg, was 
slightly lower than that recorded at the time of production (124 U/mg) (196), which 
was expected after long term storage. The fusion protein was also shown to be 
thermostable over 96 hr at 37°C.  
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The removal of sugars from glycoproteins is usually achieved by enzymatic or 
chemical methods. The main drawback of these methods is the lack of specific 
approaches to remove O-linked sugars. Previous studies identified N-linked 
glycosylations on the enzyme moiety of MFECP (137) as a result of yeast expression 
in P. pastoris, and O-linked glycosylations were believed to exist on the protein but 
this was not proven. Enzymes currently available for deglycosylation are only 
specific for the removal of N-linked glycosylations. These enzymes removed the N-
linked glycosylations on MFECP at Asn/GlcNAc sites and detection with 
biotinylated Con A revealed the presence of a small, single band on the Western blot. 
A Con A column was used to check the glycosylation status of PNGase F- and 
EndoHf-treated MFECP and revealed an apparently non-glycosylated fusion protein 
since it eluted in the binding phase. The same occurred when the Con A column was 
used to check the glycosylation status of the genetically mutated CPG2 construct, 
CPG2_3Q. Thus, genetic substitution of the N-glycosylated sites meant that either O-
linked glycosylations were absent on CPG2 or the O-linked glycosylations were 
short-chained branches that could not be distinguished by the Con A in the column. 
Nevertheless, it was certain that no N-glycosylations existed on CPG2_3Q since Con 
A primarily recognises α-mannose residues part of the N-glycan core structure, that 
is, residues arranged in a tri-mannosyl {Manα(1,3)[Manα(1,6)]Man} configuration 
(346) (347) (348) (16). As a result, the Con A column only verified the N-
glycosylation status of enzyme-treated MFECP and CPG2_3Q but not the overall 
glycosylation status. Furthermore, the rapid blood clearance of CPG2_3Q (compared 
to non-glycosylated bacterial CPG2) in vivo proved that the CPG2_3Q remained 
glycosylated, and thus the absence of N-glycosylations were insufficient to halt the 
enhanced clearance of the enzyme by the mannose receptors in the liver. By 5 hr 
CPG2_3Q and bacterial CPG2 had cleared from the circulation at 1.12 and 38.6 % 
injected enzyme activity/g, respectively. Previous clearance studies showed that by 6 
hr 13 and < 0.004 % injected enzyme activity/g of bacterial CPG2 (136) and P. 
pastoris-expressed MFECP (138), respectively, remained in the circulation.  
 
The FPLC profile of CPG2_3Q presented a skewed Gaussian-shaped peak, which 
indicated partial dimerization, perhaps resulting from an improperly folded protein. 
Since CPG2 naturally dimerises non-covalently, the N-linked mutation on residue 
Asn-264 may have impeded the complete dimerisation of CPG2_3Q. This was 
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supported by the fact that the Asn-264 residue in MFECP was not glycosylated 
because it appeared to be an important residue involved in dimerisation and enzyme 
activity (342). Besides, Springer and colleagues (342) showed that mutation of all 3 
N-glycosylation sites in CPG2 led to recovery of the enzyme’s activity and affinity 
for the prodrug.  
 
The presence of O-linked glycosylations, which occupy the Ser/Thr residues upon 
post-translational modification in P. pastoris, was addressed separately. O-linked 
glycosylations are less easy to categorise and there is no specific enzyme to cleave 
O-linked glycosylations, like there is for N-linked glycosylations. Thorpe and 
colleagues (349) (350) were first to mention the removal or modification of 
glycosylation on the ricin immunotoxin in order to improve the retention of the 
protein in circulation and preventing hepatic clearance. Chemical methods for O-
deglycosylation include alkaline hydrazinolysis, trifluoromethanesulfonic acid and 
alkaline borohydride for β-elimination, which are used to liberate oligosaccharides 
from the protein. These are not specific and usually require very high or low pH 
conditions, which can lead to loss of protein structure and enzyme activity. Chemical 
treatments are usually ideal for detecting the presence and residue location of 
glycosylations in mass spectrometry (MS) analysis. To improve the tumour-to-blood 
ratios in ADEPT, Houba et al. (151) reported the complete deglycosylation of the 
human enzyme, β-glucuronidase, by treatment with sodium periodate and sodium 
borohydride. Recovery of enzyme activity was 95% and the antibody-enzyme 
conjugate cleared slower than the glycosylated conjugate. 
 
In an attempt to remove the potential O-linked glycosylations on CPG2_3Q, the 
DNA sequence was rationally mutated on 12 surface Ser/Thr residues, creating 
CPG2_3Q_12A. Unfortunately, these mutations proved detrimental to the protein’s 
enzyme activity. This was probably caused by the mutations, such that, too many 
residues were mutated, the wrong residues were mutated, alanine was used for all 
substitutions, and/or the lack of residues to glycosylate by P. pastoris led to improper 
protein folding. Alanine is the smallest hydrophobic amino acid and using this 
residue to replace otherwise larger, polar amino acids may have caused difficulties in 
proper folding of the protein. Indeed, glycosylation in yeast aids in the proper folding 
and expression of proteins, such that many proteins do not fold properly when 
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unglycosylated, and instead aggregate (351) (352) (353). Protein O-glycosylation has 
roles in modulating the function of secretory proteins by enhancing their stability and 
solubility and affording protection from degradation by proteases (354). In 
filamentous fungi, protein O-glycosylation contributes to proper maintenance of 
fungal morphology, development and differentiation (355). 
 
In a second attempt to remove the O-glycosylations from CPG2_3Q, MS analysis 
was used to identify the residues that were glycosylated. MS is a valuable tool for 
analysing protein modifications, and is being increasingly used in glycoproteomics 
(356) to, 1) distinguish and identify glycosylated protein and peptides, 2) determine 
the N- and O-glycosylation sites and the degree of occupancy, and 3) analyse the 
structures of the attached glycan moieties (357) (358) (359) (360) (361). MS analysis 
revealed 10 O-glycosylated Ser/Thr sites to potentially mutate. Interestingly, only 3 
of the 10 experimentally identified O-glycosylation sites were amongst the 12 
predicted by NetOGlyc and neither of the definitively ascribed T55 nor T57 were 
amongst the 3 sites predicted by both approaches. With the O-glycosylated residues 
identified, the substituting residues were predicted, this time, taking into account the 
sites of occupancy within the protein molecule.  
 
Interestingly, in computer-modelling of the bacterial CPG2 crystal structure, it 
became clear that the orientation of some of the residues may have shifted as a result 
of glycosylation processing, which doesn’t exist in bacteria. For example, S245 on 
CPG2_3Q, which was found to be O-glycosylated in P. pastoris, appeared to be 
buried in bacterial CPG2. This was probably because the protein had to 
accommodate for the glycan chains and therefore would have folded in a different 
orientation. Furthermore, this residue is located at the dimerization interface, which 
may explain the reduced enzyme activity observed for glycosylated P. pastoris-
expressed MFECP and CPG2 compared to the non-glycosylated bacterial CPG2 (~ 
600 U/ml, reported by Mologic Ltd). In fact, studies have clearly demonstrated that 
glycosylation can impact enzyme catalysis (362) (363). For example, Grinnell and 
colleagues found that elimination of the glycosylation sites on various glycoforms of 
the antithrombotic serine protease human protein C (HPC), by site-directed 
mutagenesis, led to an increase in the catalytic rates (Kcat) without apparent changes 
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in substrate binding affinities (KM) (364). Similar findings have been found with 
other proteins (365) (366) (367).  
 
The codon-optimised mCPG2_3Q from Mologic Ltd was more amenable to genetic 
manipulation and has resulted in a higher enzyme activity when expressed in P. 
pastoris compared to CPG2_3Q constructed from the original bacterial plasmid 
sequence in-house. The T55/T57 mutated constructs were, therefore, cloned into 
mCPG2_3Q gene sequence and the T55V mutant, which possessed the highest 
enzyme activity in shake flask cultures, was taken forward for large-scale production. 
The success of the genetic manipulation led to the production of two T55_T57 
double mutants. Asn was chosen for the T55V_T57N mutant because of its size and 
polar nature which is similar to threonine. Valine was chosen for T55V_T57V 
simply because of the success with T55V, alone. Unfortunately, the enzyme activity 
of CPG2 was further reduced by the extra mutations, although the protein yield was 
high when expressed in yeast. Conservation analysis of the CPG2 sequence revealed 
T55 and T57 to be highly conserved residues, which may be the contributing to the 
reduced enzyme activities of the double T55_T57 mutants in relation to the singly 
mutated T55V construct and, subsequently, the reduced enzyme activity of this 
mutant in relation to mCPG2_3Q. Conservation grades for the N-linked residues, 
Asn-222, -264 and -272, are 1, 9 and 3, respectively (9 indicates a highly conserved 
residue). This clearly explained the reason for glycosylation occurring on Asn-222 
and -272, but not -264 when CPG2 is expressed in P. pastoris.  
 
The major advantage of using a yeast expression system is the ease of protein 
production, including shorter process times and high production yields, especially of 
recombinant mAbs and mAb fragments (368). P. pastoris glycosylation processing is 
not complex in the type of glycan structures or patterns it forms, like in mammalian 
cells, but rather the challenge is determining the site and occupancy of O-linked 
glycosylation on a single residue. Bacterial protein expression systems are popular 
because bacteria are easy to culture, grow fast and produce high yields of 
recombinant protein. However, multi-domain eukaryotic proteins expressed in 
bacteria are often non-functional because the cells are not equipped to accomplish 
the required post-translational modifications and molecular folding. Also, many 
proteins may be expressed as insoluble aggregates in inclusion bodies and are often 
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difficult to recover without harsh denaturants and subsequent cumbersome refolding 
procedures. For example, bacterial expression of MFECP was previously shown to 
generate impractically low yields (136) (195). Mammalian expression systems 
usually produce functional protein, but the yield is low, cost of production is high 
and mammalian cell culturing is time-consuming. Nevertheless, their comprehensive 
post-translational processing machinery results in glycosylation patterns suitable for 
clinical use and different to those in P. pastoris, so potentially, will not bind to the 
mannose receptors in the liver.  
 
Approaches to deglycosylate proteins produced in P. pastoris have principally 
focused on N-glycosylation, which exhibits an organised post-translational pattern. 
Strategies have included: glycosylation inhibitors, for example, tunicamycin, which 
has previously been used to block N-linked glycosylation on CPG2 in mammalian 
cells (342); and N-linked glycoengineering in P. pastoris by inactivation and/or over-
expression of certain enzymes (369) (370) (371) (372) (373). Characterisation and 
removal of O-linked glycosylations in P. pastoris in this manner have been more 
difficult to achieve. Until very recently, only inhibitors of the protein O-
mannosyltransferase (pmt) enzyme had been employed as a means to inhibit O-
linked glycosylation in  P. pastoris, S. cerevisiae and the protease-deficient yeast 
strain, Ogataea minuta (374) (375). A means to reduce non-desirable mannose O-
glycosyations would be to genetically engineer yeast P. pastoris. A recent paper 
identified and characterised the protein-O-mannosyltransferase (PMT) gene family in 
P. pastoris and demonstrated how O-glycosylation in P. pastoris could be 
manipulated by creating PMT-knockout strains and/or using PMT inhibitors (376). 
The authors noted the importance of O-mannose chain-length in addition to the 
overall extent of glycosylation. For example, it was found that PMT1 and PMT2 
knockouts led to significantly reduced O-glycosylation on the expressed protein, 
which correlated with a decrease in O-glycan occupancy from 20 to 3-4 moles of 
glycan per mole of protein (376).   
 
Other strategies, which do not involve removal of glycosylation, instead focus on 
slowing clearance of the fusion protein by using blocking reagents (377); and/or 
increasing circulation time of the protein by polyethylene glycol (PEG) modification, 
or FcRn-mediated recycling (378) (379). Mannan, which blocks the mannose 
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receptors in the liver, increased blood enzyme levels in mice by 200-fold 5 hr-post 
administration of MFECP, compared to MFECP alone (196). PEG-modification of 
bacterial β-glucuronidase was investigated in order to improve the stability and 
pharmacokinetics of antibody-β-glucuronidase conjugates in ADEPT (209). 
PEGylated conjugates exhibited greater tumour uptake and decreased normal tissue 
binding of antibody-β-glucuronidase conjugates. Although, more than 3 PEG 
molecules were found to affect enzyme activity, the antibody-enzyme conjugate was 
stable in serum regardless of PEG modification.  
 
 
3.4 Summary 
 
This Chapter proposed that the current ADEPT system could be modified in order to 
improve the pharmacokinetics of ADEPT in a 3-phase treatment system. In principle, 
a non-glycosylated fusion protein would slow clearance of the fusion protein from 
blood resulting in increased enzyme retention in the tumour. To this end, the use of 
deglycosylating enzymes was too expensive and was effectively limited to the 
removal of N-linked glycosylations on MFECP. Genetic manipulation of the N-
linked glycosylated residues on CPG2 generated a functionally active protein 
(CPG2_3Q) upon expression in P. pastoris. However, its rapid clearance in vivo 
suggested the presence of O-linked glycosylation. Mass spectrometry revealed 10 O-
linked residues in CPG2_3Q, of which, 2 (T55 and T57) were definitively ascribed. 
Various mutated constructs were generated, with T55V exhibiting the highest 
activity. The success of this mutant led to the creation of the double mutated 
constructs, T55V_T57N and T55V_T57V, both of which exhibited lower enzyme 
activities compared to T55V. T55 and T57 were found to be highly conserved 
residues, and thus proved that the removal of P. pastoris O-linked glycosylation on 
CPG2 is challenging.  
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4 Investigating the DNA Damage Response to 
ADEPT   
 
4.1 Introduction 
 
It is believed that certain DNA damage response mechanisms play a role in the lack 
of effective therapeutic benefit after one cycle of ADEPT. In mice bearing colorectal 
carcinoma xenografts, a single therapy dose of MFECP followed by the ZD2767P 
prodrug led to a short-lived tumour response, whilst repeat dosing led to sustained 
tumour regression (138). This implies that a single treatment with ADEPT does not 
result in tumour eradication. However, multiple cycles of treatment are likely to 
invoke an immune reaction against CPG2 leading toxicity (380) and induce drug 
resistance. Immunosuppression is also not an ideal solution (381).  
 
Early ADEPT studies indicated that potent DNA interstrand cross-links (ICLs) are 
induced following successful prodrug-to-active drug conversion in vitro, in vivo and 
clinical biopsies (242) (246) (139). Initial repair of these ICLs, by unhooking, was 
found to take place over time post-ADEPT (246), however the occurrence of other or 
downstream DNA repair processes was not indicated. It is proposed that DNA 
damage repair processes, in addition to ICL unhooking, are occurring in response to 
a single cycle of ADEPT and contributing to the low therapeutic efficacy.  
 
4.1.1 Aims and Objectives 
 
The aim: to investigate the formation of and response to DNA damage following a 
single cycle of ADEPT in vitro and in vivo. The objectives: 
1. To determine the growth inhibitory effect of ADEPT on antigen-positive and 
antigen-negative cancer cell lines. 
 
 
2. To measure the formation and initial repair of DNA ICLs.  
3. To measure the γ-H2AX response. 
4. To determine the RAD51 response. 
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4.2 Results  
 
4.2.1 Growth inhibition studies: Determining the effect of ADEPT on cell 
proliferation 
 
The growth inhibitory effect of a single cycle of ADEPT was tested on CEA
+ve
 
(SW1222) and CEA
-ve
 (A375M) cell lines. The SRB assay was performed to 
determine the concentration of prodrug required to inhibit the growth of cells by 50% 
following conversion to the active drug by the localised antibody-enzyme fusion 
protein, MFECP. The cells were incubated with 0.1 U/ml MFECP for an hour 
followed by the ZD2767P prodrug at various concentrations for another hour and 
subsequently incubated in drug-free media for 96 hr, as described in Section 2.2.4.1. 
The MFECP concentration was chosen based on previous studies conducted by 
Monks (382), who showed that 0.1 U/ml of CPG2 was sufficient for maximal 
ZD2767P activation within 1 hr incubation. The cells were fixed and stained with 
SRB - a bright pink aminoxanthene dye with two sulphonic acid groups, which under 
mildly acidic conditions binds electrostatically to basic amino acid residues of 
proteins in fixed cells. Figure 4.1 revealed a mean GI50 of 0.12 (±0.03) µM prodrug 
for SW1222 cells, although growth inhibition was initiated at prodrug concentrations 
> 0.03 µM. For CEA
-ve
 A375M cells (Figure 4.2), growth inhibition was apparent but 
the effect was observed with a greater concentration of prodrug, that is, mean GI50 
0.55 (±0.06) µM. This was more than 5 times higher than the GI50 value for ADEPT-
treated SW1222 cells. These results demonstrated the highly specific nature of the 
enzyme for the prodrug, and furthermore that prodrug was activated and conversion 
to the active drug has a growth inhibitory effect on the cells. However, it is likely 
that due to the nature of the in vitro protocol, in which the prodrug was added 
directly to the fusion protein, residual unbound fusion protein was contributing to 
growth inhibition, as demonstrated by the non-antigen-specific A375M cells.  
 
 
Chapter 4 
124 
 
 
Figure 4.1 In vitro growth inhibition in CEA-expressing SW1222 cells treated with a single cycle 
of ADEPT  
SW1222 cells were treated with 0.1 U/ml MFECP for 1hr followed by various concentrations of the 
prodrug for 1 hr. Cells were then incubated in drug-free media for 96 hr and treated with SRB. For the 
graph indicated in green, fusion protein was removed from the media prior to adding the prodrug. 
(mean ± SEM). 
 
 
 
Figure 4.2 In vitro growth inhibition in non-CEA-expressing A375M cells treated with a single 
cycle of ADEPT  
A375M cells were treated with 0.1 U/ml MFECP for 1hr followed by various concentrations of the 
prodrug for 1 hr. Cells were then incubated in drug-free media for 96 hr and treated with SRB. For the 
graph indicated in green, fusion protein was removed from the media prior to adding the prodrug. 
(mean ± SEM). 
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In view of this, the protocol was adapted accordingly. Growth inhibition was 
evaluated on cells that had been washed of excess MFECP prior to prodrug addition. 
The effect of growth inhibition caused by ADEPT on SW1222 cells was the same 
whether or not residual fusion protein is removed prior to prodrug (Figure 4.1). The 
only difference was the mean GI50 was greater, at 0.19 (±0.03) µM, when the 
unbound fusion protein was removed. When the same protocol was applied to 
A375M cells, no growth inhibitory effect was observed. This clearly demonstrated 
the highly specific targeting effect of ADEPT provided by the anti-CEA antibody. 
Thus, although the fusion protein did not bind to the cells, its presence in the media 
still rendered it active towards the prodrug, unless it was removed. This could be a 
potential problem in vivo if the fusion protein is not permitted to clear from the blood 
and healthy tissues prior to prodrug administration.   
 
The prodrug and fusion protein were also tested individually in order to verify that 
these components on their own did not have a growth inhibitory effect on the cells. 
The fusion protein did not have any effect on the cells and was similar to that of non-
treated cells. Prodrug alone also showed no growth inhibitory effect on the cells up to 
10 µM. However, there was a growth inhibitory effect on cells at prodrug 
concentrations >10 µM, as shown in Figure 4.3. Interestingly, the effect in SW1222 
cells was greater than in A375M cells, with a mean GI50 of 27 (±6.75) µM and 96 
(±12.12) μM, respectively.  
 
 
 
Chapter 4 
126 
 
 
 
Figure 4.3 In vitro growth inhibition in CEA- and non-CEA-expressing cells treated with 
prodrug only  
SW1222 and A375M cells were treated various concentrations of prodrug for 1 hr, incubated in drug-
free media for 96 hr and then treated with SRB. (mean ± SEM). 
 
4.2.2 DNA ICL damage by ADEPT 
 
The modified single-cell gel electrophoresis assay, also known as the comet assay, 
was originally developed to measure strand breaks, and has been adapted to measure 
interstrand cross-linking and repair (383) (384). The comet assay uses X-ray 
irradiation to introduce a fixed level of random DNA strand breaks in the cells. The 
strand breaks migrate in an electrophoretic field depending on the presence (and 
extent) of interstrand cross-linking. The extent of DNA damage is quantitated by 
image analysis to produce a tail moment, defined by Olive et al. (385). The method 
is described in more detail in Section 2.2.4.2. Examples of the typical comet images 
were taken, where each orange sphere represents a single cell-containing DNA 
(Figure 4.4).  
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Figure 4.4 Typical comet images of SW1222 colorectal carcinoma cells treated with increasing 
concentrations of the ZD2767 prodrug  
(A) Non-ADEPT-treated, unirradiated tumour cells. After irradiation (17.5 Gy) of non-ADEPT-treated 
tumour cells, distinct comets were observed (B). ADEPT-treated, irradiated tumour cells (C-I) were 
exposed to 0.1 U/ml MFECP for 1hr followed by 0.005-2 µM prodrug for 1 hr. (J) Prodrug-only (2 
µM), unirradiated tumour cells. In all images nuclei were stained with propidium iodide. Original 
magnification, x20. 
 
4.2.2.1 Measuring ICL formation and unhooking (initiation of repair) in vitro  
 
A standard curve for X-ray irradiation dose in non-drug-treated SW1222 cells was 
performed to establish an optimum radiation dose (Gy) that produced satisfactory 
DNA strand break levels in the cells. Ideally, the dose should give a head-to-tail 
DNA ratio of approximately 1:1. An X-ray dose of 17.5 Gy was sufficient for all 
comet assay experiments. In untreated, unirradiated SW1222 cells no DNA damage 
was detected and the DNA remained intact, as shown in Figure 4.4 A. Following 
irradiation of cells with 17.5 Gy, the resulting shorter DNA fragments migrated from 
the bulk of the DNA during electrophoresis to produce the typical comet images 
(Figure 4.4 B).   
 
Cells were treated with ADEPT following the in vitro protocol previously outlined 
for the growth inhibition assays and varying the prodrug concentration. When 
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ADEPT-treated cells were irradiated (Figure 4.4 C-I), comet tails were visible but 
with decreased length and intensity compared with irradiated untreated cells. The 
images showed that comet tail length is inversely proportional to prodrug 
concentration (Figure 4.4 C-I). The comet heads were larger and of greater intensity 
compared with the untreated irradiated cells (Figure 4.4 B) as a result of the retention 
of DNA by the prodrug-induced ICLs. The decrease in comet tail moment compared 
with untreated irradiated cells was used to quantitate the level of DNA ICLs formed 
upon treatment with ADEPT, as shown in the dose-response curve, Figure 4.5. The 
concentration of prodrug required to cause 50% cross-linking in SW1222 cells was 
0.21 (± 0.02) µM.  
 
 
Figure 4.5 Formation of ADEPT-induced DNA ICLs in SW1222 colorectal carcinoma cells  
Cells were treated with 0.1U/ml of MFECP for 1 hr followed by various concentrations (0-2µM) of 
prodrug for 1hr, and DNA ICLs measured using the comet assay. Results are expressed as percentage 
decrease in tail moment for 50 cells per experiment analysed (n = 3, mean ± SEM). Percentage 
decrease in tail moment is directly proportional to the levels of cross linking.  
 
Prodrug alone did not induce single-strand breakage in unirradiated cells (Figure 4.4 
J) and these cells showed similar profiles to the untreated cells (Figure 4.4 A). A 
dose response curve of irradiated prodrug-only-treated SW1222 cells is shown in 
Figure 4.5. The results indicated low-level cross-linking <30%, which appeared to 
correlate with the low toxicity seen in the growth inhibition assays up to 3 μM 
prodrug. However, at concentrations >3 µM, the formation of DNA ICLs steadily 
increased with increasing prodrug concentration but less than 50% cross-links were 
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formed at prodrug concentrations as high as 100 μM (Figure 4.6). To investigate the 
cross-linking effect of the prodrug over a longer incubation period, the prodrug was 
incubated with the cells for 3 hr, as opposed to 1hr. As shown in Figure 4.6, there 
was no difference in the formation of ICLs with increasing prodrug concentration 
over time, except by 3hr some ICLs may have repaired, as indicated by the lowered 
response. ICL formation in cells treated with only the fusion protein were 
comparable with the untreated cells, indicating that the fusion protein alone had no 
cytotoxic effect on the tumour cells. 
 
 
 
Figure 4.6 In vitro formation of DNA ICLs produced by the prodrug alone in SW1222 colorectal 
carcinoma cells measured using the comet assay  
Cells were treated with 0.3-100µM prodrug for 1hr. Results are expressed as percentage decrease in 
tail moment for 50 cells per experiment analysed (mean ± SEM). 
 
Next, the time course of ICL formation and repair was assessed in SW1222 cells 
treated with ADEPT using 0.25 μM prodrug, which was previously shown to 
generate > 50% cross-links. ICLs were found to form rapidly following ADEPT 
treatment, peaking at 1hr (Figure 4.7). This rapid increase was followed by an 
equally rapid reduction in ICLs by 4 hr. The decrease in level of ICLs at 48 hr 
(expressed as the % unhooking at 48 hr-post-ADEPT) was 72%. The experiment 
indicated that ICLs form immediately following ADEPT, and this most likely 
commenced during prodrug incubation (as indicated by the 40% cross-linking at 0 
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hr). Moreover, the data indicated that DNA damage repair occurred, albeit the initial 
stages of ICL repair, in colon carcinoma cells exposed to ADEPT. 
 
 
 
 
Figure 4.7 DNA ICL formation in SW1222 cells over time post-ADEPT  
Cells were treated with ADEPT using 0.25 µM prodrug. After prodrug incubation the cells were 
incubated in drug-free medium and samples were taken at different time points over 48 hr. ICLs were 
measured using the comet assay. Results are the mean ± SEM of 50 cells from 3 independent 
experiments. 
 
4.2.2.2 Measuring ICL formation and unhooking (initiation of repair) in vivo 
 
ICL formation and unhooking was measured in response to a single-cycle treatment 
of ADEPT in cells isolated from SW1222 colon carcinoma xenografts and peripheral 
blood lymphocytes (PBLs) isolated from whole blood perfusions from mice. The 
mice were given 1000 U/kg MFECP followed by 70 mg/kg ZD2767P prodrug 6, 7 
and 8 hr later. The tumours and blood were removed at 1, 3 and 24 hr post-treatment. 
This in vivo ADEPT protocol was followed according to that previously used by 
Sharma et al. (138) and is explained in Section 2.2.5.2. 
 
The results from the comet assay are presented as irradiated and unirradiated comet 
tail moments in Figure 4.8 and Figure 4.9 for tumours and PBLs (respectively), 
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which were extracted from individual mice at different time points post-ADEPT (4 
mice per time point). The presence of ICLs was indicated by a decrease in the 
irradiated tail moment of the ADEPT-treated samples compared to the untreated 
samples. (Note: tail moment is the product of the percentage DNA in the comet tail 
and the distance between the means of the head and tail distributions). As shown in 
Figure 4.8, at 1 hr-post-ADEPT there was a significant (p<0.0001) decrease in 
irradiated DNA tail moment compared to the non-treated, with a mean percentage 
reduction in tail moment of 100% (± 4.00) (using Equation 2.2, Section 2.2.5.2). This 
suggested, firstly, that ADEPT caused DNA damage in the form of DNA ICLs in the 
tumour cells in vivo, and secondly, that these ICLs formed rapidly. At 3 and 24hr-
post-ADEPT, ICL formation persisted with statistically significant (p<0.0001) mean 
percentage reduction in tail moments of 72% (±15.75) and 55% (±13.02), 
respectively. This indicated that ICLs persisted over 24hr-post-ADEPT in vivo, and 
the fewer ICLs being formed at 24 hr implied that cross-links were being unhooked 
(statistically significant, p<0.0001). The unirradiated tail moment values indicated 
low level ICL formation, which may be background DNA damage in the tissues 
caused by various endogenous metabolic reactions.  
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Figure 4.8 DNA interstrand cross-linking in SW1222 xenograft tumour tissue  
Nude mice (4 per test group) bearing SW1222 tumours were injected (i.v.) with 1000 U/kg MFECP 
followed by 70 mg/kg ZD2767P (i.p.) at 6, 7 and 8 hr later. Tumours were excised at 1, 3 and 24 hr 
after the last prodrug dose, and processed immediately into single-cell suspensions. The study also 
included a non-ADEPT treated group. The cells were irradiated with X-rays at a dose of 17.5 Gy and 
ICLs were measured using the comet assay. Results are expressed as mean tail moment for 50 cells ± 
SEM per mouse, where the tail moment is inversely proportional to cross-linking. (Tail moment is the 
product of the percentage DNA in the comet tail and the distance between the means of the head and 
tail distributions).   
 
Figure 4.9 illustrates the irradiated and unirradiated tail moment values for PBLs 
which came from the same mice whose tumour xenografts were examined in Figure 
4.8. The tail moments for the PBLs in ADEPT-treated mice appeared to show few 
deviations from those of the PBLs in non-treated mice, with mean percentage 
reduction in tail moments of 17% (± 4.63), 6% (± 7.22) and 7% (±10.41) at 1, 3 and 
24 hr-post-ADEPT, respectively. The large difference in cross-linking at 1 hr 
compared to 3 and 24 hr may have resulted from peripheral activation of the prodrug 
or accumulation of prodrug in certain areas. Data collected from the PBLs validated 
the principle of ADEPT in vivo, that is, site-specific activation of the prodrug. 
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Figure 4.9 DNA interstrand cross-linking in peripheral blood lymphocytes derived from 
ADEPT-treated mice bearing SW1222 tumour xenografts  
Nude mice (4 per test group) bearing SW1222 tumours were injected (i.v.) with 1000 U/kg MFECP 
followed by 70 mg/kg ZD2767P (i.p.) at 6, 7 and 8 hr later. Blood perfusions were collected at 1, 3 
and 24 hr after the last prodrug dose, and processed immediately into single-cell suspensions. The 
study also included a non-ADEPT treated group. The cells were irradiated with X-rays at a dose of 
17.5 Gy and ICLs were measured using the comet assay. Results are expressed as mean tail moment 
for 50 cells ± SEM per mouse, where the tail moment is inversely proportional to cross-linking. (Tail 
moment is the product of the percentage DNA in the comet tail and the distance between the means of 
the head and tail distributions).   
 
 
4.2.3 The DNA damage response to ADEPT 
 
To complement the findings of ICL unhooking in vitro and in vivo, phosphorylation 
of H2AX histone protein, that is, γ-H2AX, was measured following a single cycle of 
ADEPT. It has been reported γ-H2AX accumulates at sites of DSBs to form discrete 
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nuclear foci (308) (310). Since its discovery, γ-H2AX has been widely used as a 
highly sensitive, prognostic marker of DNA damage and has been clinically 
validated as a pharmacodynamic marker of DNA damage in response to ICL-
inducing agents (320) (386) (338) (387). 
 
4.2.3.1 Measuring γ-H2AX foci formation in vitro 
 
Figure 4.10 shows a dose response of γ-H2AX foci in SW1222 cells was measured at 
3 hr-post-ADEPT (blue) or prodrug alone (red). Briefly, cells were incubated with 
0.1 U/ml fusion protein for 1 hr (or drug-free media for prodrug alone) followed by 
various concentrations of prodrug for 1 hr and incubated in drug-free medium for 3 
hr. The cells were then trypsinised, fixed onto slides and incubated with an anti-γ-
H2AX monoclonal antibody. Foci were detected when a fluorophore-conjugated 
antibody was applied and microscope images were acquired for counting. In the 
ADEPT-treated cells, the γ-H2AX response, which is defined as the average number 
of foci per cell, steadily increased with increasing prodrug concentration post-
treatment. In the prodrug-only treatment a weak γ-H2AX response indicated low 
levels of DNA damage incurred, with an average number of foci per cell less than 2. 
Foci formation in cells treated with fusion protein alone were comparable with the 
untreated cells.  
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Figure 4.10 Dose response of γ-H2AX foci in SW1222 cells following exposure to ADEPT (blue) 
or prodrug alone (red)   
Cells were incubated with fusion protein for 1hr followed by the prodrug for 1 hr at various 
concentrations (blue), or incubated with prodrug only (red). Following 3 hr in drug-free medium, the 
cells were trypsinised, fixed and stained with an anti-γ-H2AX antibody. 100 foci were counted per 
dose per experiment and normalised against foci in the non-treated cells (mean ± SEM).  
 
In order to determine the persistence of γ-H2AX over time, foci formation was 
measured in cells post-ADEPT over 48 hr, as previously conducted with the comet 
assay. Representative images of γ-H2AX foci detected in SW1222 cells over time 
post-ADEPT are shown in Figure 4.11. This pattern is graphically represented as 
average foci per cell at the same time points in Figure 4.12. γ-H2AX foci induction 
clearly peaked at 3 hr-post ADEPT, although foci were present as early as 0-1 hr-
post ADEPT, as shown in Figure 4.12. A weaker peak of induction followed at 16 
and 24 hr-post treatment. The strong γ-H2AX response at 3 hr-post-ADEPT was 
found to lag behind the peak ICL formation by 2 hr, suggesting the recruitment of 
repair proteins at the site of DNA damage is stimulated by ICL-associated DSBs 
(320) (307) (306) (319). Furthermore, the rapid increase in foci formed by 3 hr was 
followed by a rapid decline to near-baseline levels by 8 hr, which probably indicated 
resolution of the intermediary DSBs by downstream repair pathways. The second γ-
H2AX peak observed at 24 hr-post-ADEPT is thought to be linked to growth arrest 
of cells in G2 phase of the cell cycle (see Section 5).  
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Figure 4.11 Representative images of SW1222 cells showing γ-H2AX foci over time post-ADEPT  
Cells were treated with ADEPT using a prodrug concentration of 50 nM followed by post-incubation in drug-free medium for the times shown. Nuclei (blue) were stained 
with 4’,6-diamidino-2-phenylindole (DAPI), and foci (green) were detected with an anti-γ-H2AX antibody/Alexa Fluor 488 fluorophore-conjugated antibody. Images were 
visualised with a Perkin Elmer Ultraview Spinning Disk Confocal, driven by Volocity Acquisition (63x oil immersion objective).  
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Figure 4.12 γ-H2AX foci induction in SW1222 cells over time post-ADEPT  
Cells were incubated with the fusion protein for 1 hr followed by 50 nM prodrug for 1 hr and post-
incubation in drug-free medium for the times shown. 100 foci were counted per time point per 
experiment and average foci per cell was normalised against non-treated cells. (mean ± SEM).  
 
4.2.3.2. Measuring γ-H2AX foci formation in vivo 
 
The versatile nature of the immunofluorescence assay allowed subsequent 
measurement of γ-H2AX foci in tumour cells and PBLs from immune-compromised 
mice bearing SW1222 xenografts treated with a single cycle of ADEPT (as 
previously mentioned in Section 4.2.2.2). Gamma-H2AX foci were detected at each 
time point post-ADEPT for each individual mouse (Figure 4.13). The background 
level of γ-H2AX foci in the non-treated tumour samples was less than 1 focus per 
cell. At 1hr-post-ADEPT the levels of foci were almost comparable to the control 
with a mean number of foci per cell (compared to the untreated) of 1.90 (±0.48). 
Gamma-H2AX foci formed increased at 3 hr and 24 hr-post-ADEPT, with mean 
number of foci per cell 4.03 (±0.50) (p<0.0001) and 6.75 (±0.49), respectively. This 
pattern demonstrated that a DNA damage response formed and persisted over time in 
response to ADEPT-induced DNA damage. Furthermore, the γ-H2AX response 
increased relatively rapidly, doubling in foci formation, between 1 and 3 hr-post-
ADEPT. This suggested a very active period of time during which repair proteins 
likely accumulated at the site of DNA damage in vivo.  
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Figure 4.13 γ-H2AX response in ADEPT-treated SW1222 tumour xenografts 
Gamma-H2AX foci were detected and quantified in colorectal carcinoma tumour cells by 
immunofluorescence using a biotin conjugated anti-γ-H2AX antibody/Alexa Fluor 488 conjugated 
streptavidin. Tumours derived from the previously described in vivo study where mice were treated 
with ADEPT and tissues excised at 1, 3 and 24 hr after the last prodrug dose. (100 cells were counted 
per mouse ± SEM).  
 
Figure 4.14 represents the γ-H2AX response in PBLs analysed at various time points 
post-ADEPT in mice. The levels of foci formed at each time point changed relatively 
little compared to the untreated tumour cells, with mean foci per cell (compared to 
the untreated) 0.12 (±0.16), 0.85 (±0.15) and 1.61 (±0.32) at 1, 3 and 24 hr-post-
ADEPT, respectively. Although the response is low compared to the tumours, 
detection of foci probably indicated presence of peripheral damage caused by 
activation of prodrug or accumulation of inactivated prodrug.    
 
 139 
 
 
 
Figure 4.14 γ-H2AX response in peripheral blood lymphocytes (PBLs) derived from ADEPT-
treated mice bearing SW1222 tumour xenografts  
Gamma-H2AX foci were detected and quantified in PBLs by immunofluorescence using a biotin 
conjugated anti-γ-H2AX antibody/Alexa Fluor 488 conjugated streptavidin. PBLs derived from the 
previously described in vivo study where mice were treated with ADEPT and tissues excised at 1, 3 
and 24 hr after the last prodrug dose. (100 cells were counted per mouse ± SEM).  
 
 
4.2.4 DNA damage repair: Is there a role for homologous recombination (HR) 
following ADEPT?   
 
To determine whether HR was involved in the later stages of ICL repair, RAD51 
response was measured by immunofluorescence in the same way as previously 
described in Section 4.2.3. In humans, RAD51 is a 339-amino acid protein and is the 
essential initiator of the HR repair pathway, which is responsible for mediating error-
free repair of DSBs (388). RAD51 protein forms nuclear complexes in the form of 
microscopically-detectable foci in response to ionising radiation and DNA damaging 
agents. It is these foci which are thought to represent sites where repair takes place 
(328) (389).  
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In SW1222 cells the RAD51 response was marked at 6 hr-post-ADEPT followed by 
a smaller peak of induction at 24 hr (Figure 4.15). The 6-hr peak observed here 
followed the γ-H2AX response peak at 3 hr, and suggested that repair by HR 
occurred in response to ADEPT-induced ICL damage. In addition, the data is 
supportive of the formation of DSBs as intermediates during ICL repair. The second 
wave of foci induction is probably linked to the γ-H2AX peak also observed at 24 hr 
and may indicate repair occurring during later stages in the cell cycle. 
 
 
 
Figure 4.15 RAD51 foci induction in SW1222 cells over time post-ADEPT  
Cells were incubated with the fusion protein for 1 hr followed by 50 nM prodrug for 1 hr and post-
incubation in drug-free medium for the times shown. Cells were fixed and stained with anti-RAD51 
antibody followed by an Alexa Fluor conjugated antibody. Results are mean of 100 foci counted per 
time point (mean ± SEM). 
 
When RAD51 foci were measured in SW1222 colorectal carcinoma xenografts, there 
was no clear pattern in response to ADEPT-induced damage (Figure 4.16), in 
contrast to that seen in vitro. There was a difference in foci levels between the non-
treated and treated tumour samples, however mean foci per cell per time point post-
ADEPT was relatively equal, that is 5.5 (±0.33), 5.4 (±0.33) and 5.4 (±0.33) at 1, 3 
and 24 hr, respectively. This was probably because peak of induction in vivo was 
missed if it had occurred between 3 and 24 hrs-post ADEPT. Besides, the presence 
of detectable foci at each time point varied between the mice per time point and this 
variation was more evident at 24 hr, which could suggest varied rates of DSB repair.  
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Figure 4.16 RAD51 foci measured in ADEPT-treated SW1222 tumour xenografts  
RAD51 foci were detected and quantified in colorectal carcinoma tumour cells by 
immunofluorescence using an anti-RAD51 antibody and Alexa Fluor 488 conjugated secondary 
antibody. Tumours derived from the previously described in vivo study where mice were treated with 
ADEPT and tissues excised at 1, 3 and 24 hr after the last prodrug dose. (100 cells counted per mouse 
± SEM).  
 
 
4.3 Discussion 
 
The work detailed in this Chapter contributes to the understanding of the processes 
involved in DNA damage formation and repair in response to a single cycle of 
ADEPT in colon carcinoma SW1222 cells in vitro and in vivo. Studies showed that 
the cytotoxicity of ADEPT is the result of potent DNA damage lesions, that is ICLs. 
Experimental work investigating the γ-H2AX response in ADEPT-treated cells 
suggested the importance and complexity of DNA repair mechanisms. The cellular 
and DNA damage response following ADEPT were evaluated.  
 
The effect of ADEPT on tumour cell proliferation was assessed using the SRB assay, 
which revealed a GI50 of 0.12 µM and 0.55 µM in colorectal carcinoma and 
melanoma cell lines, respectively. This correlated well with previously reported GI50 
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values for ADEPT using the ZD2767P prodrug, which were found to be 0.04-2.2 µM 
in colorectal tumour and non-small cell lung cancer (NSCLC) cell lines (247) (246). 
These were relatively cytotoxic GI50 concentrations in comparison to other nitrogen 
mustard drugs, such as chlorambucil (26 µM LS174T cells, 79 µM LoVo cells) 
(247), melphalan (~50 µM LoVo cells) (270) and a monofunctional analogue of 
ZD2767 (18-38 µM for all comparable colorectal cell lines) (247). Thus, the greater 
cytotoxicity of bifunctional alkylating agents is probably a result of their ability to 
induce toxic DNA ICLs.  
 
Earlier studies that reported GI50 values with the ZD2767P prodrug were conducted 
without the antibody component of the fusion protein (246). All in vitro protocols 
described, incorporated the antibody-enzyme fusion protein, however it was 
necessary to rule out any binding by the fusion protein to the CEA
-ve
 A375M cells. 
Thus, to mimic the treatment conditions in vivo (where the fusion protein is allowed 
to clear from the circulation before prodrug can be given), unbound fusion protein 
was removed from the cells prior to prodrug addition. The GI50 in SW1222 cells was 
0.19 µM, with the removal/wash step proving to be a less sensitive protocol but a 
more genuine reflection of ADEPT (difference of 0.07 μM compared to when 
unbound fusion protein was not removed). As expected, there was no growth 
inhibitory effect in A375M cells. This demonstrated the highly specific targeting 
action of ADEPT and also the importance of the individual components of ADEPT.  
 
The growth inhibitory effect of the ZD2767P prodrug alone was also assessed and 
proved to have no effect on SW1222 cells at prodrug concentrations less than 10 µM, 
which is in accordance with data obtained with LS174T cells (246). In vivo, 
administration of prodrug alone was found not to slow tumour growth (138); and in 
patients the prodrug was shown to cause little toxicity (135). However, the prodrug 
was found to have an effect on tumour cells at concentrations greater than 10 μM, 
that is, approximately 100-fold differential in potency compared to ADEPT (or rather 
the active drug) in SW1222 and A375M cells, with GI50 of 27 and 96 μM, 
respectively. Similar findings were also found when LoVo cells were exposed to the 
active drug alone or the prodrug alone (133). A number of possible physiochemical-
related reasons could explain the growth inhibition observed at high concentrations 
of prodrug alone. For example, the balance between the lipophilicity and 
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hydrophilicity of the ZD2767P prodrug may be compromised at high concentrations 
(390), and this is in addition to its short half-life. Its ability to induce DNA damaging 
ICLs with increasing prodrug dose up to 100 μM was ultimately weaker than the 
action of the active drug in ADEPT, with low levels of ICLs persisting up to 3 μM 
before a notable increase was observed. The potency of ADEPT prodrugs has been 
relatively low, in the micromolar (μM) range. It is theoretically possible to use new 
and more potent prodrugs that would be too toxic to administer as standard 
chemotherapeutics. Tietze and colleagues (391) (392) showed that it is possible to 
design and apply in vivo prodrugs >4800 times less toxic than the corresponding 
active drug. Two novel pyrrolobenzodiazapiene-based prodrugs were investigated for 
use in ADEPT and found to be more potent (picomolar range) than nitrogen mustards 
(393).  
 
Clonogenic assays are useful for determining the potency of a drug but provide little 
detail as to how the drug affects the cell. Since the prodrug used here in ADEPT was 
a nitrogen mustard derivative, cross-links were believed to be the principle DNA 
damage lesion responsible for its potency, and therefore, cytotoxicity (394) (242) 
(395) (396) (264). A good correlation between the extent of cross-linking and 
cytotoxicity was previously demonstrated in response to ADEPT (246) (247). The 
modified comet assay was used to measure ICLs and their subsequent unhooking in 
response to a single cycle of ADEPT, in vitro and in vivo. The comet assay was 
originally developed to measure DNA strand breaks (397). The modified comet 
assay is more sensitive, requires fewer cells and can be appropriately applied for 
clinical blood and tissue samples (398) (246) (399) (400) (401) (402) (403) (139) 
(404) (387). The dose response experiment revealed a prodrug concentration of 0.21 
µM was required to cause 50% cross-linking in SW1222 cells. LS174T colorectal 
carcinoma cells were shown to be less sensitive to cross-linking at prodrug 
concentrations of 0.5-1 µM (246). It has been suggested that cross-linking may be a 
determinant of cellular sensitivity, more so than genetic p53 status (247) (338), 
especially since SW1222 cells are p53-defective and LS174T cells are p53 wild-type 
(405).  
 
Drug concentrations that give rise to 50-70% cross-links are routinely used for 
investigating ICL induction and repair. The time course experiment for ICL 
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formation post-ADEPT showed that ICLs formed rapidly in vitro and in vivo. The 
data revealed that ADEPT-induced ICLs peaked at 1hr in SW1222 cells, and 
suggested they probably start forming immediately upon prodrug administration. 
ICLs formed within 10 min upon exposure of cells to 0.02, 0.2, 2 µM ZD2767P 
(+CPG2) with no increase in damage seen over 50 min (247). Furthermore, there was 
no evidence of a decrease in ICL levels over 1 hr (suggesting no repair or stable 
adducts). Rapid cross-link formation is consistent with studies investigating the 
highly reactive ZD2767D active drug, which has a short plasma half-life (< 2 min) 
(133). Mechlorethamine-induced ICLs have been shown to peak at 1 hr-post-
treatment (322) (288) (320) (406), and for melphalan this was 16 hr in NSCLC cells 
(338). Nitrogen mustard-induced ICLs are generally quite unstable with a half-life of 
2 hr, which contributes to their decreased toxicity and therapeutic benefit compared 
to other, more stable ICLs (407) induced by pyrrolobenzodiazapienes (PBD) (393). 
DNA cross-links formed by PBDs have been shown to be more resistant to repair 
(408) (409,), reducing the probability of clinical resistance developing. 
  
Unhooking of these ICLs commenced within an hour following the peak of damage 
in SW1222 cells, with 47% cross-links unhooked by 24 hr and 72% unhooked by 48 
hr. Unhooking of ICLs is thought to be carefully orchestrated by specific NER 
nucleases that cause the covalent bond holding the strands of DNA together to flip 
out and leave a stable adduct, thus removing the cytotoxic lesion (see Figure 1.6). 
When mice bearing SW1222 xenografts were treated with ADEPT, cross-links 
formed rapidly within 1 hr and they persisted in samples taken at 3 and 24 hr-post-
treatment, with an estimated 45% of cross-links unhooked by 24 hr (considering 
there were 100% cross-links at 1 hr). This correlated well with the in vitro data, 
although earlier time points (before 1 hr) would be required in order to elucidate a 
definite peak in cross-linking in vivo. Despite the overall consensus, ICL unhooking 
varied between the tumours over time, in particular, tail moments for tumour samples 
from mice no.9 at 3 hr and no.15 at 24 hr. Webley et al. (246) also showed that cells 
from LS174T xenografts exposed to ADEPT (using the F(ab’)2 conjugate plus 
ZD2767P) had extensive ICL formation after 1 hr, which was significantly reduced 
at 24 hr, supposedly as a result of repair activity. In the Phase I ADEPT clinical trial, 
a reduction in tail moment by 58% was seen in a tumour sample from one patient, 
indicating effective localisation of MFECP and prodrug activation in the tumour 
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(139). Cross-linking was not observed in PBLs taken from the same patient at the 
same time as the treated tumour biopsy, thus, demonstrating the specificity and 
selectivity of ADEPT. Similarly, PBLs taken from the ADEPT-treated mice 
displayed low levels of cross-linking, though, ICLs detected at 1 hr-post-ADEPT 
were notably higher (17% reduction in tail moment) than at 3 and 24 hr. DNA 
damage exhibited here may be the result of peripheral prodrug activation, since the 
tumours exhibited extensive cross-linking. Indeed, cross-linking in PBLs from the 31 
patients treated in the ADEPT trial ranged from 0% to 27%, with only two patient 
samples displaying >20% reduction in tail moment (139).  
 
Mammalian ICL repair is complex, involving the concerted action of multiple repair 
pathways (303). Studies investigating ICL repair suggest DSBs are formed as an 
intermediary lesion during unhooking (323) (284) (269) (288). DSBs have been 
shown to trigger a γ-H2AX response following IR (310) and, to a less proportional 
extent, following alkylating agents (313) (410) (320) (411) (338). The role of γ-
H2AX is to recruit DNA repair and cell cycle checkpoint proteins required for the 
efficient processing of DNA DSBs. Thus, γ-H2AX induction following ICL DNA 
damage is a way of determining the DNA damage response. Specifically, the DNA 
damage response to ADEPT-induced ICLs was less understood and thus, explored. 
In SW1222 cells, γ-H2AX foci could be detected at very low concentrations of 
prodrug (in combination with the fusion protein), as low at 12.5 nM. The peak of γ-
H2AX formation was detected at 3 hr-post-ADEPT, that is 2 hr following the peak of 
ICLs. Similar timings were observed in mechlorethamine-treated human fibroblasts 
(320). The findings suggested that H2AX is phosphorylated within a few hours of 
DNA damage, possibly in response to ICL-associated DSBs, which are believed to 
form upon unhooking of ICLs. An additional smaller γ-H2AX foci peak was 
observed at 24 hr-post-ADEPT, the significance of which cannot be explained from 
these assays alone. The response was believed to be associated with repair of (non-
ICL-related) DSBs, which are thought to occur in the G2/M phase of the cell cycle 
(411). Additionally, ICL-induced DSBs (and other repair intermediates) may arise at 
later time points post-treatment as replication forks, previously blocked by ICLs, are 
restored, bypassed or restarted (411).  
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When the DNA damage response was measured in vivo, a statistically significant 
increase in γ-H2AX foci formation was observed over time post-ADEPT in SW1222 
tumour xenografts. Gamma-H2AX levels ranged from 2 foci per cell at 1 hr to 10 
foci per cell at 24 hr-post-treatment. Encouragingly, higher levels of γ-H2AX foci 
were observed in the tumours than in time-matched PBLs. The γ-H2AX foci per cell 
in PBLs ranged from 1 at 1 hr to 4 at 24 hr-post-treatment. The γ-H2AX response 
pattern observed in the tumours tied in well with the increase in comet tail moment, 
or rather, unhooking of cross-links over time. For example, where ICL formation was 
found to be greatest at 1 hr, the γ-H2AX response was weakest and vice versa at 24 
hr-post-ADEPT. In particular, tumour cells from one mouse (no.15) that exhibited 
the greatest number of γ-H2AX foci per cell, also displayed the largest comet tail 
moment post-treatment, further indicating that ICL unhooking correlated with γ-
H2AX response as a result of ICL-associated DSB formation. The γ-H2AX response 
was found to persist over time in vivo, although more time points before and after 24 
hr would be needed to clarify the biphasic response observed in vitro. Disappearance 
of γ-H2AX foci is believed to reflect dephosphorylation by protein phosphatases 
(412) (413), and thus, the removal of crosslinks (414) leading to the release of repair 
proteins to complete the DNA repair process (415). 
 
There is conflicting evidence on the functional relevance of γ-H2AX (416). The 
formation of γ-H2AX does not simply imply a direct repair response to DSBs 
induced during ICL repair, since γ-H2AX has been shown to be induced in HR-
defective cells and independently of readily detectable ICL-associated DSBs (319) 
(320) (288) (322). H2AX-deficient cells showed only mild defects in DNA damage 
checkpoint control and DNA repair, suggesting that H2AX assists in, but is not 
critical for DNA damage checkpoint activation and DNA repair processes (319) 
(321) (321). Interestingly, a potent pyrrolobenzodiazepene, SJG136, was found to 
induce a γ-H2AX response in clinical tumour samples and PBLs at 24 hrs-post-
treatment (417) (387), despite the persistence of ICLs, with very little ICL unhooking 
(408). This may reflect the non-distorting nature of the cross-links produced by this 
agent and which may evade early detection by the repair machinery (418).  
 
According to the literature, the γ-H2AX response in SW1222 cells exposed to 
ADEPT likely indicated the accumulation of proteins required for repair, namely the 
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HR and TLS pathways which are involved in the processing of (ICL-associated) 
DSBs (268) (269) (270) (411) (271) (272). DNA damage repair proteins recruited by 
γ-H2AX to the site of DNA damage include the MRE11/RAD50/NBS1 (MRN) 
complex, BRCA1, RAD51, MDC1 and FANCD2 – all major components of HR 
repair pathway (307) (419) (296). Paull et al. (307) demonstrated that γ-H2AX foci 
formed within a few minutes of DNA damage and accounted for the patterns of 
RAD50, RAD51 and BRCA1 foci seen much later during recovery from DNA 
damage.  
 
RAD51 is the central protein involved in controlling strand invasion and 
recombination in human cells during repair in response to DNA damage by DSBs 
(420) (421). RAD51 foci have been previously visualised by immunofluorescence 
after exposure of cells to exogenous agents (338) (85) (337). RAD51 foci induction 
over time post-ADEPT displayed a biphasic response, with the earlier 6-hr peak 
being the strongest and this was followed by another smaller peak at 24 hr. This 
biphasic response was also observed in cells treated with cisplatin (338). It would 
appear that the first peak is indicative of HR repair of ICL-associated DSBs, 
especially since there was a γ-H2AX response 3 hr earlier. However, the recruitment 
of RAD51 to damage sites has been shown to function independently of H2AX 
phosphorylation status (422) (423). RAD51 foci were found to interact with ICL-
stalled forks before DSB formation (330) and it is believed this may function to 
prevent fork breakage/degradation in order to initiate strand invasion as soon as the 
DSB has formed (424). RAD51 has also been shown to mediate restart of transiently 
stalled forks, but this function is not linked to foci formation or to its role in DSB 
repair (425). The control of RAD51 protein levels is thought to be partially cell-cycle 
dependent (426), which may explain the 24 hr peak of induction and it’s possible link 
to repair of non-ICL-related DSBs.  
 
The RAD51 response was detected in tumour xenografts, but in contrast to in vitro 
data, there was no obvious pattern of induction post-ADEPT, as seen with γ-H2AX. 
With the peak of induction occurring at 6 hr in vitro, it is likely the peak in vivo was 
missed, as only a few selected time points were obtained. Nevertheless, the results 
could also indicate the existence of RAD51-independent mechanisms of repair taking 
place in vivo (427) (428) (429) (430). Mixed responses for RAD51 upon treatment 
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with ICL-inducing agents have been previously reported (338) (387). For example, 
Wu and colleagues (387) found that RAD51 foci persisted or were absent in HR-
defective cells in response to cisplatin treatment. The role of RAD51 and other HR-
related proteins would need to be investigated further in response to ADEPT-induced 
ICL damage in vitro and in vivo.  
 
 
4.4 Summary 
 
The results presented here have clearly shown that there is a DNA damage response 
to a single cycle of ADEPT. Growth inhibition assays with antigen-positive and –
negative cell lines showed that ADEPT is specific in its action. The comet assay 
demonstrated that ADEPT is selectively toxic causing ICL damage, which formed 
rapidly by 1 hr in colorectal carcinoma cells in vitro and in vivo. ICLs were found to 
unhook over 48 hr and this correlated with a DNA damage response, represented by 
an increase in the γ-H2AX response at 3 hr-post ADEPT and 24 hr in vivo. The γ-
H2AX response indicated the accumulation of repair factors at the site of DNA 
damage and the possible presence of ICL-associated DSBs. A marked increase in 
RAD51 foci at 6 hr in vitro confirmed the presence of DSBs and moreover, the repair 
of these DSBs by HR. Further investigation of HR status in vivo is warranted. Taken 
together, the results indicate DNA damage repair in response to a single-cycle of 
ADEPT, which could potentially be manipulated to improve clinical therapeutic 
efficacy. 
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5 Approaches to Target the DNA Damage 
Response Pathway  
 
5.1 Introduction 
 
The pharmacodynamic response to a single cycle of ADEPT, as assessed in Chapter 
4, indicated the occurrence of DNA damage repair contributing to the lack of an 
effective tumour response. This was evidenced by the unhooking of ICLs, a γ-H2AX 
response and a RAD51 response; with the latter indicating the involvement of HR 
repair which is favoured in S or G2 phases of the cell cycle. In order to improve the 
therapeutic efficacy of ADEPT, it was proposed that selected genes and/or proteins 
could be inactivated (or activated) which would interfere with the repair process. 
 
The development of inhibitors for targeting the DNA damage repair pathway has 
been of considerable interest over the last few years as novel cancer therapeutic 
agents in their own right and/or in combination with existing therapies (431) (259). 
Of particular interest is targeting the cell cycle. In the event of DNA damage, normal 
cell cycling activity must halt in order for repair (or apoptosis) to take place; and this 
is mediated by cell cycle checkpoint kinases, Chk1 and Chk2, depending on the type 
of damage incurred and/or cell cycle phase (432) (257). Chk1 is important in 
regulating the intra-S and G2 phases in preparation for cell division, as demonstrated 
in biochemical and genetic analyses (433) (434). Selectively targeting and inhibiting 
Chk1 has emerged as an interesting therapeutic strategy for p53-deficient/defective 
cancers (435) (436) (437). By inhibiting Chk1, cancer cells are forced through the 
G2-to-M transition in the face of DNA damage induced by genotoxic agents (e.g. 
ADEPT), as the G1/S phase arrest will be compromised by the lack of p53. An 
explanation of the proposed mechanism is illustrated in Figure 5.1. This is the 
principle of synthetic lethality, which is a term used to describe two events (e.g. 
mutations/inactivation/inhibition) that individually do not compromise survival but 
together are lethal (438) (439). With this strategy in mind, it was hypothesised that 
the therapeutic potential of a single cycle of ADEPT could be enhanced by inhibiting 
Chk1 using clinically tested Chk1 inhibitors. 
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Figure 5.1 Synthetic lethal interaction as a proposed approach to improving the therapeutic 
response of ADEPT  
Normal cells are capable of sustaining checkpoints in the presence of functional p53 and active Chk1 
for as long as needed when DNA is damaged (A). Most cancer cells lack a functional p53 pathway 
and therefore are unable to arrest in G1 when their DNA is damaged, but they are able to activate the 
S- and G2-checkpoints through the Chk1 pathway (B). This gives tumour cells time to repair any 
damage and promotes their survival. When p53-deficient cancer cells are subjected to genotoxic 
agents that induce replicative stress in combination with Chk1 inhibition they lose all three 
checkpoints and progress through the cell cycle without repairing their DNA damage. This results in 
A 
B 
C 
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preferential killing of p53-deficient tumour cells whilst avoiding normal cell toxicity (C). (Taken and 
adapted from Ma et al., 2011 (440)). 
 
5.1.1 Aims and Objectives 
 
The aim: to investigate an intervention strategy to augment tumour cell-kill by a 
single cycle of ADEPT. The objectives: 
1. To determine the transcript regulation profile of a defined set of genes involved 
in DNA damage response signalling.  
2. To identify cell cycle checkpoints that would impede DNA damage repair 
3. To evaluate the effect of Chk1 inhibitors in combination with ADEPT. 
 
 
5.2 Results 
 
5.2.1 Identifying changes in regulation of DNA damage response genes post-
ADEPT 
 
Real-time PCR is generally considered the gold standard for gene expression 
measurement. The specificity of the RT
2 
PCR array system, which uses the SYBR® 
Green assay, guarantees the amplification of a single gene in each reaction meaning 
that levels of expression confidently reflects the gene of interest.  
 
The expression of 84 genes involved in DNA damage signalling and repair was 
measured in response to a single-cycle of ADEPT in order to determine, and possibly 
manipulate, the DNA damage response or repair mechanisms (as observed in 
Chapter 4) at the mRNA level. Cells were treated with ADEPT using a prodrug 
concentration of 0.25 μM, which is equivalent to the concentration used to determine 
ICL peak formation and unhooking post-ADEPT. Total RNA extracted from the 
cells was converted to cDNA and gene expression was quantified using real-time 
PCR. Figure 5.2 shows the gene expression pattern of SW1222 cells at 1, 3 and 24 
hr-post-ADEPT, compared to untreated cells. The difference in gene expression in 
the ADEPT-treated samples compared to the non-treated samples was conveyed as a 
fold regulation value using the RT
2 
Profiler PCR array data analysis software. The 
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fold regulation value is the difference between the normalised gene expression (that 
is, average cycle threshold (Ct) value of gene of interest minus average Ct value of 
house-keeping genes) in the ADEPT-treated samples compared to the normalised 
gene expression of the untreated samples. Genes that exhibited greater than 2-fold 
increase in gene expression in ADEPT-treated cells compared to untreated cells are 
highlighted in red, and those that exhibited a greater than 2-fold decrease in 
expression are shown in green. The values for these genes are represented in Table 
5.1. Gene nomenclature and average Ct values per gene analysed are documented in 
the Appendix 1A and 1B. 
 
Due to the cost of the assay, time points investigated post-ADEPT were limited to 1, 
3 and 24 hr. These time points were chosen based on the in vitro assays used to 
determine ICL formation, ICL unhooking and γ-H2AX response. Internal quality 
control genes were included in each plate per sample analysed. These included 
house-keeping genes for normalising Ct values, a genomic DNA control for 
detecting non-transcribed DNA contamination, reverse transcriptase control genes 
for detecting efficiency of the cDNA synthesis and positive PCR control genes for 
detecting efficiency of the PCR reaction.  
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Figure 5.2 Real time PCR analysis of the change in expression of 84 genes involved in DNA damage signalling at 1 (A), 3 (B) and 24 (C) hr-post-ADEPT in SW1222 
cells 
Cells were treated with ADEPT and, following 1hr incubation with 0.25 μM prodrug,, cells were post-incubated with drug-free media for 1, 3 and 24 hr. RNA was extracted 
at these time points and cDNA synthesised prior to PCR. Mean Ct values were computed from four separate ADEPT experiments. A change in gene expression in the 
ADEPT-treated cells compared to the untreated cells is conveyed as a fold regulation value. Genes which show increased expression by more than 2-foldcompared to non-
ADEPT-treated cells are shown in red and those which show decreased expression less than -2-foldare shown in green. Data was analysed using the RT
2
 Profiler PCR data 
analysis software (SABiosciences).
B 
A C B 
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Table 5.1 DNA damage response gene expression values that changed more than two-fold 
following ADEPT compared to untreated cells  
Values were computed from four independent ADEPT experiments, as mentioned in Figure 5.2 using 
the RT
2
 Profiler PCR data analysis software (SABiosciences). *Values regarded as significant p value 
≤ 0.008 (when compared to non-treated).  
 
Gene name 
 
Fold regulation values (compared 
to non-treated) 
Abbreviation Full name/description 1hr 3hr 24hr 
BTG2 B-cell translocation gene 2 1.20 1.03 2.71 
*DDIT3 DNA-damage-inducible transcript 3 1.20 1.09 3.71 
DMC1 
DMC1 dosage suppressor of mck1 
homolog, meiosis-specific 
homologous recombination (yeast) 
-1.18 -1.47 2.00 
FEN1 
Flap structure-specific 
endonuclease 1 
-1.08 -1.05 -3.36 
XRCC6 
X-ray repair complementing 
defective repair in Chinese hamster 
cells 6 
-1.06 -1.12 -2.03 
IGHMBP2 
Immunoglobulin mu binding protein 
2 
-1.01 1.05 -2.02 
LIG1 Ligase 1 -1.10 -3.74 -2.11 
*MLH3 MutL homolog 3 (E. coli) 1.06 1.09 2.09 
NBN Nibrin -1.15 1.21 -2.77 
*PCNA Proliferating cell nuclear antigen -1.01 1.03 -2.24 
PNKP 
Polynucleotide kinase 3'-
phosphatase 
-1.03 -1.41 -2.17 
TP73 Tumour protein p73 1.11 1.17 -2.77 
*UNG Uracil-DNA glycosylase 1.22 1.25 -2.35 
*XPA 
Xerodermapigmentosum, 
complementation group A 
1.13 -1.05 -2.16 
 
It is interesting to note that the change in gene expression increases over time post-
ADEPT, being greater at 24 hr-post-ADEPT compared to 1 hr. This is illustrated, in 
Figure 5.2, by the broad distribution of the data points (fold regulation values) at 24 
hr compared to the more centralised distribution at 1 hr. This confirms that even at 
the gene level ADEPT is having an effect on the cells up to 24 hr after receiving 
treatment. Nevertheless, of the 84 DNA damage signalling/repair genes analysed, 
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only four genes showed a greater than 2-fold increase in expression (red) at 24 hr-
post-ADEPT (Figure 5.2) (Table 5.1). The number of genes that decreased in 
expression by more than 2-fold (green) was much greater at 24 hr and, additionally, 
LIG1 (ligase) gene showed decreased expression at 3 hr-post-ADEPT. The down-
regulation of the genes, FEN1, LIG1, PCNA, PNKP and UNG, suggested that base 
excision repair (BER) may be involved, possibly repairing ADEPT-induced DNA 
monoadducts. The down-regulated expression of these genes indicated a form of 
negative feedback regulation at 24 hr. This is supported by the fact that expression of 
BTG2, which encodes a protein involved in cell cycle regulation, is up-regulated at 
the same time. In addition, DDIT3 - an inducer of cell cycle arrest (441), was also 
found to be up-regulated. Thus, ADEPT may be having an effect on the regulation of 
the cell cycle. The large number of genes down-regulated post-ADEPT was an 
unexpected finding and the results of the analysis provided little information for 
targeted intervention studies.  
 
To determine possible biological interactions of the differently regulated genes at 24 
hr post-treatment, the PCR array dataset was imported into the Ingenuity Pathway 
Analysis Tool (IPA) (Ingenuity H Systems, Redwood City, CA, USA 
www.ingenuity.com). The IPA tool was used here to determine direct and indirect 
interactions between the products of those genes with altered expression and also of 
those not involved in the PCR array analysis. A graphical representation of these 
interactions at 24 hr-post-ADEPT is shown in Figure 5.3. There appeared to be a 
strong association with PCNA, which suggested an important role for this 
gene/protein following ADEPT-induced DNA damage. In addition, there was an 
association with cyclin A, with direct links to FEN1, LIG1 and PCNA. Cyclin A is 
associated with control of DNA replication (442) and mediating cell cycle 
progression by interacting with cyclin-dependent kinases (CDKs). 
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Figure 5.3 Ingenuity Pathways Analysis (IPA) summary of the 24 hr-post-ADEPT PCR array 
dataset 
The protein molecules with altered gene expression are highlighted in red (up-regulated) or green 
(down-regulated). The protein molecules of genes are represented as nodes and the biological 
relationship between two nodes is represented as a line. A solid line represents a direct interaction and 
a dotted line represents an indirect interaction. All lines are supported by at least one reference from 
the Ingenuity Knowledge database (www.ingenuity.com; Ingenuity H Systems, Redwood City, CA, 
USA). 
 
To establish whether protein expression correlated with the altered gene expression 
observed at 24 hr-post-ADEPT, SW1222 cells were treated with ADEPT in the same 
way (as above), lysed at 1, 3, 24 and 48 hr-post-treatment and 15 µg cell lysate 
loaded onto 4-20% Tris/Gly gels for separation by SDS-PAGE. Protein was 
transferred onto PVDF membrane and stained with respective antibodies for 
detection of PCNA and NBS1 (gene name, NBN, Table 5.1). Protein was detected at 
all time points in ADEPT-treated and untreated cells as shown in Figure 5.4. 
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Interestingly, protein expression levels of PCNA increased at 24 hr-post-ADEPT by 
an average density of 1.4-fold (±0.2) compared to untreated; contrary to its relative 
gene expression (Table 5.1). By 48 hr, expression had reduced to levels comparable 
to the untreated with an average density of 1.1 (±0.13).  
 
 
 
 
 
 
 
 
Figure 5.4 SW1222 cellular expression of PCNA and NBS1 proteins at 1, 3, 24 and 48 hr-post-
ADEPT  
Cells were treated with a single cycle of ADEPT and then incubated in drug-free media. Cells were 
lysed at respective time points post-ADEPT and lysate loaded onto Tris/Gly gels. Protein was 
separated by SDS-PAGE, and PCNA and NBS1 were detected by Western blot. β-actin protein was 
used as experimental loading control. Images are representative of at least two independent 
experiments. 
 
NBS1 protein expression appeared to increase over time post-ADEPT with an 
average density of 3-fold (±0.6) at 24 hr and 3.8-fold by 48 hr, compared to the non-
treated (Figure 5.4). In contrast, the relative gene expression at 24 hr post-ADEPT 
was down-regulated. Thus, it was deduced that protein expression appeared not to 
correlate directly with gene expression from the PCR arrays but showed a different 
pattern of regulation that is probably more suggestive of real-time DNA repair 
mechanisms taking place in response to ADEPT. The expression of other proteins 
with altered gene expression was not pursued further as antibodies for these were not 
available in our lab, and would have been a costly expense solely for this purpose.  
 
5.2.2 Analysing cell cycle activity in response to ADEPT 
 
Negative regulation of the cell cycle, as highlighted by the up-regulation of anti-
proliferative genes - BTG2 and DDIT3, prompted an investigation into cell cycling 
activity post-ADEPT in SW1222 cells. To investigate the cell cycling activity in 
PCNA (36 kDa) 
NBS1 (95 kDa) 
β-actin (42 kDa) 
   1        3       24     48 (hrs) untreated 
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response to a single cycle of ADEPT, the proportion of cells at different phases of 
the cell cycle was analysed by fluorescence activated cell sorting (FACS), and Chk1 
and Chk2 proteins, which control cell cycle progression, were measured.  
 
Cells were treated with ADEPT using experimental conditions which caused > 50% 
cross-links. Propidium iodide was used to stain fixed cells and cell cycle analysis 
was conducted by FACS. Cell cycle phases were gated and analysed as follows: sub-
G1 consists of cell debris; G0/G1 represents cells in resting phase or preparing for 
DNA replication (all cells are 2N); S represents cells in the process of DNA 
replication; G2/M consists of cells preparing to divide and/or in the process of 
mitosis (all cells are 4N). There was no difference in the proportion of cells in each 
cell cycle phase at 3 or 6 hr with or without ADEPT, as shown in Figure 5.5. In 
untreated SW1222 cells the fraction of cells in G0/G1 remained unchanged over time 
(Figure 5.5 B); although a decrease in cells in G2/M phase was observed from 23% 
at 3 hr to 11% at 48 hr. In contrast, ADEPT induced an apparent growth arrest at 
G2/M phase at 24 hr following treatment and causing a large proportion of cells to 
reside in G2/M phase at 24 hr (35%) (Figure 5.5 A), compared to untreated normal 
cycling cells (15%) (Figure 5.5 B). At 48 hr-post-ADEPT, the proportion of cells in 
G2/M remained greater than in the untreated cells, but had reduced to 23%, which 
may suggest recovery from the growth arrest. The proportion of cells in S-phase 
remained relatively constant over time for untreated (19-24%) and ADEPT-treated 
cells (20-28%). There was also no significant difference in the sub-G1 fraction, 
which was used to assess the level of cell death, between ADEPT-treated and 
untreated cells. These data suggested that cells exposed to ADEPT are not killed 
more than untreated cells, and cells can overcome an initial cell cycle arrest at G2/M 
caused by ADEPT.     
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Figure 5.5 Cell cycling activity in ADEPT-treated (A) and untreated (B) SW1222 cells 
G2/M cell cycle arrest is evident in ADEPT-treated cells compared to untreated cells. SW1222 cells 
were treated with or without ADEPT followed by incubation in drug-free medium for different lengths 
of time. Cells were fixed with 70% cold ethanol and stained with 50 μg/ml propidium iodide (PI) 
solution per million cells. Cell solution was analysed by flow cytometry. Cell cycle phases: Sub G1, 
G0/G1, S and G2/M. Data are representative of at least 4 independent experiments, mean ± SEM.   
 
The activation of the cell cycle checkpoint kinases, Chk1 and Chk2, in ADEPT-
treated cells was assessed by measuring the expression of phosphorylated Chk1 
(Chk1-p) and phosphorylated Chk2 (Chk2-p) by Western blotting (Figure 5.6). 
Briefly, SW1222 cells were treated with ADEPT in the same way (as mentioned in 
Section 5.2.1), lysed at 1, 3, 24 and 48 hr-post-ADEPT and 15 µg cell lysate was 
loaded onto 4-20% Tris/Gly gels and separated by SDS-PAGE. Protein was 
transferred onto a PVDF membrane and stained with anti-Chk1-p and Chk2-p 
antibodies. The relative difference in protein expression in ADEPT-treated cells 
A 
B 
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compared to untreated cells was quantified using Image J analysis software. Chk1-p 
levels increased over 24 hr-post-ADEPT by up to 2.3-fold (±0.07), relative to the 
untreated cells. By 48 hr, expression had decreased to 0.8-fold (±0.38) compared to 
untreated cells. Chk1-p expression in untreated SW1222 cells did not change over 48 
hr, and its presence, and change in expression levels, has previously been detected in 
normal cycling cancer cells (443). Chk2-p expression was also detected post-ADEPT 
and increased over time by more than double from 1.5-fold (±0.09) at 1 hr to 4.4-fold 
(±2.5) at 48 hr, relative to the untreated.  
 
 
 
 
 
 
 
 
 
Figure 5.6 Chk1-p and Chk2-p expression is up-regulated in ADEPT-treated SW1222 cells  
Cells were treated with a single cycle of ADEPT (as described in the Methods) and lysed at different 
time points. Data is representative of at least 2 independent experiments, and protein expression 
relative to the untreated was quantified by densitometry using Image J. β-actin protein was used as an 
experimental control. 
 
Collectively, these data suggested a link between increased presence of activated 
Chk1 and G2/M growth arrest at 24 hr following ADEPT, as a result of DNA 
damage repair. Furthermore, the decrease in activation of Chk1 at 48 hr and increase 
in Chk2 over time may be associated with the recovery of cells back to normal cell 
cycling activity in response to ADEPT.  
 
5.2.3 Evaluating the cellular response to ADEPT in combination with Chk1 
inhibitors   
 
The first Chk1 inhibitor to be developed was UCN-01 (7-hydroxystaurosporine). It is 
classified as a non-specific inhibitor because it has been shown to act on several 
kinases, including Chk1, Chk2, MAPKAP kinase (MK2) and protein kinase C (PKC) 
Chk1-p (pSer
296
) (56kDa) 
β-actin  
   1        3       24     48 (hrs) 
Chk2-p (pThr
68
) (62kDa) 
untreated 
   1            1.2         2.1       2.3         0.8 
β-actin  
   1              1.5       2.9        4.1        4.4 
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(444) (445) (446). Due to the non-selective nature of UCN-01, more potent, specific 
Chk1 inhibitors were subsequently developed, some of which are analogues of the 
UCN-01 compound, for example, PF-477736. Both UCN-01 and PF-477736 were 
assessed for their Chk1 inhibitory effect on SW1222 cells in combination with 
ADEPT. 
 
5.2.3.1 Determining the growth inhibition potential of ADEPT in combination 
with Chk1 inhibitors  
 
SRB assays were used to determine whether combination treatment of ADEPT and 
Chk1 inhibitors, UCN-01 or PF-477736, could potentiate growth inhibition of 
SW1222 cells compared to ADEPT alone. Preliminary experiments were conducted 
to determine the concentrations of each inhibitor which would inhibit 10-20% of 
cells. Briefly, cells were exposed to increasing concentrations of each Chk1 inhibitor 
(separately) for 96 hr before SRB reagent was applied (Figure 5.7). Sub-toxic doses 
of the inhibitors on SW1222 cells that could be used in combination with ADEPT 
were found to be 25 nM UCN-01 and 0.1 μM PF-477736.   
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Figure 5.7 Determining the sub-toxic dose of UCN-01 or PF-477736 
SW1222 cells were treated with increasing concentrations of each inhibitor and incubated for 96 hr 
and SRB applied. Data are representative of 3 independent experiments, mean ± SEM. 
 
Combination experiments were conducted using increasing concentrations of the 
ADEPT prodrug (alone or with the fusion protein) in the presence of either 25 nM 
UCN-01 or 0.1 μM PF-477736. ADEPT combined with PF-477736 caused 50% 
growth inhibition at a lower prodrug concentration than ADEPT did alone (Figure 
5.8). This corresponded to a GI50 of 0.13 (± 0.03) µM for ADEPT/PF-477736, as 
opposed to 0.17 (± 0.02) µM for ADEPT alone. The GI50 of ADEPT in combination 
with UCN-01 was 0.18 (± 0.02) µM, which was similar to ADEPT alone (Figure 
5.8). However, at concentrations of > 0.2 μM prodrug, there appeared to be a more 
rapid increase in growth inhibition compared to ADEPT alone. We also showed that 
UCN-01 
PF-477736 
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the prodrug or fusion protein alone in combination with either Chk1 inhibitor had no 
growth inhibitory effect on the cells (Figure 5.8). Additionally, there was no effect 
on cells incubated in the presence of 25 nM UCN-01 or 0.1 μM PF-477736 over 96 
hr and absorbance readings were similar to that of untreated cells.  
 
 
 
 
 
Figure 5.8 Growth inhibitory effect of Chk1 inhibitors in combination with ADEPT  
Cells were treated with: ADEPT alone; ADEPT plus Chk1 inhibitor (0.1 μM PF-477736 or 25 nM 
UCN-01); prodrug alone; or prodrug plus Chk1 inhibitor (0.1 μM PF-477736 or 25 nM UCN-01). 
Following treatment cells were incubated in drug-free medium with or without Chk1 inhibitor (0.1 μM 
PF-477736 or 25 nM UCN-01) for 96 hr and SRB applied. Plots are representative of 3 independent 
experiments, mean ± SEM.  
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Unfortunately, these results do not show that the combination therapy is 
(statistically) favourable, in terms of growth inhibition, compared to ADEPT alone. 
In the context of combination therapy, it would be necessary to investigate the 
methodology of these growth experiments further and to determine the existence of 
synergy. [Note: the Chou-Talalay combination index (CI) method (447, 448)) was 
used to test for synergy between the effect of ADEPT and Chk1 inhibition using the 
growth inhibition values. The CI algorithm, based on the laws of mass action, has 
been used by researchers to determine synergism with drug combinations, 
particularly in cancer therapy as listed in the review by Chou and Talalay (449). 
However, appropriate assumptions regarding synergism using these growth 
inhibition values could not be deduced at the time]. In light of the data presented, it 
was postulated whether the effect of the drug combinations could be recognised in a 
different experiment, namely cell cycling by FACs. A concentration of 0.3 μM 
prodrug, which was found to induce approximately 75% growth inhibition, was 
sufficiently potent but not too toxic to test therapeutic efficacy in subsequent in vitro 
experiments.  
 
5.2.3.2 Chk1 inhibitors attenuate G2/M arrest and augment cell death in 
ADEPT-treated cells  
 
In light of the growth inhibition experiments it was think that To determine whether 
the combination therapies had an effect on cell cycling, The established 
concentrations of ADEPT and Chk1 inhibitor combinations were subsequently used 
to assess the effect on cell cycling activity. SW1222 cells were treated with ADEPT 
using 0.3 µM prodrug in the presence of 25 nM UCN-01 or 0.1 µM PF-477736. Cells 
were then cultured in media containing Chk1 inhibitor and harvested at different time 
points post-ADEPT. In the presence of Chk1 inhibition, ADEPT-treated cells 
appeared to undergo normal cell cycling for at least 6 hours after treatment (Figure 
5.9, and also Appendix 2 for individual stacked column charts). At 24 hr-post-
ADEPT in the presence of inhibitor, cells underwent growth arrest at the G2/M 
phase, compared to cells treated with the inhibitor alone. This demonstrated that 
changes in the cell cycle were due to the effect of ADEPT. In cells treated with the 
sub-toxic dose of Chk1 inhibitor alone, cell cycling was comparable to normal 
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untreated cells (Figure 5.9). This confirms that any changes in the cell cycle are due 
to the effect of ADEPT, with Chk1 acting as a sensitiser. At 24 hr-post-ADEPT plus 
UCN-01, 34% cells were in G2/M phase compared to 19% with UCN-01 alone; and 
ADEPT plus PF-477736, 38% cells were in G2/M phase compared to 15% with PF-
477736 alone (Figure 5.10). Notably, at 48 hr post-treatment, cells treated with 
ADEPT in presence of UCN-01 or PF-477736 showed a significant (p < 0.001) 
decrease in the proportion of cells in G2/M, 13% and 10% (respectively) (Figure 
5.10). This equated to 72% (ADEPT plus PF-477736) or 63% (ADEPT plus UCN-
01) decrease from 24 to 48 hr post-treatment, compared to 35% with ADEPT alone. 
This suggested that in the presence of Chk1 inhibition a greater proportion of cells 
were able to overcome the G2/M block and re-enter the cell cycle (mitosis) compared 
to ADEPT alone. 
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Figure 5.9 Representative cell cycle analyses of SW1222 cells treated with or without ADEPT 
and in the presence of Chk1 inhibitors  
Cells were exposed to Chk1 inhibitor alone (25 nM UCN-01 or 0.1 µM PF-477736) alone, or in 
combination with ADEPT (0.3 µM prodrug). Following treatment, cells were fixed with 70% cold 
ethanol and stained with 50 μg/ml propidium iodide (PI) solution per million cells. Cell solution was 
analysed by flow cytometry. Data taken from individual experiments are representative of the 
calculated means. Graphical portions refer to cell cycle phases (L to R): Sub G1, G0/G1, S, G2/M. 
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Figure 5.10 G2/M cell fraction at 24 and 48 hr-post-ADEPT (± Chk1 inhibition)  
SW1222 cells were treated with or without ADEPT in combination with UCN-01 or PF-477736, as 
described in Figure 5.9. Non-treated and ADEPT data were taken from Figure 5.5. Data are 
representative of at least 3 independent experiments, mean ± SEM. *** p < 0.001 of the difference 
between 24 and 48 hr. 
 
Interestingly, the large decrease in the G2/M fraction at 48 hr-post ADEPT in the 
presence of Chk1 inhibitor coincided with an increase in sub-G1 fraction (dead cells) 
(Figure 5.9 and Figure 5.11). Up to 24 hr, any differences in the sub-G1 fraction 
between non-treated, ADEPT alone and ADEPT in the presence of Chk1 inhibitors 
had been relatively small and non-significant. By 48 hr cell death was significantly 
higher in ADEPT plus Chk1 inhibitor with 49% and 52% fraction of cells in sub-G1, 
compared to 33% following ADEPT alone (p< 0.001) (Figure 5.11). When the data 
was analysed without the sub-G1 portion (data not shown), there was little difference 
between cell cycling of the ADEPT-treated cells in the presence and absence of Chk1 
inhibitors. These data suggested that UCN-01 and PF-477736 promote cell cycle 
progression through the G2-to-M checkpoint, and any cells containing damaged 
DNA, ultimately die. 
 
*** *** 
*** 
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Figure 5.11 Change in proportion of dead cells post-ADEPT (± Chk1 inhibition)  
SW1222 cells were treated with or without ADEPT in combination with UCN-01 or PF-477736, as 
described in Figure 5.9. Non-treated and ADEPT data were taken from Figure 5.5. Data are 
representative of at least 3 independent experiments, mean ± SEM. *** p < 0.001 of the difference 
between 24 and 48 hrs. 
 
The expression of Chk1-p and Chk2-p following treatment with ADEPT plus UCN-
01 or PF-477736, was determined by Western blotting. SW1222 cells were treated 
with ADEPT in the presence of 25 nM UCN-01 or 0.1 μΜ PF-477736, as described 
previously, and non-ADEPT-treated cells were exposed to the same concentrations 
of inhibitor only. Cells were lysed at 1, 3, 24 and 48 hr-post-ADEPT, 15-20 µg cell 
lysate loaded onto 4-20% Tris/Gly gels and the protein mixture separated by SDS-
PAGE. Protein was transferred onto PVDF membrane and stained with anti-Chk1-p 
and Chk2-p antibodies. The relative difference in expression of ADEPT-treated cells, 
compared to non-ADEPT-treated cells, was quantified by Image J. In the presence of 
UCN-01 or PF-477736, Chk1-p expression increased at 3 hr in ADEPT-treated cells 
1.6- and 1-fold (±0.65 and ±0.21), respectively, relative to the non-ADEPT-treated 
(Figure 5.12A and B). By 24 hr-post-ADEPT expression levels of Chk1-p were 
down-regulated by 0.5- and 0.4-fold difference (±0.3 and ±0.37) in the presence of 
UCN-01 or PF-477736 (respectively). By 48 hr-post-ADEPT, Chk1-p levels below 
baseline levels of the non-ADEPT-treated cells were sustained. These findings 
suggested diminished Chk1 activity at 24 hr-post ADEPT as a result of Chk1 
inhibition, when compared with the increased Chk1-p levels observed in ADEPT-
only-treated cells (Figure 5.13 B). Chk2-p expression in cells treated with ADEPT 
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plus UCN-01 increased up to 24 hr by 2-fold (± 0.7), and by 48 hr levels decreased to 
0.8-fold (±0.03), relative to non-ADEPT-treated cells. In the presence of PF-477736, 
Chk2-p expression increased steadily over 48 hr following ADEPT by 1.4-fold 
(±0.4), relative to the non-ADEPT-treated cells (Figure 5.12A). The data suggested 
low levels of Chk2 activity possibly caused by Chk1 inhibition following ADEPT, 
compared to ADEPT alone (Figure 5.12B), and may indicate a role for Chk2 in 
response to ADEPT.    
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
Figure 5.12 Expression of Chk1-p (Ser296) and Chk2-p (Thr68) in SW1222 cells treated with 
ADEPT in combination with Chk1 inhibitors  
Cells were treated with ADEPT in combination with UCN-01 or PF-477736, as described previously. 
A) Specific bands for Chk1-p and Chk2-p generated by Western blotting. B) In the presence of Chk1 
inhibitors, low levels of activated Chk1 and Chk2 were observed compared to cells treated with 
ADEPT alone (data taken from Figure 5.6), where < 1-fold difference was considered below levels of 
that in the non-ADEPT-treated cells. Data are representative of at least 2 independent experiments, 
and protein expression relative to the non-ADEPT-treated cells was quantified by densitometry using 
Image J. β-actin protein was used as an experimental control. 
 
A 
B 
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Together, the results revealed that Chk1 inhibitors sensitised ADEPT-treated cells to 
cell death, although the overall cycling of live ADEPT-treated cells remained 
unchanged; and Chk1 inhibition by UCN-01 and PF-477736 was specific for Chk1.  
 
 
5.3 Discussion 
 
The data presented in this Chapter described and investigated approaches to enhance 
the therapeutic potential of a single cycle of ADEPT by attempting to target the DNA 
damage signalling/repair pathways. In the first instance, DNA damage response to 
ADEPT at the gene level was investigated but found to provide little information 
regarding strategies for intervention. Secondly, it was hypothesised that the 
therapeutic potential of a single cycle of ADEPT would be enhanced by inhibiting 
cell cycle checkpoint activation. The hypothesis was tested using clinically validated 
Chk1 inhibitors, UCN-01 and PF-477736, which were found to potentiate the 
cytotoxicity of ADEPT in SW1222 cells.   
 
5.3.1 Identifying changes in regulation of DNA damage response genes post-
ADEPT 
 
Regulation of gene expression was assessed in response to a single cycle of ADEPT 
using the RT
2 
PCR array system containing 84 primers for genes involved in DNA 
damage signalling. Of the large pool of genes quantified in SW1222 cells treated 
with to ADEPT, only 14 were found to undergo changes in their transcript levels at 
24 hr post-treatment compared to the non-treated cells. Furthermore, the gene 
expression changes were small in magnitude and down-regulation was the 
predominant effect. Similarly, in an assessment of various DNA damaging 
compounds, alkylating agents caused fewer and less robust changes in the expression 
of the smallest number of genes, although they were found to be the most mutagenic 
compounds tested (compared to reactive oxygen species and topoisomerase 
inhibitors) in lymphoma cells (450). It is believed that the down-regulation of the 
genes, namely, PCNA, FEN-1, LIG1, UNG, PNKP, may be the result of a negative 
feedback mechanism linked to BER. BER is a highly coordinated, multistep pathway 
that corrects small DNA modifications or damaged DNA bases resulting from 
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cellular metabolism such as methylation, deamination and hydroxylation (451). 
Bifunctional alkylating agents induce monoadducts, in addition to ICLs, which may 
be repaired via the BER pathway. In fact, monoadducts constitute the majority of 
lesions by nitrogen mustards; however they are not potent enough to cause a tumour 
response.  
 
In long-patch BER, PCNA recruits base-specific glycosylases and 
apurinic/apyrimidinic (AP) endonuclease (452) (453) to the damaged site (454) 
(455). The damaged DNA fragment, otherwise known as a 5' overhanging flap, is 
removed by the FEN-1 protein (456) (457), which is recruited by PCNA (458). 
PNKP primes the DNA strand-break ends with hydroxyl or phosphate groups prior to 
ligation by DNA ligase I (LIG1) in DNA synthesis (459). Uracil DNA glycosylases 
(UNG) recognise uracil in DNA, which may arise either by spontaneous deamination 
of cytosine or by the mis-incorporation by DNA polymerases during DNA synthesis 
in BER (460).  
 
In addition to its role in BER, FEN-1 also has important roles in DNA replication and 
homologous recombination (HR) (461) (462). In fact, research has linked HR repair 
in response to BER strand-break intermediates (463), and BER in ICL repair has also 
been noted (273). Furthermore, there is evidence to support the role of BER in 
mediating cisplatin toxicity (464). Thus, targeting proteins involved in BER has been 
suggested as a strategy to enhance the sensitivity of tumour cells to alkylating agents 
(465). One study showed that targeting FEN-1 with an inhibitor increased the 
cytotoxic effect of the alkylating agent, temozolomide (466). 
 
Quantifying changes in mRNA levels does not provide any information about the 
post-transcriptional and post-translational modifications of mRNA-to-protein 
product. These modifications, including acetylation, phosphorylation, methylation 
and ubiquitinylation (to name a few), are involved in orchestrating the chromatin 
responses to DNA damage (312) and may have dramatic effects on the overall 
function of the resulting protein. Thus, two genes were selected to assess their 
respective cellular protein levels post-ADEPT. Western blot analysis revealed up-
regulation of PCNA at 24 hr, which did not correlate with the down-regulated gene 
expression at this time point. This probably tells us: a) the protein undergoes post-
Chapter 5 
 
173 
 
translational modifications that allow it to have a significant impact (or not) on the 
cell; and/or b) gene regulation is an early event in response to the constant changing 
cell environment. Since PCNA, along with other BER/replication-related genes, were 
down-regulated, it would suggest that the decrease in PCNA transcript levels was a 
negative response to the elevated protein levels reflecting the real-time changes 
occurring in the cells. With that, the elevated PCNA protein levels at 24 hr-post-
ADEPT was supportive of its role in repair and/or DNA synthesis which 
corresponded to cell cycle arrest at 24 hr-post-ADEPT. By 48 hr, PCNA protein 
levels returned to normal suggesting repair was complete and cells returned to 
normal cycling. NBS1 protein was also analysed since gene expression was down-
regulated at 24 hr and it is a protein involved in DNA damage repair, specifically 
being recruited by γ-H2AX to sites of DSBs. Similar to PCNA, NBS1 protein levels 
were found to be up-regulated at 24 and 48 hr-post-ADEPT.  
 
The genes that exhibited up-regulated expression at 24 hr following exposure to 
ADEPT - BTG2 and DDIT3 – have been shown to be involved in the negative 
regulation of cell cycle progression (467) (468) (441) and cell proliferation (469) in 
response to DNA damage, and are also associated with apoptosis. The up-regulation 
of these genes in SW1222 cells may be associated with G2/M growth arrest observed 
in these cells at 24 hr upon exposure to ADEPT. In lymphoma cells exposed to 
alkylating agents, G2/M arrest was also observed at 24 hr post-treatment (470) (450) 
and this was accompanied by an increase in transcript levels of BTG2 (450). DDIT3 
(CHOP) protein elevation was also observed in response to alkylating agents, 
including methyl methanosulphate (471) (472). 
 
5.3.2 Analysing cell cycle activity in response to ADEPT   
 
The G2/M growth arrest observed in SW1222 cells at 24 hr-post-ADEPT indicated 
that cells were undergoing DNA damage repair, as discussed in Chapter 4. It would 
appear that this arrest was most likely induced by stalled replication forks caused by 
ICLs (424), since there is no evidence that ICLs alone inactivate G1 or G2 cell cycle 
checkpoints, suggesting that they are tolerated by the cell until the DNA replication 
fork is encountered (281). ADEPT-treated cells appeared to overcome this G2 arrest 
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at 48 hr, indicating perhaps the presence of non-damaged and/or repaired cells that 
resumed normal cycling as a viable population. Thus, a delay in the cell cycle was 
sufficient to circumvent the potentially toxic effects of the activated nitrogen mustard 
drug (473) (470). Moreover, there appeared to be little difference in the dead cell 
(sub-G1) population between non-treated and ADEPT-treated cells over 48 hr, 
further highlighting the fact that repair was occurring in response to a single cycle of 
ADEPT. 
 
Cell cycling activity was also assessed by means of Chk1 and Chk2 kinases, which 
are involved in checkpoint control and DNA damage repair in the G2-to-M and G1-
to-S phases (respectively) (435) (474). Up-regulated expression of Chk1-p at 3 and 
24 hr-post-ADEPT indicated activation of Chk1. Interestingly, this increase in Chk1 
phosphorylation appeared to correlate with the G2/M growth arrest observed at 24 
hr-post-ADEPT. Activated Chk1 phosphorylates the cell cycle phosphatase, Cdc25C, 
which prevents the dephosphorylation and activation of cyclin-dependent kinase 1 
(Cdk1), resulting in blockade of G2/M transition and delay in mitotic entry (475) 
(476). Another role for Chk1 is in DNA repair, notably HR, which preferentially 
occurs in G2 phase (477). This is supported by studies showing that Chk1 is involved 
in the phosphorylation and recruitment of RAD51 (Chapter 4) to DNA repair foci 
(478) (479) (335). By 48 hr, activated Chk1 levels decreased to less than 
baseline/control levels, which may correlate with the resume of normal cell cycling 
and possibly resolution of DNA damage repair.  
 
When the same cells were analysed for Chk2 activity, protein levels of Chk2-p were 
found to increase over 48 hr-post-ADEPT reaching 4-fold difference compared to the 
untreated cells by 24 hr. The findings may implicate a role for Chk2 in controlling or 
mediating DNA damage repair and/or cell cycle arrest (478) (480). In camptothecin-
treated colon cancer cells, Chk2-p increased progressively up to 72 hr-post-drug 
treatment whilst phosphorylated Chk1 was found to disappear by 48 hr (478). 
Indeed, activation of Chk2 at later time points post-drug treatment may function as a 
negative regulatory mechanism in the cell cycle and have an anti-apoptotic effect in 
response to DNA damage (481). There is substantial overlap in the activities of Chk1 
and Chk2. For example, in cisplatin-induced DNA cross-linking and replication 
stress, both Chk1 and Chk2 were activated in an ATR-dependent manner (482).  
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5.3.3 Evaluating the cellular response to ADEPT in combination with Chk1 
inhibitors   
 
With data supporting a role for Chk1 activation during ADEPT-induced G2/M arrest, 
it was hypothesised that inhibition of Chk1 would impede growth arrest and DNA 
repair and lead to increased tumour cell death (483) (484). Mechanistic studies to 
inhibit G2/M arrest induced by alkylating agents had already begun in the early 
1990s (470) (485). UCN-01 was one of the first Chk1 inhibitor compounds to show 
promising pre-clinical anti-cancer therapy as a single agent (486) (487) (488), and in 
combination with various DNA damaging agents (489) (490) (491), due to its anti-
proliferative effects and cytostatic properties in several human tumour cells lines 
(492) (493). UCN-01 is the only inhibitor to have undergone extensive pre-clinical 
and clinical investigation, however due to its relative high affinities for multiple cell 
cycle kinases, second-generation inhibitors were developed with greater selectivity 
for Chk1. Second-generation Chk1 inhibitors include: PF-477736 (494) (495), 
AZD7762 (496) (497), SAR-020106 (498) and XL-844 (499). Potentiation of 
gemcitabine efficacy by these compounds has been demonstrated in xenograft 
models and clinical trials (500) (440). UCN-01 and second-generation Chk1 
inhibitors in combination with DNA damaging agents have demonstrated particular 
success in p53-defective/deficient tumour cells (501) (502) (503) (504) (505). The 
combined effect of loss of p53 and inhibition of Chk1 are believed to create a 
synthetic lethal interaction. Synthetic lethality was first shown to be an effective anti-
cancer strategy in BRCA1-deficient tumour cells with poly(ADP-ribose) polymerase 
(PARP) inhibitors. Inhibition of Chk1 in p53
-/-
colon carcinoma cell lines was shown 
to abrogate G2/M arrest and increase cytotoxicity induced by irradiation and cisplatin 
(506); and gemcitabine (496). Nevertheless, there is surmounting evidence to show 
that Chk1 inhibition can be just as effective in cancer cells irrespective of p53 status 
(507) (508) (509). The SW1222 colon carcinoma cell line studied here possessed a 
p53-defective gene (405) and its corresponding protein was also shown to be absent 
in Western blotting (personal communication with Dr Hassan Shahbakhti). The 
effect of Chk1 inhibition in ADEPT-treated p53-defective SW1222 cells was 
proposed a synthetic lethal interaction; and first and second generation Chk1 
inhibitors, UCN-01 and PF-477736, were used to test this.  
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The growth inhibition (SRB) assay was used to determine the concentrations of Chk1 
inhibitor and prodrug that could be combined together. For combination experiments 
the concentrations of inhibitor were selected based on a GI10-20, that is, a sub-toxic 
dose that alone did not demonstrate growth inhibition on SW1222 cells. ADEPT in 
combination with PF-477736 had a greater growth inhibitory effect (GI50 of 0.13 
μM) than that observed for ADEPT alone (GI50 0.17 μM) and ADEPT in 
combination with UCN-01 (GI50 0.18 μM). These results, however, were not 
reflective of the data obtained from the cell cycling studies, which may suggest a 
review of the methodology used to determine growth inhibition/cell viability would 
be necessary for future work. Indeed, cell cycling studies showed that viable tumour 
cells (untouched by the toxic insults) continued normal cycling, and it’s these cells 
which may have been detected in the growth inhibition assay, especially if they had 
96 hr to recover post-drug regimen.  
 
Growth arrest of cells in G1, intra-S and G2 in response to DNA damage is a well-
documented phenomenon that permits cells to repair damaged DNA before, during 
or after replication and before mitosis (respectively). As inhibitors of Chk1, UCN-01 
and PF-477736 have been shown to abrogate S- and G2- phase arrest in cells 
undergoing DNA damage (438). It was shown here that UCN-01 and PF-477736 
attenuated G2/M arrest at 48 hr-post-ADEPT (fraction of cells: 13 and 10%, 
respectively), compared to ADEPT alone (23%) and inhibitor only (19 and 15%, 
respectively). This was paralleled with a significantly large increase in cell death at 
48 hr (sub-G1 fraction: 49 and 52%) when ADEPT was combined with UCN-01 and 
PF-477736 (respectively), compared to ADEPT alone (33%). The findings suggested 
that a greater proportion of cells in G2/M (at 24 hr-post-ADEPT) exited this arrest, 
by 48 hr. An increase in cell death was observed in Chk1-deficient/-inhibited cells 
exposed to antimetabolites, cytarabine or gemcitabine (510) (504). Since the integrity 
of the replication fork during cell cycling relies on Chk1, in the absence of Chk1, 
increased cell death was found to result from three cellular events (according to 
researchers (511) (512)): activation of late origin firing, destabilization of stalled 
replication forks and cell cycle progression from G1/S directly to mitosis. The 
increased sub-G1 fraction at 48 hr, observed here, implied that cells were probably 
forced to enter mitosis regardless of DNA damage incurred or repaired. It is thought 
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that the damaged cells died by a process known as mitotic catastrophe, prior to 
apoptosis. Mitotic catastrophe is an event in which a cell is destroyed during mitosis 
because of aberrant chromosome segregation or DNA damage resulting in multiple 
micronuclei (513). The occurrence of mitotic catastrophe was not determined here, 
although it has been shown to be a feature of ICL-induced death in mammalian cells 
(251, 513).  
 
A change in Chk1 and Chk2 was also observed in cells treated with ADEPT in 
combination with UCN-01 or PF-477736. A small increase in Chk1-p expression 
was observed over 3 hr-post-ADEPT, and this was followed by a decrease in levels 
by 24 hr to below baseline/control levels, and low Chk1-p expression levels persisted 
up to 48 hr. This was in contrast to the increase in Chk1-p expression in ADEPT-
only-treated cells. Indeed, decreased Chk1-p (Ser
296
) expression is a recognised 
biomarker of Chk1 inhibition (514) (438) (498) (497). Knockdown of ATR mediates 
the phosphorylation of Ser
345
 and Ser
317
 on Chk1, which in turn mediates 
autophosphorylation of Ser
296
 (515). In general, levels of Chk1-p were low 
(compared to non-ADEPT-treated), which suggested Chk1 activation was being 
inhibited by UCN-01 or PF-477736. Chk1 activity was particularly low in PF-47736-
treated cells, emphasising the selective nature of this inhibitor. PF-477736 has been 
shown to specifically inhibit Chk1 with an IC50 value of 0.49 nM (494), and for 
UCN-01 an IC50 value of 11 nM was reported (440). Both inhibitors have been 
shown to inhibit Chk2 with a 100-fold selectivity ratio (440). Interestingly, the 
pattern or timing of inhibition observed here occurred earlier (24 hr-post-ADEPT) 
compared to the attenuation of G2/M growth arrest (48 hr-post-ADEPT). Like most 
protein kinase inhibitors, Chk1 inhibitors function by competitive inhibition of the 
ATP binding pocket (516) (515). It would be interesting to assess the lasting 
inhibitory activity (> 48 hr-post-ADEPT) of these agents at the phosphorylation level 
and the corresponding cell cycling phases. Measuring total Chk1 levels would have 
provided further quantitative information regarding the relative levels of 
phosphorylated Chk1 compared to non-phosphorylated Chk1.  
 
Chk2 activity was observed in ADEPT-treated cells in the presence of Chk1 
inhibitors, and there were differences between the two inhibitors. Chk2-p expression 
levels increased up to 24 hr post-ADEPT/UCN-01 combination, which was similar to 
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that in ADEPT-only-treated cells. At 48 hr, expression decreased to levels below 
baseline, which was not observed in ADEPT-only-treated cells. This is may have 
indicated suppression of Chk2 phosphorylation by Chk1 inhibitors, since Chk1 
inhibitors have been shown to target Chk2 (514). In the presence of PF-477736, 
Chk2-p expression increased over 48 hr in ADEPT-treated cells. The increase in 
Chk2 observed with the Chk1 inhibitors implied that Chk2 may have had a 
compensatory effect as a result of the inhibition of Chk1 phosphorylation (517), 
concomitant with cell cycle arrest at 24 hr-post-ADEPT. It is believed that G2/M 
arrest (with or without inhibitors) is mediated in part by Chk2 (478) (480) (518) 
(519). One event demanding Chk2 function is the generation of DSBs in S phase, 
that is, when Chk2 increases the rate of phosphate exchange on Cdc25A residues 
targeted by Chk1 (520), and amplifying the “housekeeping” function of Chk1. The 
findings implicated a role for Chk2 inhibitors in increasing ADEPT-induced cell 
death. Castedo and colleagues (481) showed that inhibition of Chk2 reduced 
doxorubicin-induced G2 blockade and concomitantly increased the frequency of 
apoptotic cells. However, the rationale for Chk2 inhibitors remains unclear and may 
depend on the cell’s genetic background and the genotoxic agent employed (521). 
The equivocal findings observed here with Chk2 activity in response to the 
ADEPT/Chk1 inhibitor combination would require further investigation to 
determine, specifically, the role of Chk2 in ADEPT.   
 
To-date the majority of clinical trials designed to test pre-clinically well-established 
Chk1 inhibitors in combination with DNA-damaging agents have yet to produce 
reliable proof-of-concept data. Clinical trial dose-limiting toxicities have varied 
between compounds and various combinations. Clinical progression with UCN-01 as 
a single agent or in combination with chemotherapy has been hindered by 
unfavourable pharmacokinetic and toxicity profiles owing to the compound’s high 
affinity for human α1-acid glycoprotein (522) (523) (524). LY2603618 – one of the 
first-generation inhibitors - is currently undergoing phase II trials in combination 
with cisplatin and pemetrexed in metastatic non-small cell lung cancer, and with 
gemcitabine in pancreatic cancer (525). In the phase I trial of PF-477736 in 
combination with gemcitabine, 3 patients (out of 36 at the time of publication) 
exhibited partial responses (526). The trial was terminated early, although one patient 
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remained on the study until a complete response was observed (study completion 
2011) (527).  
 
 
5.4 Summary 
 
It was proposed that control and/or regulation of the DNA damage response to a 
single cycle of ADEPT could be manipulated to enhance the tumour cell response. To 
this end it was shown that DNA damage signalling gene profile arrays did not 
generate a tractable strategy for intervention studies. However, it did provide a genetic 
fingerprint of the tumour response to ADEPT. A number of genes involved in DNA 
damage repair and replication were down-regulated at 24 hr-post-treatment, and 
additionally the small number of genes involved in cell cycle control, prompted an 
investigation into the cycling activity of SW1222 cells post-ADEPT. A G2/M arrest 
24 hr-post-treatment was observed and coincided with an elevation in phosphorylated 
Chk1 expression at 3 hr and 24 hr compared to unperturbed cells. It was hypothesised 
that Chk1 inhibition represented a therapeutic strategy for creating a “synthetic lethal” 
response by overriding the last checkpoint defence against damage induced by 
genotoxic agents in p53-defective tumour cells. A 75% growth inhibitory 
concentration of the ADEPT prodrug was established in combination with Chk1 
inhibitors, UCN-01 or PF-477736, and found to augment the cell killing capacity of 
ADEPT in p53-defective SW1222 cells by attenuating G2/M-phase arrest and 
increasing cell death 48 hr-post treatment. The data indicated that inhibition of Chk1 
activity could significantly improve the therapeutic response to single-cycle ADEPT.   
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6 Thesis Summary and Future Directions 
 
The aim of the work undergone in this thesis has been to investigate the parameters 
that would facilitate the development of an enhanced single-cycle ADEPT system. 
Two parameters were investigated: the first was to develop a favourable 
pharmacokinetic profile of the current antibody enzyme fusion protein; and the 
second was to define and manipulate the pharmacodynamic tumour profile of the 
response to a single cycle of ADEPT.  
 
 
6.1 Addressing the pharmacokinetic challenges 
 
How can ADEPT be delivered most safely and effectively to tumours? In the most 
recent Phase I ADEPT trial where patients were administered multiple cycles of 
ADEPT, an increased incidence of myelosuppression was observed (199). The 
myelosuppression was most likely caused by the generation of activated prodrug in 
non-tumour tissues, possibly due to the presence of MFECP in these tissues. 
Furthermore, it had been noted by single and repeated ADEPT trials that the fusion 
protein cleared too rapidly. A successful ADEPT system requires that a) tumour 
CPG2 is high and b) non-tumour CPG2 activity is low or absent, at the time of 
prodrug administration. Failure to achieve a) would lead to reduced therapeutic 
efficacy, and failure of b) would lead to increased toxicity. It was hypothesised in 
Chapter 3 that a non-glycosylated fusion protein would accomplish both a) and b), if 
combined with a glycosylated clearing agent, as outlined in the proposed 3-phase 
ADEPT (Figure 3.1). Two factors had to be considered - firstly the need to 
characterise the glycosylations, particularly the O-glycosylations, on the fusion 
protein/CPG2 and, this was followed by the need to generate a functional and intact 
non-glycosylated fusion protein/enzyme.  
 
Various approaches to remove the N- and O-linked glycosylations from CPG2 in P. 
pastoris were explored. N-linked glycosylations proved relatively easy to remove 
without greatly affecting the enzyme activity. O-linked glycosylations were 
identified by mass spectrometry, but proved more challenging to remove. T55/T57 
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mutated CPG2 constructs exhibited reduced enzyme activity and exhibited rapid 
clearance in vivo. Full characterisation of glycosylations on proteins from biological 
systems remains a challenge because of the attachment of structurally different 
glycans (microheterogeneity) that can occupy different glycosylation sites 
(macroheterogeneity) on a protein. Mass spectrometry (MS) is widely used for the 
analysis of glycans because it provides a link between mass and composition. One of 
the major challenges that hinder the analysis of O-glycosylations is the unwanted 
side reactions occurring once the oligosaccharides are released from the protein 
backbone (termed ‘peeling’) (528). For this purpose, the analysis of the intact 
glycoprotein and/or glycopeptides, obtained after protease or chemical digestion, is 
required, especially for identifying site-specific glycosylation. The T55 and T57 
residues, in particular, were characterised in this way - in a glycopeptide. Analysis of 
glycopeptides is by far the most efficient but also challenging process of 
characterising O-linked glycosylations. As O-glycosylation sites are not indicated by 
specific consensus motifs, direct analysis of these glycopeptides is especially 
difficult. Glycosylation analysis at the native intact protein level has the advantage of 
requiring less sample handling, but chromatography and MS techniques are still in 
their infancy compared with measurements at the peptide and glycan level. A recent 
study described a highly sensitive MS technique to profile, characterise and quantify 
the complex micro-heterogeneity, such as glycosylation, on intact native monoclonal 
antibodies and antibody-drug conjugates (529).    
 
To produce glyco-free MFECP in yeast P. pastoris would be ideal, but whilst it was 
relatively uncomplicated to identify, characterise and manipulate N-linked 
glycosylations, the same was not true for O-linked glycosylations. However, 
obtaining glyco-free MFECP is not impossible, and additionally, progress has been 
made to try and remove O-linked glycosylations in P. pastoris-derived proteins (376) 
(374). Nevertheless, O-linked glycosylations are mostly linear and complete removal 
of these glycosylations in MFECP may disrupt the tertiary and quaternary structure 
of the protein, which in turn, would affect overall protein function, such as antigen 
binding and enzyme activity. Thus, an alternative solution would be to generate a 
non-mannosylated glycosylated fusion protein that exhibits mammalian 
glycosylation patterns. Springer and colleagues (342) were able to successfully 
generate enzymatically functional CPG2 in mammalian cells, provided the N-linked 
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glycosylated residues had been mutated. With the current availability and practicality 
of employing mammalian cell lines for protein production, stable (non-transient) 
expression of MFECP could effectively be established. For example, the FIp-In™ 
technology (Invitrogen) is a stable mammalian expression system that allows for site-
specific integration of the gene of interest into the mammalian genome. Moreover, it 
would be of interest to use a glycoengineered P. pastoris strain capable of producing 
mammalian-like glycoforms (530).   
 
 
6.2 Addressing the pharmacodynamic challenges 
 
How can the therapeutic response to ADEPT be augmented? Repair of DNA damage 
inflicted by the activated prodrug was previously shown to be a limiting factor in the 
efficacy of ADEPT (246). Alkylating agents were originally chosen for use in the 
CPG2 ADEPT system because in vitro they maintain a log-linear tumour cell kill 
over a wide range of doses (531). The data presented in Chapter 4 demonstrated the 
cytotoxicity of the activated prodrug in vitro and in vivo, and also the repair capacity 
of cancer cells to effectively remove DNA damaging adducts. Activation of the 
prodrug was evidenced by the rapid formation of DNA ICL damage, whilst repair 
was found to occur slowly. In fact, 72% of ICLs, which formed within 1 hr following 
ADEPT, were unhooked by 48 hr in vitro. ICL damage poses a unique DNA repair 
problem. ICLs are repaired via a multistep process composed mainly of the 
nucleotide excision repair (NER), translesion synthesis (TLS) and homologous 
recombination (HR) pathways, as current literature states (270) (338) (411) (532). 
Future work would investigate the role of other DNA repair pathways activated in 
response to ADEPT, including (but not limited to): BER (base excision repair), 
which was evidenced from the gene profiling arrays; and the Fanconi anaemia 
pathway, which is important in co-ordinating and regulating ICL repair processes 
(533).  
 
As part of identifying the DNA damage response to ADEPT, γ-H2AX foci induction 
was detected in ADEPT-treated cells at 3 and 24 hr-post-ADEPT (Chapter 4). The 3 
hr timing of induction appeared to fit well with previous findings observed in tumour 
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cells exposed solely to nitrogen mustard drugs (320); and this indicated an immediate 
repair response to ICL damage, namely, ICL repair-associated DSBs. This pattern 
was also consistent with the biphasic RAD51 response. The first (and more 
prominent) peak of RAD51 foci induction was detected at 6 hr-post-ADEPT, which 
was considered to reflect repair of ICL-associated DSBs by homologous 
recombination (HR). However, if HR repair occurs during S or G2 phase of the cell 
cycle (477) then this did not fit with the G2 arrest observed at 24 hr-post-ADEPT. 
Additionally, a clear RAD51 response pattern was not observed in vivo, and it was 
deduced that the role and regulation of RAD51 in HR in response to ADEPT would 
need to be explored further (421).    
 
In vivo data obtained on ICL damage and unhooking over time were found to follow 
a similar pattern to that obtained in vitro. Moreover, the γ-H2AX response correlated 
well with ICL unhooking at 24 hr following therapy, such that, tumours exhibiting 
the greatest number of γ-H2AX foci per cell, also displayed the largest comet tail 
moment post-treatment. The biphasic γ-H2AX pattern observed in vitro (but not in 
vivo) was a novel finding, and the peak in γ-H2AX foci at 24 hr would appear to 
coincide with a number of other genetic, protein and cellular changes discovered in 
this thesis, in response to ADEPT. Olive at al. (414) suggested that cells must transit 
S phase in order to stimulate H2AX phosphorylation leading to foci induction at 24 
hr. Indeed, G2/M growth arrest (Chapter 5) was found to occur at 24 hr-post-
ADEPT, and the γ-H2AX response here was thought to reflect the slow repair of 
(non-ICL-related) DSBs (411). This was further supported by the second (smaller) 
peak of RAD51 induction also detected at 24 hr-post-ADEPT (534). It was also 
interesting to note that the increase in activated Chk1 observed at 3 and 24 hr in 
ADEPT-treated cells (Chapter 5) correlated with γ-H2AX foci peak induction. It is 
believed that activation (phosphorylation) of Chk1 following therapy could be an 
indirect (rather than direct) consequence of ICL-associated DNA damage (535), such 
as the signals induced by stalled replication forks and/or γ-H2AX. 
 
As an important cell cycle signalling molecule in the DNA damage response 
pathway, the relative gene expression of Chk1 in SW1222 cells was found to be 
unchanged over time following ADEPT. This was not the case when levels of the 
protein were analysed (as mentioned above); and the same pattern ensued for Chk2, 
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PCNA and NBS proteins, and their respective genes. When an array of DNA damage 
signalling genes were analysed from cells treated with ADEPT, a noticeable change 
in gene expression was observed at 24 hr (Chapter 5). However, a change in 
expression was found in only 17% of the gene array, and most of the genes were 
down-regulated at 24 hr-post-ADEPT. Interestingly, this down-regulation was 
thought to reflect the negative regulation of transcription activity, in particular the 
genes involved in the BER pathway and DNA replication. Thus, ceasing repair 
activity when it was no longer needed. Negative regulation of repair activity was 
observed at 48 hr-post-ADEPT, which was denoted by a reduction in γH2AX foci 
(regulated by the dephosphorylating phosphatases), a significant reduction in the 
proportion of cells in G2/M phase, and decreased levels of phosphorylated Chk1 (as 
the G2/M arrest was lifted).  Furthermore, the genes (BTG2 and DDIT3), whose 
levels of expression were up-regulated at 24 hr following ADEPT, are negative 
regulators of cell cycle progression suggesting their possible involvement in 
mediating G2/M growth arrest. Negative regulation of the DNA damage response is 
a crucial event in cells and serves to limit signalling and repair in space and time, 
disassembly of repair complexes and prevent unwanted DNA repair (536).   
 
ICL unhooking, γ-H2AX and RAD51 responses all pointed towards repair activity in 
response to a single cycle of ADEPT. Yet, when the cell cycle was analysed, repair 
activity was most strikingly observed in the negligible differences in cell death 
populations between ADEPT-treated and non-treated cells (Chapter 5). In general, 
tumour cells are relatively resistant to cell death induction. DNA ICL repair reflects, 
in part, acquired drug resistance which is a major clinical impediment to successful 
cancer therapy (399) (400). This “chemoresistance” is coupled with intrinsic tumour 
resistance including, epigenetic mechanisms, tumour microenvironmental influences 
and tumour heterogeneity (537). A prominent feature of tumours is their p53 genetic 
signature, which may also contribute to tumour drug resistance or sensitivity. 
Although the p53 gene is not a clinical marker of drug resistance, tumour cells 
harbouring mutated p53 are likely to be more resistant to drugs compared to p53 
wild-type cells when treated with a variety of molecules (538). The p53-defective 
nature of the SW1222 cell-line was used to our advantage to increase the therapeutic 
response to ADEPT by inhibiting the mediator of G2/M arrest, Chk1, in the proposed 
synthetic lethal interaction. Since G2/M arrest and elevated levels of phosphorylated 
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Chk1 were active in ADEPT-treated SW1222 cells, it was hypothesised that 
inhibition of Chk1 would impede growth arrest and DNA repair, and lead to 
increased tumour cell death. To this end, clinically compatible Chk1 inhibitors, 
UCN-01 or PF-477736, were used as a means to improve the tumour response to 
ADEPT.  
 
UCN-01 or PF-477736 combined with the ADEPT prodrug were found to: attenuate 
ADEPT-induced G2/M arrest as demonstrated by the 72% decrease in G2/M fraction 
from 24 to 48 hr, compared to 35% reduction with ADEPT alone; and increase cell 
death to ~ 50%, compared to 33% by 48 hr. Although the cells exhibited a greater 
response to the ADEPT/PF-477736 combination, the differences between the two 
Chk1 combinations were not significant. UCN-01 and PF-477736 were shown to 
inhibit active Chk1 as phosphorylated Chk1 expression was down-regulated by 24 
hr. The effect on phosphorylated Chk2 was not clear and would require further 
investigation. There were no significant differences observed between the first and 
second generation Chk1 inhibitors, though, growth inhibition studies showed that 
ADEPT/PF-477736 combination appeared to have greater (not statistically 
significant) cell kill effect compared to ADEPT alone. However, insufficient time 
and consolidation of the methodology and data prohibited obtaining conclusive 
assumptions.  
 
Cell cycle experiments conducted here provided the initial basis for exploring the 
pharmacodynamic endpoints determining the DNA damage response (as defined in 
Chapter 4) and, ultimately, therapeutic efficacy. Indeed, depletion of Chk1 activity in 
combination with chemotherapy agents has been shown to result in persistent γ-
H2AX expression and loss of RAD51 localisation to nuclear foci in response to DNA 
damage, both of which are involved in mediating repair (497) (539). It would be 
necessary to contrast this work with the effect of Chk1 inhibition in ADEPT-treated 
p53 wild-type cells, which would essentially establish the validity of synthetic 
lethality (“hard” or “soft” (540)).  
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6.3 ADEPT in perspective 
 
Efforts to optimise cytotoxic delivery remain an important issue in cancer therapy. 
The specificity of targeting by the antibody in ADEPT provides a safe and effective 
means of delivering a toxic chemotherapeutic directly to the tumour. Similar to 
ADEPT, the concept of antibody-drug conjugates (ADCs) is based on combining the 
strengths of each molecule whilst eliminating the weaknesses of each individual 
approach. With an improvement in linker technology and the approval of two ADCs, 
there has been resurgence in ADC development and use in early phase clinical trials 
(105). However, the efficacy of ADCs is still limited by toxicity (accumulation in the 
liver and partial release of the payload), immunogenicity towards the antibody and/or 
the toxic payload and poor penetration of solid tumours (541). The challenges posed 
by ADCs presents an ideal opportunity for ADEPT to make a major contribution to 
cancer therapy. 
 
Achieving optimal clinical efficacy without toxicity is difficult to obtain in cancer 
therapy and remains a persistent challenge. Clinically, one cycle of therapy is not 
usually effective in cancer patients. Multiple cycles of therapy, however, brings with 
it the increased incidence of immunogenicity and clinical drug resistance. In this 
thesis, I proposed strategies to address the pharmacokinetic and pharmacodynamic 
challenges of ADEPT that limit its clinical efficacy. Glyco-free MFECP was 
proposed as the primary approach towards attempting to control the clearance of 
antibody-enzyme, and this would be proceeded by a clearing agent that would 
facilitate maximal tumour-to-blood ratios. The idea, although challenging, is not 
impossible to achieve, and there are opportunities to pursue this area further. 
Assessing the DNA damage response to ADEPT generated interesting information 
and indicated repair was occurring in response to a single cycle of therapy. The data 
also provided a base on which to identify a strategy to overcome DNA damage 
repair. The work with Chk1 inhibitors demonstrated a unique strategy to improve the 
therapeutic response to ADEPT, and demands further investigation in vitro and in 
vivo.
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Appendix 1 
 
Appendix 1A: PCR profiling arrays  
Average Ct values for DNA damage signalling/repair gene profiling arrays (Section 5.2.1) derived 
from ADEPT-treated and non-treated SW1222 cells using the RT
2
 Profiler PCR data analysis software 
(SABiosciences). Average of 4 independent experiments. 
 
 
Average Ct Standard Deviation 
Symbol Control 1hr 3hrs 24hrs Control 1hr 3hrs 24hrs 
ABL1 24.90 23.94 24.10 24.77 0.88 0.96 0.73 0.48 
ANKRD17 23.37 22.57 22.86 23.10 1.03 0.96 0.53 0.27 
APEX1 20.91 19.99 19.91 20.93 1.12 1.08 1.48 0.39 
ATM 29.68 28.66 29.11 28.76 1.17 1.41 0.77 0.70 
ATR 25.13 24.33 24.59 25.19 0.95 1.09 0.80 0.41 
ATRX 28.23 27.43 28.16 27.73 0.95 0.89 0.63 0.28 
BRCA1 24.07 23.26 23.62 23.45 1.34 1.18 0.78 0.28 
BTG2 28.67 27.76 28.01 26.85 2.18 1.14 0.72 1.40 
CCNH 24.81 23.96 24.43 24.94 1.12 0.98 0.75 0.41 
CDK7 24.13 23.16 23.73 23.52 1.12 1.05 0.62 0.71 
CHEK1 23.35 22.36 22.73 23.68 1.20 1.12 0.54 0.72 
CHEK2 25.18 24.07 24.65 24.76 1.16 1.10 0.55 0.95 
CIB1 21.51 20.84 21.03 21.07 0.54 0.96 0.75 0.64 
CIDEA 34.26 34.29 34.36 34.29 0.86 0.78 0.55 0.28 
CRY1 24.13 23.38 23.87 24.57 0.65 1.07 0.50 0.70 
DDB1 23.19 22.39 22.76 23.67 0.78 1.07 0.48 0.75 
DDIT3 25.43 24.52 24.70 23.16 0.67 0.76 0.98 0.55 
DMC1 33.42 33.01 33.36 32.04 0.87 1.14 0.47 0.87 
ERCC1 25.46 24.77 25.10 25.08 0.79 0.95 0.65 0.80 
ERCC2 25.18 24.51 25.54 25.41 0.86 0.98 1.71 0.78 
EXO1 24.60 23.83 23.49 24.83 0.80 1.07 0.65 1.08 
FANCG 25.56 24.98 24.99 25.39 0.88 1.01 0.47 1.22 
FEN1 23.52 22.99 22.98 24.89 1.15 1.11 0.42 1.79 
XRCC6 21.16 20.58 20.71 21.80 1.07 1.03 0.68 0.90 
GADD45A 26.86 25.93 26.01 26.41 1.05 1.16 0.71 2.02 
GADD45G 28.27 27.56 27.85 27.80 0.84 1.04 0.43 0.62 
GML 35.00 35.00 35.00 35.00 0.00 0.00 0.00 0.00 
GTF2H1 25.11 24.53 24.13 24.50 0.53 0.92 0.71 0.39 
GTF2H2 24.04 23.27 23.31 24.28 0.87 1.28 0.33 0.59 
GTSE1 25.91 25.31 25.64 25.57 0.60 0.94 0.63 0.45 
HUS1 25.15 24.38 24.56 25.36 0.96 0.98 0.52 0.61 
IGHMBP2 26.00 25.36 25.31 26.63 0.94 1.01 0.26 1.17 
IP6K3 35.00 34.50 35.00 35.00 0.00 0.67 0.00 0.00 
XRCC6BP1 26.51 25.75 25.87 26.51 0.99 1.17 0.65 0.80 
LIG1 24.78 24.27 26.07 25.48 1.21 1.20 4.21 1.47 
MAP2K6 25.16 24.66 25.15 25.24 1.29 0.85 0.55 0.96 
MAPK12 29.50 28.75 29.16 29.61 0.98 1.22 0.95 0.88 
MBD4 24.01 23.22 23.24 23.63 0.62 0.98 0.80 0.34 
MLH1 24.42 23.61 23.91 24.22 0.47 0.83 0.81 0.12 
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MLH3 26.23 25.50 25.50 24.79 0.58 1.00 0.88 0.40 
MNAT1 25.03 24.27 24.57 24.43 0.53 0.97 0.78 0.76 
MPG 23.43 22.56 22.71 22.94 0.52 0.92 0.85 0.37 
MRE11A 27.69 26.54 27.05 27.25 0.79 1.27 0.73 0.59 
MSH2 23.34 22.36 22.39 22.95 0.46 1.04 0.76 0.69 
MSH3 25.17 24.18 24.67 24.48 0.71 1.13 0.79 0.75 
MUTYH 25.46 24.49 25.25 24.87 0.75 1.17 0.64 1.14 
N4BP2 26.21 25.24 25.71 25.74 0.62 0.99 0.48 1.04 
NBN 25.24 24.79 24.36 26.33 0.65 2.46 0.59 1.59 
NTHL1 24.49 24.02 24.14 24.54 0.66 1.22 0.95 0.56 
OGG1 25.46 25.03 25.03 25.98 0.64 1.16 0.56 0.51 
PCBP4 24.48 24.06 24.14 24.99 0.57 0.94 0.24 0.55 
PCNA 21.59 20.95 20.93 22.38 0.70 1.26 0.64 0.54 
AIFM1 22.34 21.83 22.03 22.92 0.69 1.09 0.85 0.44 
PMS1 24.86 24.46 24.57 24.79 0.50 1.08 0.52 0.46 
PMS2 24.37 23.79 23.90 24.31 0.61 1.09 0.35 0.62 
PMS2P3 24.26 23.53 23.90 24.27 0.44 1.13 0.25 0.69 
PNKP 24.87 24.26 24.75 25.60 0.50 1.08 0.37 1.52 
PPP1R15A 25.10 24.19 24.98 24.69 0.70 1.26 0.30 1.34 
PRKDC 21.87 21.12 21.37 21.87 0.76 1.29 0.37 0.94 
RAD1 26.73 25.91 25.77 27.03 0.44 1.07 0.52 0.89 
RAD17 25.35 24.71 24.84 24.69 0.60 0.92 0.86 0.21 
RAD18 24.07 23.46 23.44 23.95 0.89 1.03 0.63 0.33 
RAD21 21.04 20.35 20.86 21.03 0.85 0.96 0.60 0.47 
RAD50 25.46 24.72 25.13 25.65 0.94 1.14 0.45 1.07 
RAD51 28.06 27.36 27.58 27.83 0.71 1.17 0.77 0.38 
RAD51B 25.59 24.90 25.41 24.90 0.83 0.89 0.73 0.58 
RAD9A 25.95 25.00 25.06 26.08 0.80 1.11 0.63 0.55 
RBBP8 24.48 23.69 23.67 24.64 0.71 0.85 0.80 0.40 
REV1 25.66 24.81 25.02 25.63 0.92 1.16 0.30 0.57 
RPA1 22.68 21.85 22.02 22.94 0.94 1.28 0.71 0.88 
SEMA4A 27.52 26.80 27.54 27.58 1.06 0.89 0.97 1.86 
SESN1 25.79 25.05 24.94 25.69 1.17 1.03 0.68 0.93 
SMC1A 23.09 22.52 22.76 23.52 0.80 1.07 0.39 0.63 
SUMO1 23.11 22.96 22.51 23.21 0.81 1.28 0.49 0.37 
TP53 33.82 32.78 33.70 33.65 0.51 1.11 0.63 0.87 
TP73 29.95 29.15 29.11 31.04 0.76 1.24 0.47 0.63 
TREX1 25.33 24.53 24.66 25.23 0.56 1.17 0.56 0.43 
UNG 22.34 21.41 21.41 23.19 0.59 1.08 0.87 0.34 
XPA 24.08 23.25 23.54 24.82 0.52 0.86 0.53 0.27 
XPC 25.16 24.31 24.64 24.78 0.67 0.94 0.46 0.54 
XRCC1 24.43 23.55 24.00 24.25 0.92 1.16 0.65 0.81 
XRCC2 25.71 24.81 24.92 25.62 0.79 1.10 0.34 0.95 
XRCC3 29.11 28.22 28.49 29.59 1.04 1.35 0.70 1.77 
ZAK 24.28 23.27 23.65 24.18 1.08 1.18 0.52 0.85 
B2M 20.96 20.50 20.62 20.78 0.55 1.07 0.80 0.28 
HPRT1 21.94 21.36 21.31 21.89 0.43 1.13 0.80 0.34 
RPL13A 19.95 19.37 19.50 18.76 0.44 0.91 0.74 0.68 
GAPDH 16.01 15.28 15.30 15.38 0.59 1.19 0.95 0.49 
ACTB 17.07 16.18 16.14 17.22 0.55 1.05 0.47 0.26 
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Appendix 1B: PCR profiling arrays  
The change in the regulation of DNA damage signalling/repair genes derived from ADEPT-treated 
SW1222 cells (compared to non-treated cells) was computed using the RT
2
 Profiler PCR data analysis 
software (SABiosciences). Cut-off is 2 for up-regulation and -2 for down-regulation. (Average of four 
independent experiments). According to the RT
2
 Profiler PCR data analysis software: A - the gene’s 
expression is relatively low in one sample and reasonably detected in the other sample suggesting that 
the actual fold-change value is at least as large as the calculated and reported fold-change result; B - 
gene’s average threshold cycle is relatively high (> 30), meaning that its relative expression level is 
low, in both control and test samples; C - gene’s average threshold cycle is either not determined or 
greater than the defined cut-off value (35), in both samples meaning that its expression was 
undetected, making this fold-change result erroneous and un-interpretable. 
 
 
Up/Down Regulation (comparing to control group) 
 
1hr 3hrs 24hrs 
Symbol 
Fold 
Change 
Comment 
Fold 
Change 
Comment 
Fold 
Change 
Comment 
ABL1 1.24 OKAY 1.14 OKAY 0.85 OKAY 
ANKRD17 1.11 OKAY 0.93 OKAY 0.93 OKAY 
APEX1 1.21 OKAY 1.31 OKAY 0.76 OKAY 
ATM 1.29 OKAY 0.97 OKAY 1.45 OKAY 
ATR 1.11 OKAY 0.95 OKAY 0.74 OKAY 
ATRX 1.11 OKAY 0.68 OKAY 1.09 OKAY 
BRCA1 1.12 OKAY 0.89 OKAY 1.18 OKAY 
BTG2 1.20 OKAY 1.03 OKAY 2.71 OKAY 
CCNH 1.15 OKAY 0.85 OKAY 0.70 OKAY 
CDK7 1.25 OKAY 0.87 OKAY 1.18 OKAY 
CHEK1 1.26 OKAY 1.00 OKAY 0.61 OKAY 
CHEK2 1.38 OKAY 0.94 OKAY 1.03 OKAY 
CIB1 1.01 OKAY 0.91 OKAY 1.04 OKAY 
CIDEA 0.62 B 0.61 B 0.75 B 
CRY1 1.07 OKAY 0.79 OKAY 0.57 OKAY 
DDB1 1.11 OKAY 0.88 OKAY 0.55 OKAY 
DDIT3 1.20 OKAY 1.09 OKAY 3.71 OKAY 
DMC1 0.85 B 0.68 B 2.00 B 
ERCC1 1.02 OKAY 0.84 OKAY 1.00 OKAY 
ERCC2 1.01 OKAY 0.51 OKAY 0.65 OKAY 
EXO1 1.08 OKAY 1.41 OKAY 0.65 OKAY 
FANCG 0.95 OKAY 0.97 OKAY 0.87 OKAY 
FEN1 0.93 OKAY 0.95 OKAY 0.30 OKAY 
XRCC6 0.95 OKAY 0.89 OKAY 0.49 OKAY 
GADD45A 1.21 OKAY 1.18 OKAY 1.05 OKAY 
GADD45G 1.05 OKAY 0.88 OKAY 1.07 OKAY 
GML 0.64 C 0.65 C 0.77 C 
GTF2H1 0.95 OKAY 1.29 OKAY 1.17 OKAY 
GTF2H2 1.09 OKAY 1.09 OKAY 0.65 OKAY 
GTSE1 0.97 OKAY 0.79 OKAY 0.98 OKAY 
HUS1 1.08 OKAY 0.98 OKAY 0.66 OKAY 
IGHMBP2 0.99 OKAY 1.05 OKAY 0.49 OKAY 
IP6K3 0.90 B 0.65 C 0.77 C 
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XRCC6BP1 1.08 OKAY 1.02 OKAY 0.77 OKAY 
LIG1 0.91 OKAY 0.27 OKAY 0.47 OKAY 
MAP2K6 0.90 OKAY 0.66 OKAY 0.73 OKAY 
MAPK12 1.07 OKAY 0.83 OKAY 0.71 OKAY 
MBD4 1.11 OKAY 1.12 OKAY 1.01 OKAY 
MLH1 1.12 OKAY 0.93 OKAY 0.88 OKAY 
MLH3 1.06 OKAY 1.09 OKAY 2.09 OKAY 
MNAT1 1.08 OKAY 0.90 OKAY 1.17 OKAY 
MPG 1.16 OKAY 1.08 OKAY 1.08 OKAY 
MRE11A 1.42 OKAY 1.02 OKAY 1.05 OKAY 
MSH2 1.26 OKAY 1.26 OKAY 1.01 OKAY 
MSH3 1.27 OKAY 0.93 OKAY 1.25 OKAY 
MUTYH 1.24 OKAY 0.76 OKAY 1.15 OKAY 
N4BP2 1.25 OKAY 0.92 OKAY 1.07 OKAY 
NBN 0.87 OKAY 1.21 OKAY 0.36 OKAY 
NTHL1 0.88 OKAY 0.84 OKAY 0.74 OKAY 
OGG1 0.86 OKAY 0.88 OKAY 0.54 OKAY 
PCBP4 0.85 OKAY 0.83 OKAY 0.54 OKAY 
PCNA 0.99 OKAY 1.03 OKAY 0.45 OKAY 
AIFM1 0.91 OKAY 0.81 OKAY 0.51 OKAY 
PMS1 0.84 OKAY 0.80 OKAY 0.81 OKAY 
PMS2 0.95 OKAY 0.91 OKAY 0.80 OKAY 
PMS2P3 1.06 OKAY 0.84 OKAY 0.76 OKAY 
PNKP 0.97 OKAY 0.71 OKAY 0.46 OKAY 
PPP1R15A 1.20 OKAY 0.71 OKAY 1.02 OKAY 
PRKDC 1.07 OKAY 0.93 OKAY 0.77 OKAY 
RAD1 1.13 OKAY 1.28 OKAY 0.63 OKAY 
RAD17 0.99 OKAY 0.93 OKAY 1.21 OKAY 
RAD18 0.97 OKAY 1.01 OKAY 0.83 OKAY 
RAD21 1.03 OKAY 0.74 OKAY 0.77 OKAY 
RAD50 1.06 OKAY 0.82 OKAY 0.68 OKAY 
RAD51 1.04 OKAY 0.91 OKAY 0.91 OKAY 
RAD51B 1.03 OKAY 0.74 OKAY 1.24 OKAY 
RAD9A 1.23 OKAY 1.21 OKAY 0.71 OKAY 
RBBP8 1.11 OKAY 1.15 OKAY 0.69 OKAY 
REV1 1.15 OKAY 1.02 OKAY 0.79 OKAY 
RPA1 1.14 OKAY 1.03 OKAY 0.64 OKAY 
SEMA4A 1.05 OKAY 0.65 OKAY 0.74 OKAY 
SESN1 1.07 OKAY 1.18 OKAY 0.83 OKAY 
SMC1A 0.95 OKAY 0.82 OKAY 0.57 OKAY 
SUMO1 0.71 OKAY 0.99 OKAY 0.71 OKAY 
TP53 1.31 B 0.71 B 0.86 B 
TP73 1.11 OKAY 1.17 OKAY 0.36 A 
TREX1 1.11 OKAY 1.04 OKAY 0.82 OKAY 
UNG 1.22 OKAY 1.25 OKAY 0.43 OKAY 
XPA 1.13 OKAY 0.96 OKAY 0.46 OKAY 
XPC 1.14 OKAY 0.94 OKAY 1.00 OKAY 
XRCC1 1.18 OKAY 0.88 OKAY 0.87 OKAY 
XRCC2 1.19 OKAY 1.13 OKAY 0.82 OKAY 
XRCC3 1.19 OKAY 1.01 OKAY 0.55 OKAY 
ZAK 1.28 OKAY 1.01 OKAY 0.82 OKAY 
B2M 0.88 OKAY 0.83 OKAY 0.88 OKAY 
Appendix 
193 
 
HPRT1 0.96 OKAY 1.02 OKAY 0.80 OKAY 
RPL13A 0.95 OKAY 0.89 OKAY 1.75 OKAY 
GAPDH 1.06 OKAY 1.07 OKAY 1.19 OKAY 
ACTB 1.17 OKAY 1.25 OKAY 0.69 OKAY 
 
 
Appendix 2 
 
 
Appendix 2: Cell cycle analysis of ADEPT in the presence of Chk1 inhibitors  
SW1222 cells were treated with ADEPT using 0.3 μM prodrug (or a drug-free media) and 25 nM 
UCN-01 or 0.1 μM PF-477736. Cells were subsequently cultured in medium containing respective 
Chk1 inhibitor alone and harvested at different time points.  
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Extra-Curricular Development 
 
Poster presentations 
 
 UCL Graduate School Poster Competition – March 2010 and 2011 
 Student Day (UCL/NIMR) – May 2010 
 UCL Cancer Institute Symposium – July 2011 
 
Conferences 
 
 Global Proteins Summit, London, June 2009 
 MicroRNAs and Translation Regulation in Cancer, London, November 2009 
 Phage Display symposium, Cambridge, September 2010 
 EORTC symposium Berlin, November 2010 
 NCRI, UK, November 2011 
 
Skills courses 
 
 Personal and Professional Management Skills 
 Confidence Building 
 Abstract writing and poster presentations – ThinkWrite™ courses  
 Creative thesis writing 
 Time-management 
 Various career development seminars and career fairs, including Nature Expo 2010 
and 2012 
 
Supervising and teaching  
 
 Work experience/summer project students (GCSE-level, A’Level and undergraduate 
level) 
 Practical course for MSc Cancer students (2009 and 2010) 
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 Public engagement activities, including the Open Day for the UCL Macmillan 
Cancer Centre  
 
Work experience 
 
NIHR/Wellcome Cancer Clinical Trials Centre, 2013 
 
Publications  
 
Andrady C, Sharma S, Chester K. Antibody-Enzyme Fusion Proteins for Cancer 
Therapy, 2011. Immunotherapy 3(2):193-211 (see thesis attachment at the back) 
 
Andrady C et al. Synergistic Lethality of Chk1 Inhibitors and Antibody-Directed 
Enzyme Prodrug Therapy (ADEPT), 2014. Biochemical Pharmacology (submission 
in progress) 
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